WO2011103189A1 - Methods of reducing virulence in bacteria - Google Patents
Methods of reducing virulence in bacteria Download PDFInfo
- Publication number
- WO2011103189A1 WO2011103189A1 PCT/US2011/025082 US2011025082W WO2011103189A1 WO 2011103189 A1 WO2011103189 A1 WO 2011103189A1 US 2011025082 W US2011025082 W US 2011025082W WO 2011103189 A1 WO2011103189 A1 WO 2011103189A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacterium
- acid
- aryl
- type system
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 130
- 241000894006 Bacteria Species 0.000 title claims abstract description 108
- 230000001018 virulence Effects 0.000 title claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims abstract description 279
- -1 sulfo, silyl Chemical group 0.000 claims description 176
- 239000000203 mixture Substances 0.000 claims description 157
- 230000001580 bacterial effect Effects 0.000 claims description 129
- 125000003118 aryl group Chemical group 0.000 claims description 111
- 125000000217 alkyl group Chemical group 0.000 claims description 96
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 239000000243 solution Substances 0.000 claims description 68
- 239000002253 acid Substances 0.000 claims description 56
- 150000002148 esters Chemical class 0.000 claims description 54
- 125000003368 amide group Chemical group 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 42
- 238000009472 formulation Methods 0.000 claims description 41
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 38
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000002947 alkylene group Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 32
- 241001187100 Dickeya dadantii Species 0.000 claims description 31
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 31
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 30
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 27
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 26
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 24
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- 239000003921 oil Substances 0.000 claims description 23
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 23
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 16
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 16
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 16
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 claims description 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 claims description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 150000003568 thioethers Chemical class 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 125000001475 halogen functional group Chemical group 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 239000011593 sulfur Substances 0.000 claims description 13
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 241000589516 Pseudomonas Species 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 229930192474 thiophene Natural products 0.000 claims description 8
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 7
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 7
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 239000002689 soil Substances 0.000 claims description 7
- 241000531155 Pectobacterium Species 0.000 claims description 6
- 239000004495 emulsifiable concentrate Substances 0.000 claims description 6
- 241000607598 Vibrio Species 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 4
- 241000589634 Xanthomonas Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000010410 dusting Methods 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 241000588694 Erwinia amylovora Species 0.000 claims description 3
- 241001138501 Salmonella enterica Species 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000004546 suspension concentrate Substances 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241001187099 Dickeya Species 0.000 claims description 2
- 241000588921 Enterobacteriaceae Species 0.000 claims description 2
- 241000588698 Erwinia Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241001646398 Pseudomonas chlororaphis Species 0.000 claims description 2
- 241001645955 Pseudomonas chlororaphis subsp. aureofaciens Species 0.000 claims description 2
- 241000394642 Pseudomonas marginalis pv. marginalis Species 0.000 claims description 2
- 241001148199 Pseudomonas tolaasii Species 0.000 claims description 2
- 241001464820 Pseudomonas viridiflava Species 0.000 claims description 2
- 241000232299 Ralstonia Species 0.000 claims description 2
- 241000589771 Ralstonia solanacearum Species 0.000 claims description 2
- 241000863430 Shewanella Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 241000520892 Xanthomonas axonopodis Species 0.000 claims description 2
- 241000589652 Xanthomonas oryzae Species 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 241000589151 Azotobacter Species 0.000 claims 1
- 241000589540 Pseudomonas fluorescens Species 0.000 claims 1
- 241000589615 Pseudomonas syringae Species 0.000 claims 1
- 241000589636 Xanthomonas campestris Species 0.000 claims 1
- 239000004490 capsule suspension Substances 0.000 claims 1
- 239000004548 suspo-emulsion Substances 0.000 claims 1
- 239000004552 water soluble powder Substances 0.000 claims 1
- 239000004563 wettable powder Substances 0.000 claims 1
- 239000006151 minimal media Substances 0.000 description 169
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 154
- 230000014509 gene expression Effects 0.000 description 146
- 210000004027 cell Anatomy 0.000 description 95
- 108010069584 Type III Secretion Systems Proteins 0.000 description 93
- 230000000694 effects Effects 0.000 description 93
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- 239000005090 green fluorescent protein Substances 0.000 description 83
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 82
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 82
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 76
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 76
- 101150063420 hrpA gene Proteins 0.000 description 72
- 101100476899 Ralstonia solanacearum (strain GMI1000) sctC gene Proteins 0.000 description 71
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 65
- 241000196324 Embryophyta Species 0.000 description 65
- 239000007787 solid Substances 0.000 description 65
- 101100451485 Pseudomonas syringae pv. syringae hrpL gene Proteins 0.000 description 56
- 239000013612 plasmid Substances 0.000 description 54
- 101150001435 gacA gene Proteins 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 49
- 230000015572 biosynthetic process Effects 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 44
- 239000002609 medium Substances 0.000 description 43
- 238000003556 assay Methods 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- 101100507443 Ralstonia solanacearum (strain GMI1000) hrcU gene Proteins 0.000 description 41
- 101150039191 hrpN gene Proteins 0.000 description 41
- 238000002474 experimental method Methods 0.000 description 40
- 230000001105 regulatory effect Effects 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 38
- 239000000725 suspension Substances 0.000 description 38
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 36
- 101150023643 hrpS gene Proteins 0.000 description 35
- 230000012010 growth Effects 0.000 description 33
- 239000012043 crude product Substances 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 230000002829 reductive effect Effects 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 239000012267 brine Substances 0.000 description 30
- 101150027426 rsmB gene Proteins 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- 241001515913 Dickeya dadantii 3937 Species 0.000 description 28
- 239000000306 component Substances 0.000 description 27
- 238000003752 polymerase chain reaction Methods 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- 230000037361 pathway Effects 0.000 description 22
- 238000000684 flow cytometry Methods 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 230000009467 reduction Effects 0.000 description 21
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 20
- 244000070968 Saintpaulia ionantha Species 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 125000006413 ring segment Chemical group 0.000 description 17
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 16
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 125000003277 amino group Chemical group 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 13
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 13
- 244000061176 Nicotiana tabacum Species 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 150000002431 hydrogen Chemical class 0.000 description 13
- 101150078820 pelL gene Proteins 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 12
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229960004889 salicylic acid Drugs 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 11
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 11
- 125000005488 carboaryl group Chemical group 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 108010059820 Polygalacturonase Proteins 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 108010093305 exopolygalacturonase Proteins 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 108010087558 pectate lyase Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamamide Chemical compound NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000002803 maceration Methods 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 150000002989 phenols Chemical class 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000012809 post-inoculation Methods 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- AUDPOCGNHFKZBR-RMKNXTFCSA-N 2-[(e)-3-phenylprop-2-enyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C\C=C\C1=CC=CC=C1 AUDPOCGNHFKZBR-RMKNXTFCSA-N 0.000 description 8
- MHHGQWMCVNQHLG-UHFFFAOYSA-N 2-prop-2-enylisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC=C)C(=O)C2=C1 MHHGQWMCVNQHLG-UHFFFAOYSA-N 0.000 description 8
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical class OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 8
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 235000013985 cinnamic acid Nutrition 0.000 description 8
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 8
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000004980 cyclopropylene group Chemical group 0.000 description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 8
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 8
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 125000002993 cycloalkylene group Chemical group 0.000 description 7
- PCUFRDPZBYBMLL-UHFFFAOYSA-N ethyl diethylphosphorylmethanesulfonate Chemical compound CCOS(=O)(=O)CP(=O)(CC)CC PCUFRDPZBYBMLL-UHFFFAOYSA-N 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 6
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 6
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 6
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 101100280248 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) exoS gene Proteins 0.000 description 6
- 101100329638 Pseudomonas protegens (strain DSM 19095 / LMG 27888 / CFBP 6595 / CHA0) csrA2 gene Proteins 0.000 description 6
- 241000259045 Pseudomonas syringae pv. tomato str. DC3000 Species 0.000 description 6
- 101100327931 Rhizobium meliloti (strain 1021) chvG gene Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004450 alkenylene group Chemical group 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 101150000622 csrA gene Proteins 0.000 description 6
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- MWFJXRUUPWIALU-UHFFFAOYSA-N ethyl ethenesulfonate Chemical class CCOS(=O)(=O)C=C MWFJXRUUPWIALU-UHFFFAOYSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 101150004863 ksgA gene Proteins 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001124 posttranscriptional effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 101150085310 rsmA gene Proteins 0.000 description 6
- 101150074731 rsmC gene Proteins 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 6
- QDSFNOHWQKVVEB-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)morpholine Chemical compound CCOP(=O)(OCC)CN1CCOCC1 QDSFNOHWQKVVEB-UHFFFAOYSA-N 0.000 description 5
- 238000006272 Corey-Chaykovsky cyclopropanation reaction Methods 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 229910052770 Uranium Inorganic materials 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 150000001499 aryl bromides Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 5
- 125000005544 phthalimido group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 239000004562 water dispersible granule Substances 0.000 description 5
- RDAFNSMYPSHCBK-QPJJXVBHSA-N (e)-3-phenylprop-2-en-1-amine Chemical compound NC\C=C\C1=CC=CC=C1 RDAFNSMYPSHCBK-QPJJXVBHSA-N 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- WBVWJXSDIOLYPW-UHFFFAOYSA-N 3-[4-(hydroxymethyl)phenyl]prop-2-enoic acid Chemical compound OCC1=CC=C(C=CC(O)=O)C=C1 WBVWJXSDIOLYPW-UHFFFAOYSA-N 0.000 description 4
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 4
- 101100189842 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel2 gene Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 150000003935 benzaldehydes Chemical class 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 229930016911 cinnamic acid Natural products 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- YATVRICWQKSUHN-UHFFFAOYSA-M ethenesulfonate;tetrabutylazanium Chemical class [O-]S(=O)(=O)C=C.CCCC[N+](CCCC)(CCCC)CCCC YATVRICWQKSUHN-UHFFFAOYSA-M 0.000 description 4
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 101150063121 iaaM gene Proteins 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 101150056092 pelD gene Proteins 0.000 description 4
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- LBOUHDMYVURTMA-AATRIKPKSA-N (e)-3-(4-formylphenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(C=O)C=C1 LBOUHDMYVURTMA-AATRIKPKSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 238000007341 Heck reaction Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241000588701 Pectobacterium carotovorum Species 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000232081 Streptocarpus sect. Saintpaulia Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 238000010805 cDNA synthesis kit Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 3
- DHNGCHLFKUPGPX-RMKNXTFCSA-N ethyl trans-p-methoxycinnamate Chemical compound CCOC(=O)\C=C\C1=CC=C(OC)C=C1 DHNGCHLFKUPGPX-RMKNXTFCSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003337 fertilizer Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 150000002373 hemiacetals Chemical class 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 244000052637 human pathogen Species 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 101150008233 rplU gene Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
- 229960000268 spectinomycin Drugs 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- IWOKCMBOJXYDEE-UHFFFAOYSA-N sulfinylmethane Chemical compound C=S=O IWOKCMBOJXYDEE-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PMOWTIHVNWZYFI-AATRIKPKSA-N trans-2-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1O PMOWTIHVNWZYFI-AATRIKPKSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- KJRRTHHNKJBVBO-AATRIKPKSA-N (e)-3-(2-chlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1Cl KJRRTHHNKJBVBO-AATRIKPKSA-N 0.000 description 2
- QEGNUYASOUJEHD-UHFFFAOYSA-N 1,1-dimethylcyclohexane Chemical compound CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- CTMHWPIWNRWQEG-UHFFFAOYSA-N 1-methylcyclohexene Chemical compound CC1=CCCCC1 CTMHWPIWNRWQEG-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 2
- RSWBWHPZXKLUEX-VOTSOKGWSA-N 2-Methylcinnamic Acid Chemical compound CC1=CC=CC=C1\C=C\C(O)=O RSWBWHPZXKLUEX-VOTSOKGWSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 2
- OKEAMBAZBICIFP-UHFFFAOYSA-N 3-oxido-2,1,3-benzoxadiazol-3-ium Chemical compound C1=CC=CC2=[N+]([O-])ON=C21 OKEAMBAZBICIFP-UHFFFAOYSA-N 0.000 description 2
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 2
- ZBWXZZIIMVVCNZ-UHFFFAOYSA-N 4,5-dihydroacephenanthrylene Chemical compound C1=CC(CC2)=C3C2=CC2=CC=CC=C2C3=C1 ZBWXZZIIMVVCNZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- XTAHYROJKCXMOF-UHFFFAOYSA-N Dihydroaceanthrylene Chemical compound C1=CC=C2C(CCC3=CC=C4)=C3C4=CC2=C1 XTAHYROJKCXMOF-UHFFFAOYSA-N 0.000 description 2
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241001469654 Lawsonia <weevil> Species 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000970829 Mesorhizobium Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241001148142 Pectobacterium atrosepticum Species 0.000 description 2
- 241000588702 Pectobacterium carotovorum subsp. carotovorum Species 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001148062 Photorhabdus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000589623 Pseudomonas syringae pv. syringae Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 239000012163 TRI reagent Substances 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000589649 Xanthomonas campestris pv. campestris Species 0.000 description 2
- 101150067314 aadA gene Proteins 0.000 description 2
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 2
- 125000004036 acetal group Chemical group 0.000 description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 230000010455 autoregulation Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- BWRHOYDPVJPXMF-UHFFFAOYSA-N carane Chemical compound C1C(C)CCC2C(C)(C)C12 BWRHOYDPVJPXMF-UHFFFAOYSA-N 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- AHZOHFYNIDGBKN-UHFFFAOYSA-N chloro(ethoxy)phosphinic acid Chemical compound CCOP(O)(Cl)=O AHZOHFYNIDGBKN-UHFFFAOYSA-N 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 101150106284 deoR gene Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- QWHNJUXXYKPLQM-UHFFFAOYSA-N dimethyl cyclopentane Natural products CC1(C)CCCC1 QWHNJUXXYKPLQM-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- ZTWTYVWXUKTLCP-UHFFFAOYSA-L ethenyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-L 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- DHNGCHLFKUPGPX-UHFFFAOYSA-N ethyl 4-methoxycinnamate Natural products CCOC(=O)C=CC1=CC=C(OC)C=C1 DHNGCHLFKUPGPX-UHFFFAOYSA-N 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 101150070420 gyrA gene Proteins 0.000 description 2
- 125000001976 hemiacetal group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 229940115932 legionella pneumophila Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- KKSDGJDHHZEWEP-UHFFFAOYSA-N m-hydroxycinnamic acid Natural products OC(=O)C=CC1=CC=CC(O)=C1 KKSDGJDHHZEWEP-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDJAEZRIGNCQBZ-UHFFFAOYSA-N methylcyclobutane Chemical compound CC1CCC1 BDJAEZRIGNCQBZ-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methylcyclopentane Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WPHGSKGZRAQSGP-UHFFFAOYSA-N norcarane Chemical compound C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- XDJOIMJURHQYDW-UHFFFAOYSA-N phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 2
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000024053 secondary metabolic process Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- GCTNBVHDRFKLLK-UHFFFAOYSA-N thujane Chemical compound CC1CCC2(C(C)C)C1C2 GCTNBVHDRFKLLK-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- KKSDGJDHHZEWEP-SNAWJCMRSA-N trans-3-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC(O)=C1 KKSDGJDHHZEWEP-SNAWJCMRSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- ZQVJBRJGDVZANE-MXDMHAPNSA-N (2s)-2-[(3s,6s,9z,12s,15s,18s,21r,24r,27s)-18,21-bis(2-aminoethyl)-12-benzyl-3-[(1s)-2-chloro-1-hydroxyethyl]-15-[3-(diaminomethylideneamino)propyl]-9-ethylidene-27-[[(3s)-3-hydroxydodecanoyl]amino]-24-(hydroxymethyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa Chemical compound N1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](O)CCCCCCCCC)COC(=O)[C@H]([C@H](O)CCl)NC(=O)[C@H]([C@H](O)C(O)=O)NC(=O)\C(=C\C)NC(=O)[C@@H]1CC1=CC=CC=C1 ZQVJBRJGDVZANE-MXDMHAPNSA-N 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- PLVPPLCLBIEYEA-AATRIKPKSA-N (E)-3-(indol-3-yl)acrylic acid Chemical compound C1=CC=C2C(/C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-AATRIKPKSA-N 0.000 description 1
- OFZYBEBWCZBCPM-UHFFFAOYSA-N 1,1-dimethylcyclobutane Chemical compound CC1(C)CCC1 OFZYBEBWCZBCPM-UHFFFAOYSA-N 0.000 description 1
- PBIJFSCPEFQXBB-UHFFFAOYSA-N 1,1-dimethylcyclopropane Chemical compound CC1(C)CC1 PBIJFSCPEFQXBB-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- KVFJBIQWENJTDM-UHFFFAOYSA-N 1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CCC1=CC=C3)=C1C3=C2 KVFJBIQWENJTDM-UHFFFAOYSA-N 0.000 description 1
- PUAKTHBSHFXVAG-UHFFFAOYSA-N 1,2-dimethylcyclobutene Chemical compound CC1=C(C)CC1 PUAKTHBSHFXVAG-UHFFFAOYSA-N 0.000 description 1
- TXNWMICHNKMOBR-UHFFFAOYSA-N 1,2-dimethylcyclohexene Chemical compound CC1=C(C)CCCC1 TXNWMICHNKMOBR-UHFFFAOYSA-N 0.000 description 1
- SZZWLAZADBEDQP-UHFFFAOYSA-N 1,2-dimethylcyclopentene Chemical compound CC1=C(C)CCC1 SZZWLAZADBEDQP-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- MUPYMRJBEZFVMT-UHFFFAOYSA-N 1-chloro-4-dimethoxyphosphorylsulfanylbenzene Chemical compound COP(=O)(OC)SC1=CC=C(Cl)C=C1 MUPYMRJBEZFVMT-UHFFFAOYSA-N 0.000 description 1
- AVPHQXWAMGTQPF-UHFFFAOYSA-N 1-methylcyclobutene Chemical compound CC1=CCC1 AVPHQXWAMGTQPF-UHFFFAOYSA-N 0.000 description 1
- ATQUFXWBVZUTKO-UHFFFAOYSA-N 1-methylcyclopentene Chemical compound CC1=CCCC1 ATQUFXWBVZUTKO-UHFFFAOYSA-N 0.000 description 1
- SHDPRTQPPWIEJG-UHFFFAOYSA-N 1-methylcyclopropene Chemical compound CC1=CC1 SHDPRTQPPWIEJG-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- IEMAOEFPZAIMCN-UHFFFAOYSA-N 1H-pyrazole Chemical compound C=1C=NNC=1.C=1C=NNC=1 IEMAOEFPZAIMCN-UHFFFAOYSA-N 0.000 description 1
- MREIFUWKYMNYTK-UHFFFAOYSA-N 1H-pyrrole Chemical compound C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HUEXNHSMABCRTH-UHFFFAOYSA-N 1h-imidazole Chemical compound C1=CNC=N1.C1=CNC=N1 HUEXNHSMABCRTH-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- FLNPFFMWAPTGOT-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1.C1NNC=C1 FLNPFFMWAPTGOT-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- NJCKCAMLRCAFID-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethenesulfonic acid Chemical compound OC1=CC=C(C=CS(O)(=O)=O)C=C1 NJCKCAMLRCAFID-UHFFFAOYSA-N 0.000 description 1
- ZQZHFDIVVPSEAY-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethenyl dihydrogen phosphate Chemical compound OC1=CC=C(C=COP(O)(O)=O)C=C1 ZQZHFDIVVPSEAY-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- IQIPOFWLBXKZNC-UHFFFAOYSA-N 2-diethoxyphosphorylacetic acid;lead Chemical compound [Pb].CCOP(=O)(CC(O)=O)OCC IQIPOFWLBXKZNC-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- BQTJMKIHKULPCZ-UHFFFAOYSA-N 2H-indene Chemical compound C1=CC=CC2=CCC=C21 BQTJMKIHKULPCZ-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical compound C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 description 1
- RELAJOWOFXGXHI-UHFFFAOYSA-N 3h-oxathiole Chemical compound C1SOC=C1 RELAJOWOFXGXHI-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- BBEQQKBWUHCIOU-UHFFFAOYSA-N 5-(dimethylamino)-1-naphthalenesulfonic acid(dansyl acid) Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(O)(=O)=O BBEQQKBWUHCIOU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NJBMMMJOXRZENQ-UHFFFAOYSA-N 6H-pyrrolo[2,3-f]quinoline Chemical compound c1cc2ccc3[nH]cccc3c2n1 NJBMMMJOXRZENQ-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 241000726119 Acidovorax Species 0.000 description 1
- 241001600124 Acidovorax avenae Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- 241000607574 Aeromonas veronii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- 241000589174 Bradyrhizobium japonicum Species 0.000 description 1
- 241000159535 Bradyrhizobium liaoningense Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000918666 Candidatus Hamiltonella Species 0.000 description 1
- 241000978694 Candidatus Hamiltonella defensa Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000863387 Cellvibrio Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- 241000588879 Chromobacterium violaceum Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000949031 Citrobacter rodentium Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241001528480 Cupriavidus Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- HMFHBZSHGGEWLO-AGQMPKSLSA-N D-lyxofuranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H]1O HMFHBZSHGGEWLO-AGQMPKSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000046129 Hahella Species 0.000 description 1
- 241000045411 Hahella chejuensis Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 101001094098 Homo sapiens Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-YIDFTEPTSA-N IDOSE Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-YIDFTEPTSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000556406 Pectobacterium wasabiae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 241001148064 Photorhabdus luminescens Species 0.000 description 1
- 241001216646 Photorhabdus temperata Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 241000589612 Pseudomonas savastanoi pv. glycinea Species 0.000 description 1
- 101100339667 Pseudomonas syringae pv. syringae hrpW gene Proteins 0.000 description 1
- 241000589626 Pseudomonas syringae pv. tomato Species 0.000 description 1
- GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 241000589187 Rhizobium sp. Species 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- GNSXDDLDAGAXTL-UHFFFAOYSA-N S1OCCCC1.O1SCCCC1 Chemical compound S1OCCCC1.O1SCCCC1 GNSXDDLDAGAXTL-UHFFFAOYSA-N 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 241001135312 Sinorhizobium Species 0.000 description 1
- 241000589166 Sinorhizobium fredii Species 0.000 description 1
- 241001660101 Sodalis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- RUWSLQOIGKYPEZ-YPXRAQKDSA-N Syringolin Natural products CC(C)[C@@H](C(O)=O)NC(=O)N[C@@H](C(C)C)C(=O)N[C@H]1\C=C\CCNC(=O)\C=C\[C@H](C(C)C)NC1=O RUWSLQOIGKYPEZ-YPXRAQKDSA-N 0.000 description 1
- ZQVJBRJGDVZANE-UHFFFAOYSA-N Syringomycin Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CO)NC(=O)C(NC(=O)CC(O)CCCCCCCCC)COC(=O)C(C(O)CCl)NC(=O)C(C(O)C(O)=O)NC(=O)C(=CC)NC(=O)C1CC1=CC=CC=C1 ZQVJBRJGDVZANE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 229930190196 Tolaasin Natural products 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000815873 Xanthomonas euvesicatoria Species 0.000 description 1
- 241001472254 Xanthomonas fuscans Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- GXVKHKJETWAWRR-UHFFFAOYSA-N a805143 Chemical compound C1CCNC1.C1CCNC1 GXVKHKJETWAWRR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000004808 allyl alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000010828 animal waste Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 1
- 229930006742 bornane Natural products 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229930006741 carane Natural products 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- DLTBAYKGXREKMW-UHFFFAOYSA-N cyclopropanesulfonic acid Chemical class OS(=O)(=O)C1CC1 DLTBAYKGXREKMW-UHFFFAOYSA-N 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 101150109777 cytR gene Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HGGNZMUHOHGHBJ-UHFFFAOYSA-N dioxepane Chemical compound C1CCOOCC1 HGGNZMUHOHGHBJ-UHFFFAOYSA-N 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- YDEXUEFDPVHGHE-GGMCWBHBSA-L disodium;(2r)-3-(2-hydroxy-3-methoxyphenyl)-2-[2-methoxy-4-(3-sulfonatopropyl)phenoxy]propane-1-sulfonate Chemical compound [Na+].[Na+].COC1=CC=CC(C[C@H](CS([O-])(=O)=O)OC=2C(=CC(CCCS([O-])(=O)=O)=CC=2)OC)=C1O YDEXUEFDPVHGHE-GGMCWBHBSA-L 0.000 description 1
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical compound CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 101150012763 endA gene Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- RQIFXTOWUNAUJC-UHFFFAOYSA-N ethanesulfinic acid Chemical compound CCS(O)=O RQIFXTOWUNAUJC-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LSGWSXRILNPXKJ-UHFFFAOYSA-N ethyl oxirane-2-carboxylate Chemical class CCOC(=O)C1CO1 LSGWSXRILNPXKJ-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WCVXAYSKMJJPLO-UHFFFAOYSA-N furan Chemical compound C=1C=COC=1.C=1C=COC=1 WCVXAYSKMJJPLO-UHFFFAOYSA-N 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical class C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 101150023497 mcrA gene Proteins 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- XNEFVTBPCXGIRX-UHFFFAOYSA-N methanesulfinic acid Chemical compound CS(O)=O XNEFVTBPCXGIRX-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- VNXBKJFUJUWOCW-UHFFFAOYSA-N methylcyclopropane Chemical compound CC1CC1 VNXBKJFUJUWOCW-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- QPYOEKUUIVLDGT-UHFFFAOYSA-N n-hydroxy-1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)NO)=CC2=C1 QPYOEKUUIVLDGT-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical class [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- 101150000069 nupC gene Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- GHCAUEMXBSLMGU-UHFFFAOYSA-N oxadiazole;1,2,5-oxadiazole Chemical compound C=1C=NON=1.C1=CON=N1 GHCAUEMXBSLMGU-UHFFFAOYSA-N 0.000 description 1
- GUVKYQNSMXSMMU-UHFFFAOYSA-N oxane Chemical compound C1CCOCC1.C1CCOCC1 GUVKYQNSMXSMMU-UHFFFAOYSA-N 0.000 description 1
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical compound C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 description 1
- AZHVQJLDOFKHPZ-UHFFFAOYSA-N oxathiazine Chemical compound O1SN=CC=C1 AZHVQJLDOFKHPZ-UHFFFAOYSA-N 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930006728 pinane Natural products 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003215 pyranoses Chemical class 0.000 description 1
- CRTBNOWPBHJICM-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1.C1=CN=CC=N1 CRTBNOWPBHJICM-UHFFFAOYSA-N 0.000 description 1
- UBRJWPDONDYLLX-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1.C1CNNC1 UBRJWPDONDYLLX-UHFFFAOYSA-N 0.000 description 1
- IOXGEAHHEGTLMQ-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1.C1=CC=NN=C1 IOXGEAHHEGTLMQ-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- YMXFJTUQQVLJEN-UHFFFAOYSA-N pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000018612 quorum sensing Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- KZOJQMWTKJDSQJ-UHFFFAOYSA-M sodium;2,3-dibutylnaphthalene-1-sulfonate Chemical compound [Na+].C1=CC=C2C(S([O-])(=O)=O)=C(CCCC)C(CCCC)=CC2=C1 KZOJQMWTKJDSQJ-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 150000003451 sulfinic acid amides Chemical class 0.000 description 1
- 150000003453 sulfinic acid esters Chemical class 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 108010078552 syringomycin Proteins 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000003666 tauryl group Chemical group [H]N([H])C([H])([H])C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
- BQAJJINKFRRSFO-UHFFFAOYSA-N thiolane Chemical compound C1CCSC1.C1CCSC1 BQAJJINKFRRSFO-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- WEMNATFLVGEPEW-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- PTNLHDGQWUGONS-UHFFFAOYSA-N trans-p-coumaric alcohol Natural products OCC=CC1=CC=C(O)C=C1 PTNLHDGQWUGONS-UHFFFAOYSA-N 0.000 description 1
- PTNLHDGQWUGONS-OWOJBTEDSA-N trans-p-coumaryl alcohol Chemical compound OC\C=C\C1=CC=C(O)C=C1 PTNLHDGQWUGONS-OWOJBTEDSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C243/32—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/68—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to methods and compounds for controlling virulence in bacteria, methods of identifying further compounds for controlling virulence in bacteria, and methods, compounds, and compositions for treating subjects with bacterial infections to reduce virulence of bacteria in said subjects.
- GacS/GacA is a two component signal transduction system (“TCSTS") that is widely distributed in many bacteria to respond to environmental stimuli and adapt to different environmental conditions.
- TCS is a putative histidine kinase sensor and GacA is the response regulator.
- the homologs of the TCSTS of GacS/GacA have been reported in a variety of Gram-negative bacteria, including E. coli (BarA/UvrY), Pectobacterium spp., S. typhimurium (BarA/SirA), Pseudomonas spp. (GacS/GacA), Legionella pneumophila (LetS/LetA) and Vibrio species.
- GacS/GacA and homologous systems regulate many virulence factors including, but not limited to, regulatory RNA, quorum sensing ("QS") signals, type III secretion system (“T3SS”) genes, pectate lyases, proteases, biofilm formation, and toxins.
- QS quorum sensing
- T3SS type III secretion system
- the T3SS of Dickeya dadantii which belongs to Group I T3SS of phytobacteria, is regulated by a HrpX/Y- HrpS-HrpL pathway.
- the two-component system HrpX HrpY activates the gene encoding HrpS, which is required for expression of hrpL.
- HrpL an alternative sigma factor, further activates expression of genes encoding the T3SS apparatus and its secreted products.
- the GacS/GacA and HrpX/HrpY TCSTS systems both exert a regulatory effect in D. dadantii, in particular through the T3SS system.
- the invention may provide a method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein, such as compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI) and Formula (VII) described herein.
- a compound described herein such as compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI) and Formula (VII) described herein.
- the invention may provide a compound selected from the
- FIG 1 shows a regulatory network of type III secretion system (T3SS) regulatory pathways of Dickeya dadantii 3937 (Ech3937).
- T3SS type III secretion system
- Figures 2A and 2B show the promoter activities of hrpN in Dickeya dadantii 3937
- Figure 3 shows the promoter activities of hrpA, hrpN, hrpL, and hrpS in Dickeya dadantii 3937 (Ech3937) and hrpL mutant WPP96 using FACS analysis.
- Figure 4 shows the relative mRNA level of hrpY, hrpS, hrpL, dspE, hrpA, rsmB, and gacA of Dickeya dadantii 3937 (Ech3937) using quantitative RT-PCR (qRT-PCR).
- Figure 5 shows the promoter activity of hrpN of Dickeya dadantii 3937 (Ech3937), hrpS mutant WPP90, hrpX mutant WPP67, hrpY mutant WPP92, and Ech3937 (pAT) using
- Figure 6A shows biofilm and pellicle formation in SOBG broth.
- Figure 6B shows cross sections of the pellicle observed with scanning electron microscopy at different magnifications.
- Figure 7 shows pectate lyase (Pel), protease (Prt), and cellulase (Cel) production of wild-type Ech-Rif, gacA mutant Ech137, and gacA mutant complemented strain Ech137 (pCLgacA) examined by plate assays.
- Figure 8 shows spectrophotometric quantification of pectate lyase (Pel) activity for Ech-Rif, gacA mutant Ech137, and the complementary strain Ech137 (pCLgacA).
- Figure 9 shows promoter activity of pelD and pelL in Ech-Rif (black line with black filling) and gacA mutant Ech137 (gray line).
- Figure 10A shows relative levels of rsmA, rsmB, rsmC, and hrpL mRNA in gacA mutant Ech137 compared with wild-type Ech-Rif grown for 6 or 12 h in a minimal medium.
- Figure 10B shows relative levels of gacA and rsmB mRNA in gacA mutant Ech137 and gacA mutant complemented strain Ech137 (pCLgacA) compared with wild-type Ech-Rif grown for 12 h in a minimal medium.
- Figure 11 shows local maceration lesions caused by a, Ech-Rif; b, gacA mutant Ech137; and c, complemented strain Ech137 (pCLgacA).
- Figure 12 shows the bacterial population and pectinase activity of Ech-Rif (solid diamonds) and Ech137 (solid triangles) determined by plate assay and spectrophotometric quantification, respectively.
- Figure 13 shows the development of systemic symptoms caused by Ech-Rif and Ech137 strains in African violet cv. Gauguin (Saintpaulia ionantha) plants.
- Figure 14 shows the relative mRNA level of hrpS, hrpL, dspE, hrpA, hrpN, and rsmB of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) supplemented with 0.1 mM p-coumaric acid (PCA) compared to those in MM without PCA.
- MM minimum medium
- PCA 0.1 mM p-coumaric acid
- Figure 15 shows HrpN protein expression of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) and MM supplemented with p-Coumaric acid (PCA).
- Figures 16A and 16B show the promoter activities of hrpA in Dickeya dadantii
- Figure 17 shows pectate lyase (Pel) production of Dickeya dadantii 3937
- Figure 18 shows a scheme for synthesis of various compounds.
- Figure 19 shows a scheme for synthesis of various compounds.
- Figure 20 shows a scheme for synthesis of various compounds.
- Figure 21 shows a scheme for synthesis of various compounds.
- Figure 22 are graphs of the effect of different concentrations of compound 103 on hrpA expression.
- Figure 23 shows a Northern blot for rsmB RNA of bacterial cells cultured in media supplemented with compound 103.
- Figure 24 shows a scheme for synthesis of various compounds.
- Figure 25 shows a scheme for synthesis of various compounds.
- Figure 26 shows a scheme for synthesis of various compounds.
- Figure 27 shows a scheme for synthesis of various compounds.
- Figure 28 shows a scheme for synthesis of various compounds.
- Figure 29 shows a scheme for synthesis of various compounds.
- Figure 30 shows a scheme for synthesis of various compounds.
- Figure 31 shows a Table of Bacterial strains, plasmids, and primers used in this study.
- Figure 32 shows the compounds screened for Pseudomonas syringae pv. tomato DC3000 (DC3000) hrpA inducers and inhibitors. Expression of DC3000 hrpA in HIM or HIM supplemented with different compounds.
- Figure 33 shows a hrpA promoter activity and growth of Pseudomonas syringae pv. tomato DC3000 carrying GFP reporter plasmid phrpA grown in HIM supplemented with different concentrations of TCA at (A) 6 h and (B) 9 h of growth.
- Figure 35 shows an HrpW immunoblot analysis was performed using anti-HrpW polyclonal antibody. Samples were taken at two different time points; 9 h and 12 h after subculturing cells into HIM medium. Chemiluminescent signals were detected by 6 min and 8 min exposure for cytoplasmic and supernatant fractions, respectively. Lane 1 , Pseudomonas syringae pv. tomato DC3000 (DC3000) in HIM; lane 2, DC3000 in HIM supplemented with DMSO; lane 3, DC3000 in HIM supplemented with 250 ⁇ TCA.
- DC3000 tomato DC3000
- Figure 36 shows: Bacterial suspension of Pseudomonas syringae pv. tomato DC3000 (DC3000) was diluted to 6* 10 5 CFU/ml in dH 2 0 and 0.02% Silwet L-77 for dip- inoculation.
- A DC3000 supplemented with 250 ⁇ of 001. No lesions of bacterial speck were observed in tomato plants treated with TCA.
- B DC3000 alone.
- Figure 37 shows the effects of compounds on exoS expression and bacterial growth. Gray lines represent the exoS expression levels of the cells treated with DMSO.
- Figure 38 shows an evaluation of the dose-dependent effect of compounds on exoS expression.
- Dose-dependent effect of (A) T3 inhibitors or (B) T3 inducers on exoS expression.
- X-axis represents the relative exoS expression level (compound/DMSO).
- Black lines represent asymptotic lines for the DMSO-treated samples.
- Figure 39 shows an evaluation of the dose-dependent effect of compounds on P. aeruginosa growth.
- X-axis represents the relative cell density (compound/DMSO).
- Black- lines represent asymptotic lines for the DMSO-treated samples.
- Figure 40 shows an evaluation of the dose-dependent effect of compounds on exoS expression and cell populations.
- X-axis MFI (mean fluorescence intensity);
- Y-axis cell number;
- Z-axis concentration of the compound.
- a regulatory role for the two-component system GacS/GacA on the type III secretion system ("T3SS") of Dickeya dadantii 3937 (Ech3937) has been demonstrated to channel through a regulator of secondary metabolism (Rsm) system.
- Rsm is a novel type of post-transcriptional regulatory system that plays a critical role in gene expression.
- RsmA is a small RNA-binding protein that acts by lowering the half-life of the target mRNA.
- rsmB is an untranslated regulatory RNA that binds RsmA and inhibits its activity by forming an inactive ribonucleoprotein complex.
- GacS/GacA upregulates hrpL mRNA through a post-transcriptional regulation by enhancing the rsmB RNA level, which binds to RsmA and inhibits the hrpL mRNA decay effect of RsmA ( Figure 1 ).
- FIG. 1 shows a regulatory network of type III secretion system (T3SS) of Dickeya dadantii 3937 (Ech3937). Lines with a (+) symbol designate positive regulation, and the line with a (-) symbol indicates negative regulation.
- the T3SS of Ech3937 is regulated by the HrpX/HrpY-HrpS-HrpL and GacS/GacA-rsmS-HrpL regulatory pathways.
- the two- component system HrpX/HrpY activates the gene encoding a o54-enhancer HrpS, which is required for expression of an alternative sigma factor, hrpL. HrpL further activates expression of genes encoding the T3SS apparatus and its secreted products.
- the T3SS contributes to bacterial virulence within a host.
- a gacA deletion mutant of Dickeya dadantii (Erwinia chrysanthemi 3937) was found to exhibit diminished production of pectate lyase, protease, and cellulose, enzymes that normally lead to loss of structural integrity of plant cell walls. Diminished production of enzymes that attack the plant cell walls leads to diminished bacterial virulence.
- OCA o-coumaric acid
- TCA ⁇ -cinnamic acid
- the inventors have screened compounds, including i-cinnamic acid, o-coumaric acid, m-coumaric acid, p-coumaric acid, hydrocinnamic acid, phenoxyacetic acid, frans-2-phenylcyclopropane-1-carboxylic acid, frans-3-(3-pyridyl) acrylic acid, trans-3- indoleacrylic acid, 2-methylcinnamic acid, 2-chlorocinnamic acid, methyl frans-cinnamate, and cinnamyl alcohol.
- compounds including i-cinnamic acid, o-coumaric acid, m-coumaric acid, p-coumaric acid, hydrocinnamic acid, phenoxyacetic acid, frans-2-phenylcyclopropane-1-carboxylic acid, frans-3-(3-pyridyl) acrylic acid, trans-3- indoleacrylic acid, 2-methylcinn
- PCA p-coumaric acid
- cinnamyl alcohol Two compounds, p-coumaric acid (PCA) and cinnamyl alcohol, were found to reduce induction of virulence in Dickeya dadantii. Without being limited as to theory, PCA appears to reduce virulence through the HrpX/HrpY system (see Figure 1 , Example 10).
- the synthesized compounds were tested for an ability to reduce virulence of bacteria having a two-component signal transduction system such as a GacS/GacA system (or a homolog of the GacS/GacA system), a HrpX/HrpY system (or a homolog of the HrpX/HrpY system), an Rsm system (or homolog), and/or a T3SS system (or homolog).
- a two-component signal transduction system such as a GacS/GacA system (or a homolog of the GacS/GacA system), a HrpX/HrpY system (or a homolog of the HrpX/HrpY system), an Rsm system (or homolog), and/or a T3SS system (or homolog).
- the compounds produced for testing include compounds referred to herein as "phenylpropanoid derivatives.”
- phenylpropanoid derivatives A description of phenylpropanoid derivatives generally is found in U.S. Patent Application No. 12/595,148, filed October 8, 2009, and incorporated herein by reference in its entirety.
- Alkyl refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated).
- alkyl includes the sub-classes alkenyl, alkynyl, cycloalkyl, cycloalkyenyl, cylcoalkynyl, etc., discussed below.
- the prefixes denote the number of carbon atoms, or range of number of carbon atoms.
- C ⁇ alkyl as used herein, pertains to an alkyl group having from 1 to 4 carbon atoms.
- groups of alkyl groups include alkyl ("lower alkyl"), C 1-7 alkyl, C 1-2 o alkyl and Ci-3o alkyl.
- the first prefix may vary according to other limitations; for example, for unsaturated alkyl groups, the first prefix must be at least 2; for cyclic and branched alkyl groups, the first prefix must be at least 3; etc.
- saturated alkyl groups include, but are not limited to, methyl (Ci), ethyl (C 2 ), propyl (C 3 ), butyl (C 4 ), pentyl (C 5 ), hexyl (C 6 ), heptyl (C 7 ), octyl (C 8 ), nonyl (C 9 ), decyl (C 10 ), undecyl (C ), dodecyl (C 12 ), tridecyl (C 13 ), tetradecyl (C 14 ), pentadecyl (Ci 5 ), and eicodecyl (C 20 ).
- saturated linear alkyl groups include, but are not limited to, methyl (d), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (amyl) (C 5 ), n-hexyl (C 6 ), and n-heptyl (C 7 ).
- saturated branched alkyl groups include iso-propyl (C 3 ), iso-butyl (C 4 ), sec-butyl (C ), tert-butyl (C 4 ), iso-pentyl (C 5 ), and neo-pentyl (C 5 ).
- Alkenyl refers to an alkyl group having one or more carbon-carbon double bonds. Examples of groups of alkenyl groups include C 2-4 alkenyl, C 2 . 7 alkenyl, C 2 . 20 alkenyl.
- Alkynyl refers to an alkyl group having one or more carbon-carbon triple bonds. Examples of groups of alkynyl groups include C 2 alkynyl, C 2 . 7 alkynyl, C 2 . 2 o alkynyl.
- Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C ⁇ CH) and 2-propynyl (propargyl, -CH 2 -C ⁇ CH).
- Cycloalkyl refers to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound, which carbocyclic ring may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated), which moiety has from 3 to 20 carbon atoms (unless otherwise specified), including from 3 to 20 ring atoms.
- cycloalkyl includes the sub-classes cycloalkyenyl and cycloalkynyl.
- each ring has from 3 to 7 ring atoms.
- groups of cycloalkyl groups include C 3 . 3 o cycloalkyl, C 3 . 2 o cycloalkyl, C 3 .i 0 cycloalkyl, C 3 . 7 cycloalkyl.
- cycloalkyl groups include, but are not limited to, those derived from: saturated monocyclic hydrocarbon compounds (cyclopropane (C 3 ), cyclobutane (C 4 ), cyclopentane (C 5 ), cyclohexane (C 6 ), cycloheptane (C 7 ), methylcyclopropane (C 4 ), dimethylcyclopropane (C 5 ), methylcyclobutane (C 5 ), dimethylcyclobutane (C 6 ), methylcyclopentane (C 6 ), dimethylcyclopentane (C 7 ), methylcyclohexane (C 7 ), dimethylcyclohexane (C 8 ), menthane (C 10 )); unsaturated monocyclic hydrocarbon compounds (cyclopropene (C 3 ), cyclobutene (C 4 ), cyclopentene (C 5 ), cyclohexene (C 6 ), methylcyclo
- Hydroxyalkyl refers to an alkyl group in which a hydrogen atom has been replaced with a hydroxyl group.
- Heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms.
- each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.
- the prefixes denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms.
- the term "C 5 ⁇ heterocyclyl” as used herein pertains to a heterocyclyl group having 5 or 6 ring atoms. Examples of groups of heterocyclyl groups include C 3-30 heterocyclyl, C 3 . 20 heterocyclyl, Cs.
- heterocyclyl C 3- i 5 heterocyclyl, Cs-is heterocyclyl, C 3- 2 heterocyclyl, C5.i 2 heterocyclyl, C 3 .i 0 heterocyclyl, C 5 . 10 heterocyclyl, C 3 . 7 heterocyclyl, C$. 7 heterocyclyl, and heterocyclyl.
- Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from: aziridine (C 3 ), azetidine (C 4 ), pyrrolidine (tetrahydropyrrole) (C 5 ), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C 5 ), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C 5 ), piperidine (C 6 ), dihydropyridine (C 6 ), tetrahydropyridine (C 6 ), azepine (C 7 ); ⁇ oxirane (C 3 ), oxetane (C 4 ), oxolane (tetrahydrofuran) (C 5 ), oxole (dihydrofuran) (C 5 ), oxane (tetrahydropyran) (C 6 ), dihydropyran (C 6 ),
- substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C 5 ), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C 6 ), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.
- furanoses C 5
- arabinofuranose such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse
- pyranoses C 6
- allopyranose altropyranose
- glucopyranose glucopyranose
- mannopyranose gulopyranose
- idopyranose galactopyranose
- Aryl refers to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified). Preferably, each ring has from 5 to 7 ring atoms.
- the prefixes denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms.
- C 5 -6 aryl as used herein, pertains to an aryl group having 5 or 6 ring atoms. Examples of groups of aryl groups include C 3 . 30 aryl, C 3 .
- the ring atoms may be all carbon atoms, as in "carboaryl groups".
- carboaryl groups include C 3 . 20 carboaryl, C 5 . 20 carboaryl, Cs-is carboaryl, C 5-12 carboaryl, C 5 . 10 carboaryl, C 5 . 7 carboaryl, C5-3 carboaryl and C 6 carboaryl.
- carboaryl groups include, but are not limited to, those derived from benzene (i.e., phenyl) (C 6 ), naphthalene (C 0 ), azulene (C 10 ), anthracene (Ci 4 ), phenanthrene (C 14 ), naphthacene (C 18 ), and pyrene (C 16 ).
- aryl groups which comprise fused rings include, but are not limited to, groups derived from indane (e.g., 2,3-dihydro- 1 H-indene) (C 9 ), indene (C 9 ), isoindene (C 9 ), tetraline (1 ,2,3,4-tetrahydronaphthalene (C 0 ), acenaphthene (Ci 2 ), fluorene (C 3 ), phenalene (Ci 3 ), acephenanthrene (C 15 ), and aceanthrene (C 16 ).
- indane e.g., 2,3-dihydro- 1 H-indene
- indene C 9
- isoindene C 9
- tetraline (1 ,2,3,4-tetrahydronaphthalene
- acenaphthene Ci 2
- fluorene C 3
- phenalene Ci 3
- acephenanthrene
- the ring atoms may include one or more heteroatoms, as in "heteroaryl groups".
- heteroaryl groups include C 3 . 20 heteroaryl, CS-M heteroaryl, C 5 . 15 heteroaryl, Cs. 12 heteroaryl, C5.10 heteroaryl, C 5-7 heteroaryl, ⁇ heteroaryl, C 5 heteroaryl, and C 6 heteroaryl.
- Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from: pyrrole (azole) (C 5 ), pyridine (azine) (C 6 ); 0 ⁇ : furan (oxole) (C 5 ); S,: thiophene (thiole) (C 5 ); ⁇ , ⁇ , oxazole (C 5 ), isoxazole (C 5 ), isoxazine (C 6 ); N 2 0 ⁇ oxadiazole (furazan) (C 5 ); N3O1: oxatriazole (C 5 ); NTSI: thiazole (C 5 ), isothiazole (C 5 ); N 2 : imidazole (1 ,3-diazole) (C 5 ), pyrazole (1 ,2-diazole) (C 5 ), pyridazine (1 ,2-diazine) (C 6 ), pyrimidine (1
- heteroaryl groups which comprise fused rings include,' but are not limited to: C 9 heteroaryl groups (with 2 fused rings) derived from benzofuran (O ⁇ ), isobenzofuran (O1), indole (N ⁇ , isoindole (N ⁇ , indolizine ( ⁇ , indoline (N ⁇ , isoindoline (N ⁇ , purine (N 4 ) (e.g., adenine, guanine), benzimidazole (N 2 ), indazole (N 2 ), benzoxazole (NTCM), benzisoxazole (NiOi), benzodioxole (0 2 ), benzofurazan (N 2 Oi), benzotriazole (N 3 ), benzothiofuran (Si), benzothiazole (NTSI), benzothiadiazole (N 2 S); Ci 0 heteroaryl groups (with 2 fused rings) derived from chromene ( ⁇ ), isobenzofur
- Heteroaryl groups which have a nitrogen ring atom in the form of an -NH- group may be N-substituted, that is, as -NR-.
- pyrrole may be N-methyl substituted, to give N-methylpyrrole.
- N-substituents include, but are not limited to C1.7 alkyl, C 3 . 20 heterocyclyl, C5. 2 o aryl, and acyl groups.
- quinoline may be substituted to give quinoline N-oxide; pyridine to give pyridine N-oxide; benzofurazan to give benzofurazan N- oxide (also known as benzofuroxan).
- the above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below.
- Halo -F, -CI, -Br, and -I.
- Ether -OR, wherein R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a alkoxy group, discussed below), a C3-20 heterocyclyl group (also referred to as a C 3 . 2 o heterocyclyloxy group), or a C 5 . 20 aryl group (also referred to as a C5.20 aryloxy group), preferably a C -7 alkyl group.
- R is an ether substituent, for example, a C 1-7 alkyl group (also referred to as a alkoxy group, discussed below), a C3-20 heterocyclyl group (also referred to as a C 3 . 2 o heterocyclyloxy group), or a C 5 . 20 aryl group (also referred to as a C5.20 aryloxy group), preferably a C -7 alkyl group.
- R is an ether substituent, for example, a C 1-7 alkyl group (also referred
- Alkoxy -OR, wherein R is an alkyl group, for example, a 0 1-7 alkyl group.
- C alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec- butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).
- Acetal -CH(OR) 2 , wherein each R is independently an acetal substituents, for example, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a C 1-7 alkyl group, or, in the case of a "cyclic" acetal group, R and R 2 , taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms.
- acetal groups include, but are not limited to, -CH(OMe) 2 , -CH(OEt) 2 , and -CH(OMe)(OEt).
- Hemiacetal -CH(OH)(OR), wherein R is a hemiacetal substituent, for example, a Ci- alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a C 1- alkyl group.
- R is a hemiacetal substituent, for example, a Ci- alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a C 1- alkyl group.
- hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and - CH(OH)(OEt).
- Ketal -CR(OR) 2 , where each R is defined as for acetals, and each R is independently a ketal substituent other than hydrogen, for example, a d. 7 alkyl group, a C3-20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a C 1-7 alkyl group.
- ketal groups include, but are not limited to, -C(Me)(OMe) 2 , -C(Me)(OEt) 2 , -C(Me)(OMe)(OEt), - C(Et)(OMe) 2 , -C(Et)(OEt) 2 , and -C(Et)(OMe)(OEt).
- Hemiketal -CR(OH)(OR), where R is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci- alkyl group.
- hemiacetal groups include, but are not limited to, -C(Me)(OH)(OMe), -C(Et)(OH)(OMe), -C(Me)(OH)(OEt), and -C(Et)(OH)(OEt).
- Imino (imine): NR, wherein R is an imino substituent, for example, hydrogen, C 1 .7 alkyl group, a C 3 . 20 heterocyclyl group, or a C5.20 aryl group, preferably hydrogen or a C 1-7 alkyl group.
- R is an acyl substituent, for example, a C 1-7 alkyl group (also referred to as C . 7 alkylacyl or C,. 7 alkanoyl), a C 3 - 2 o heterocyclyl group (also referred to as C 3 . 2 o heterocyclylacyl), a C 5 . 2 o aryl group (also referred to as C 5 . 2 o arylacyl), preferably a C1.7 alkyl group or a halo.
- R is an acyl substituent, for example, a C 1-7 alkyl group (also referred to as C . 7 alkylacyl or C,. 7 alkanoyl), a C 3 - 2 o heterocyclyl group (also referred to as C 3 . 2 o heterocyclylacyl), a C 5 . 2 o aryl group (also referred to as C 5 . 2 o arylacyl), preferably a C1.7 alkyl
- R is an acyloxy substituent, for example, a C1.7 alkyl group, a C 3 . 20 heterocyclyl group, or a C ⁇ o aryl group, preferably a C 1-7 alkyl group.
- Oxycarboyloxy: -OC( 0)OR, wherein R is an ester substituent, for example, a C 1-7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci. 7 alkyl group.
- each R is independently an amino substituent, for example, hydrogen, a C 1-7 alkyl group (also referred to as Ci_ 7 alkylamino or di-C 1-7 alkylamino), a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably H or a C 1-7 alkyl group, or, in the case of a "cyclic" amino group, both R's, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms.
- a C 1-7 alkyl group also referred to as Ci_ 7 alkylamino or di-C 1-7 alkylamino
- a C 3 . 20 heterocyclyl group or a C 5 . 20 aryl group, preferably H or a C 1-7 alkyl group, or, in the case of a "cyclic" amino group, both R's, taken together with the nitrogen atom to which they are attached, form a hetero
- Amino groups may be primary (-NH 2 ), secondary (-NHR), or tertiary (-NHR 2 ), and in cationic form, may be quaternary (- + NR 3 ).
- Examples of amino groups include, but are not limited to, -NH 2 , -NHCH 3 , -NHC(CH 3 ) 2 , -N(CH 3 ) 2 , -N(CH 2 CH 3 ) 2 , and -NHPh.
- Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.
- Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): -C( 0)NR 2 , wherein each R is independently an amino substituent, as defined for amino groups.
- R 10 is an amide substituent, for example, hydrogen, a C- ⁇ . 7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 20 aryl group, preferably hydrogen or a alkyl group
- R 1 is an acyl substituent, for example, a Ci -7 alkyl group, a C 3-20 heterocyclyl group, or a C 5 - 2 oaryl group, preferably hydrogen or a C ⁇ . 7 alkyl group.
- R 0 and R 1 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl: succinimidyl maleimidyl phthalimidyl
- each R is independently an amino substituent, as defined for amino groups, and R 12 is a ureido substituent, for example, hydrogen, a C 1-7 alkyl group, a C 3 . 20 heterocyclyl group, or a Cs ⁇ o aryl group, preferably hydrogen or a alkyl group.
- ureido groups include, but are not limited to, -NHCONH 2 , -NHCONHMe, -NHCONHEt, -NHCONMe 2 , -NHCONEt 2 , -NMeCONH 2 , -NMeCONHMe, -NMeCONHEt, - NMeCONMe 2 , and -NMeCONEt 2 .
- Imino: NR, wherein R is an imino substituent, for example, for example, hydrogen, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C ⁇ o aryl group, preferably H or a C 1-7 alk l group.
- C 1-7 alkylthio groups include, but are not limited to, -SCH 3 and -SCH 2 CH 3 .
- Disulfide -SS-R, wherein R is a disulfide substituent, for example, a C1.7 alkyl group, a C 3-20 heterocyclyl group, or a C5-20 aryl group, preferably a C1.7 alkyl group (also referred to herein as C -7 alkyl disulfide).
- C1.7 alkyl disulfide groups include, but are not limited to, -SSCH 3 and -SSCH 2 CH 3 .
- Sulfine (sulfinyl, sulfoxide): -S( 0)R, wherein R is a sulfine substituent, for example, a alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C1.7 alkyl group.
- R is a sulfine substituent, for example, a alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C1.7 alkyl group.
- Sulfone (sulfonyl): -S( 0) 2 R, wherein R is a sulfone substituent, for example, a Ci.7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C 1-7 alkyl group, including, for example, a fluorinated or perfluorinated Ci_ 7 alkyl group.
- R is a sulfone substituent, for example, a Ci.7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C 1-7 alkyl group, including, for example, a fluorinated or perfluorinated Ci_ 7 alkyl group.
- Sulfonic acid sulfo
- Sulfinate sulfinic acid ester
- R is a sulfinate substituent, for example, a Ci- 7 alkyl group, a C3-20 heterocyclyl group, or a C5.20 aryl group, preferably a Ci_ 7 alkyl group.
- R is a sulfonate substituent, for example, a alkyl group, a C3-20 heterocyclyl group, or a C5.20 aryl group, preferably a C 1 -7 alkyl group.
- R is a sulfinyloxy substituent, for example, a alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C 1-7 alkyl group.
- R is a sulfonyloxy substituent, for example, a Ci.7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C 1-7 alkyl group.
- R is a sulfate substituent, for example, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a alkyl group.
- R is independently an amino substituent, as defined for amino groups.
- R is an amino substituent, as defined for amino groups.
- Silyl -SiR 3 , wherein each R is independently a silyl substituent, for example, H, a Ci.7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a Ci -7 alkyl group.
- phosphino groups include, but are not limited to, -PH 2 , -P(CH 3 ) 2 , -P(CH 2 CH 3 ) 2 , -P(t-Bu) 2 , and -P(Ph) 2 .
- Phosphate (phosphonooxy ester): -OP( 0)(OR) 2 , wherein each R is independently a phosphate substituent, for example, -H, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably -H, a Ci -7 alkyl group, or a C 5 . 20 aryl group.
- Phosphorous acid -OP(OH) 2 .
- Phosphite -OP(OR) 2 , wherein each R is independently a phosphite substituent, for example, -H, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably -H, a C 1-7 alkyl group, or a C ⁇ o aryl group.
- phosphite groups include, but are not limited to, -OP(OCH 3 ) 2 , -OP(OCH 2 CH 3 ) 2 , -OP(0-t-Bu) 2 , and -OP(OPh) 2 .
- Phosphoramidite -OP(OR)-NR 2 , wherein each R is independently a phosphoramidite substituent, for example, -H, a (optionally substituted) C 1-7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably -H, a Ci. 7 alkyl group, or a C 5 - 20 aryl group.
- Examples of phosphoramidite groups include, but are not limited to, -OP(OCH 2 CH 3 )- N(CH 3 ) 2 , -OP(OCH 2 CH 3 )-N(i-Pr) 2 , and -OP(OCH 2 CH 2 CN)-N(i-Pr) 2 .
- alkylene refers to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 1 to 12 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated.
- alkylene includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.
- linear saturated alkylene groups include, but are not limited to, -(CH 2 ) n - where n is an integer from 3 to 12, for example, -CH 2 CH 2 CH 2 - (propylene), -CH 2 CH 2 CH 2 CH 2 - (butylene), -CH 2 CH 2 CH 2 CH 2 CH 2 - (pentylene) and -CH 2 CH 2 CH 2 CH- 2 CH 2 CH 2 CH 2 - (heptylene).
- Examples of branched saturated alkylene groups include, but are not limited to, -CH(CH 3 )CH 2 -, -CH(CH 3 )CH 2 CH 2 -, -CH(CH 3 )CH 2 CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, -CH 2 CH(CH 3 )CH 2 CH 2 -, -CH(CH 2 CH 3 )-, -CH(CH 2 CH 3 )CH 2 -, and -CH 2 CH(CH 2 CH 3 )CH 2 -.
- alicyclic saturated alkylene groups include, but are not limited to, cyclopropylene (e.g. cycloprop-1 ,2-ylene), cyclobutylene (e.g. cyclobut-1 ,2- ylene), cyclopentylene (e.g. cyclopent-1 ,3-ylene), and cyclohexylene (e.g. cyclohex-1 ,4-ylene).
- Examples of alicyclic partially unsaturated alkylene groups include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1 ,3-ylene), cyclohexenylene (e.g. 2-cyclohexen-1 ,4-ylene; 3-cyclohexen-1 ,2-ylene; 2,5-cyclohexadien- 1 ,4-ylene).
- cyclopentenylene e.g. 4-cyclopenten-1 ,3-ylene
- cyclohexenylene e.g. 2-cyclohexen-1 ,4-ylene; 3-cyclohexen-1 ,2-ylene; 2,5-cyclohexadien- 1 ,4-ylene.
- C 1-3 alkylene as used herein, is an alkylene as defined above group and having from 1 to 3 carbon atoms.
- Alkylene includes cyclopropylene groups.
- heteroalkylene refers to an alkylene group in which at least one carbon atom has been replaced with a heteroatom such as O, S or NR, wherein R is hydrogen, a Ci_ 7 alkyl group, a C3- 20 heterocyclyl group, or a C5- 20 aryl group, preferably H or a C . 7 alkyl group .
- heteroalkylene groups include, but are not limited to, - O-CH 2 -, -NH-CH 2 -, -S-CH 2 -, -O-CH 2 -CH 2 -, -S-CH2-CH2-, -NH-CH 2 -CH 2 -, -CH 2 -0-CH 2 -, -CH 2 - S-CH 2 - and -CH 2 -NH-CH 2 -.
- Heteroalkylene groups also include cyclic heteroalkylene (heterocycloalkylene) groups, examples of which include, but are not limited to, oxirane, oxetane, aziridine and azetidine rings from which two hydrogen atoms are removed.
- GacS/GacA-type system refers to the signal transduction system in D. dadantii as well as homologous systems in other bacteria (e.g. E. coli (BarA UvrY), Pectobacterium spp., S. typhimurium (BarA/SirA), Pseudomonas spp. (GacS/GacA), and Legionella pneumophila (LetS/LetA), Vibrio species) that have a similar structure and function to the GacS/GacA system of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria.
- GacA-type polypeptide and “GacS-type polypeptide” refer to the respective polypeptides in D. dadantii as well as homologous polypeptides having similar structure and function in other bacteria.
- HrpX/HrpY-type system refers to the signal transduction system in D. dadantii as well as homologous systems in other bacteria that have a similar structure and function to the HrpX/HrpY system of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria.
- HrpY-type polypeptide and HrpX-type polypeptide refer to the respective polypeptides in D. dadantii as well as homologous polypeptides having similar structure and function in other bacteria.
- Rsm-type system refers to the regulator of secondary metabolism (Rsm) system of D. dadantii as well as homologous systems in other bacteria that have a similar structure and function to the Rsm system of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria.
- T3SS-type system refers to the type III secretion system (T3SS) of D. dadantii as well as homologous systems in other bacteria that have a similar structure and function to the T3SS of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria.
- the control conditions may include exposing the bacterium to the same conditions without contacting the bacterium with the test compound.
- Reducing virulence in a bacterium refers to altering expression of genes associated with virulence, including regulators of virulence. Reducing virulence also refers to physical and biochemical manifestations of virulence including those manifestations associated with any step of the bacterial life cycle when it is associated with a host, including without limitation the adherence, invasion, replication, evasion of host defenses, and transmittal to a new host. Reduced bacterial virulence may be manifested in the form of reduced symptoms in a host, and thus may be detected by monitoring the host for a reduced reaction to the bacteria associated therewith.
- Reduced virulence may arise as a result of either inhibition or stimulation of a two-component regulatory system such as a GacS/GacA- type system or a HrpX/HrpY-type system, which could lead to increases or decreases of polynucleotide and polypeptide production.
- reduced virulence may be associated with increase production of a repressor, reduced production of a transcription factor, or increased production of enzymes or toxins.
- Regulation of bacterial virulence may lead to alterations in the production of pectinase, exoprotease, syringomycin, syringolin, alginate, tolaasin, siderophores, pyocyanin, cyanide, lipase, type III secretion system (T3SS) genes, cholera toxin, polyhydroxybutyrate, or a polynucleotide controlled by a GacS/GacA- type system or a HrpX/HrpY-type system in a Gram negative bacterium.
- T3SS type III secretion system
- a reduction in virulence may be at least about a 1 % reduction, at least about a 10% reduction, at least about a 20% reduction, at least about a 30% reduction, at least about a 40% reduction, at least about a 50% reduction, at least about a 60% reduction, at least about a 70% reduction, at least about a 80% reduction, at least about a 90% reduction, or at least about a 100% reduction of virulence, as measured by any assay described herein or known to those of skill in the art, when measured against a suitable control.
- Components of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS- type system, and a Rsm-type system include without limitation polynucleotides and polypeptides that are part of the respective systems (including genes arid gene products of the named operons) as well as polynucleotides, polypeptides, and other molecules that regulate the systems including genes and gene products that are upstream or downstream of the system.
- “Components” also includes molecules that are products of the genes or gene products of the systems as well as genes or gene products that generate posttranslational modifications of polynucleotides or polypeptides of the systems.
- a “regulator” is a component that changes (increases or decreases) an expression or activity level of a component.
- a “repressor” is a component that decreases an expression or activity level of a component, arising from either an increase or a decrease in the amount or activity level of the repressor.
- An “effector” is a component that puts into effect the activity of the system, e.g. exoenzymes of the T3SS-type system are nonlimiting examples of effectors.
- a component is "associated with virulence” if a change in an amount or activity of the component leads, directly or indirectly, to an increase or reduction in some aspect of bacterial virulence.
- a "phenylpropanoid-type inhibitory compound” as used herein includes phenylpropanoid compounds, such as p-coumaric acid or cinnamyl alcohol, that reduce bacterial virulence.
- phenylpropanoid-type inhibitory compound also includes phenylpropanoid derivative that have been found to be “active compounds,” i.e. compounds that have shown through screening to have bacterial virulence-reducing activity.
- a bacterium is "associated with" (or “associated therewith") a host or subject such as a plant or animal (including a human) when the bacterium is in or on the host or subject.
- a host or subject such as a plant or animal (including a human) when the bacterium is in or on the host or subject.
- an associated bacterium can be on a plant part such as a root, stem, leaf, flower, or fruit of the plant, or in the soil adjacent to the roots or base of the stem.
- an associated bacterium can be on the outer surface of the animal or on an inner surface such as an intestinal surface, or the associated bacterium can be within the animal, e.g. in a tissue or fluid of the animal or any other internal portion of the animal.
- Treating or “treatment,” as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human, an animal (e.g. in veterinary applications), or plants, in which some desired therapeutic effect is achieved, for example, the reduction of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e. prophylaxis) is also included. “Treating” and “treatment” also refer to reducing the symptoms associated with the condition that is being treated.
- Effective amount when used herein in the context of contacting a bacterium associated with a plant with a compound described herein, refers to an amount of a compound that can be therapeutically effective to inhibit, prevent or treat the symptoms of particular disease, disorder, or side effect, particularly those associated with bacterial virulence.
- An effective amount of the active compound may be used alone or as part of a composition as described herein.
- an effective amount of active compound in the composition may be from about 0.1 ⁇ g/g to about 0.9 g/g, about 1 pg/g to about 100 mg/g, about 10 pg/g to about 10 mg/g, and about 100 pg/g to about 1 mg/g.
- the amount of active compound applied to a surface may be about 0.1 pg/sq.ft., about 1 pg/sq.ft., about 10 pg/sq.ft., about 100 pg/sq.ft., about 1 mg/sq.ft., about 10 mg/sq.ft., about 100 mg/sq.ft., about 1 g/sq.ft., about 10 g/sq.ft., or about 100 g/sq.ft.
- Effective amount when used herein in the context of contacting a bacterium associated with an animal (e.g., a human) with a compound described herein, refers to an amount of a compound that can be therapeutically effective to inhibit, prevent or treat the symptoms of particular disease, disorder, or side effect, particularly those associated with bacterial virulence.
- an effective amount of the active compound may be used alone or as part of a composition as described herein to treat an animal subject having a bacterium associated therewith in order to reduce the virulence of the bacterium.
- the composition may be prepared as appropriate for oral, topical, pulmonary, parenteral, or other route of administration.
- the concentration of active compound in the composition may be from about 0.1 pg/g to about 0.9 g/g, about 1 pg/g to about 100 mg/g, about 10 pg/g to about 10 mg/g, and about 100 pg/g to about 1 mg/g.
- the dose to the subject may be about 0.1 pg/kg body weight to about 1.0 g/kg body weight, about 1 pg/kg body weight to about 100 mg/kg body weight, about 10 pg/kg body weight to about 10 mg/kg body weight, and about 100 pg/kg body weight to about 1 mg/kg body weight.
- Effective amount when used herein in the context of contacting a bacterium associated with a surface with a compound described herein, refers to an amount of the active compound that can be effective to reduce virulence of a bacterium associated with a surface when the compound, or a composition comprising the compound, is administered to a surface that includes the bacterium.
- An effective amount of the active compound may be used alone or as part of a composition as described herein.
- an effective amount of the active compound in the composition may be from about 0.1 pg/g to about 0.9 g/g, about 1 pg/g to about 100 mg/g, about 10 pg/g to about 10 mg/g, and about 100 pg/g to about 1 mg/g.
- the amount of active compound applied to a surface may be about 0.1 pg/sq.ft., about 1 pg/sq.ft., about 10 pg/sq.ft., about 100 pg/sq.ft., about 1 mg/sq.ft., about 10 mg/sq.ft., about 100 mg/sq.ft., about 1 g/sq.ft., about 10 g/sq.ft., or about 100 g/sq.ft.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g., human or other animal) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a subject e.g., human or other animal
- Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- substituent groups are specified by their conventional chemical formulae, written from left to right, they optionally encompass substituents resulting from writing the structure from right to left, e.g., -CH 2 0- optionally also recites -OCH 2 -.
- R is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- R4, R 5 , and R 6 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyi, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, alkylamino, formyl and heterocyclyl groups; and
- R 7 is selected from hydroxy, hydroxyalkyi, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonate, substituted or unsubstituted bicyclic heteroaromatic, and carboxamide groups.
- Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- R 2 , R5, and R 6 are each independently selected from hydrogen, hydroxy, hydroxyalkyi, alkoxy, alkyl, alkenyl, alkynyl, halo, carboxy, and amino groups;
- R 3 is selected from hydrogen, hydroxy, hydroxyalkyi and alkoxy groups
- R is selected from hydrogen, alkyl, alkenyl, alkynyl, halo, hydroxy, hydroxyalkyi and alkoxy groups
- R 7 is selected from hydroxy, hydroxyalkyi, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonate, substituted or unsubstituted bicyclic heteroaromatic, and carboxamide groups.
- Ri is C 2 -C 3 alkylene (e.g., C 2 -C 3 alkenylene or C 2 -C 3 alkynylene.
- Ri is heteroalkylene, such as -0-CH 2 - or -S-CH 2 -.
- Ri is cycloalkenylene, such as cyclopropylene.
- R is heterocycloalkylene, such as oxetane or aziridine.
- R4 is alkoxy (e.g., methoxy) or hydroxy.
- R 7 is hydroxamic acid, allylic alcohol, hydroxy, carboxy, alkoxy (e.g., methoxy), or ester (e.g., C0 2 Et). In some embodiments, R 7 is hydroxamic acid.
- the compound is compound 103:
- A is aryl or heteroaryl
- Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- n 0, 1 , 2, 3, 4 or 5;
- each R 2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, alkylamino, formyl and heterocyclyl groups;
- R 7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonate, substituted or unsubstituted bicyclic heteroaromatic, and carboxamide groups.
- A is aryl (e.g., phenyl or naphthyl).
- A is heteroaryl (e.g., thiophene, furan, indole, pyridyl, imidazole, benzofuran, benzothiofuran, quinoline or carbazole.)
- Ri is C 2 -C 3 alkylene (e.g., C 2 - C 3 alkenylene or C 2 -C 3 alkynylene).
- R is cycloalkenylene, such as cyclopropylene.
- Ri is heterocycloalkylene, such as oxetane or aziridine.
- Ri is a bond.
- n is at least 1.
- at least one R 2 is alkoxy (e.g., methoxy) or hydroxy.
- R 7 is hydroxamic acid, allylic alcohol, hydroxy, carboxy, alkoxy (e.g., methoxy), or ester (e.g., C0 2 Et).
- the compound is compound 127:
- A is aryl or heteroaryl
- Ri is selected from oxygen, sulfur and a bond
- n 0, 1 , 2, 3, 4 or 5;
- each R 2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, fomnyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
- R 7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
- A is aryl (e.g., phenyl).
- A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole).
- n is 0. In some embodiments, n is 1 or 2.
- each R 2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH 2 OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH 2 or -NMe 2 ), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups.
- R 7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., -C(0)OMe or -C(O)OEt), amino (e.g., -NH 2 ), amido (e.g., -C(0)NH 2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0) 2 OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt) 2 ), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido).
- R 7 is carboxy.
- R 7 is hydroxamic acid.
- A is aryl or heteroaryl
- alkylene is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- n 0, 1 , 2, 3, 4 or 5;
- each R 2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
- R 7 is selected from hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
- A is aryl (e.g., phenyl).
- A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole).
- Ri is heteroalkylene, such as -0-CH 2 - or -S-CH 2 -.
- R is cycloalkylene, such as cyclopropylene.
- R ⁇ is heterocycloalkylene, such as oxetane or aziridine.
- R ⁇ is a bond.
- n is 0. In some embodiments, n is 1 or 2.
- each R 2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH 2 OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH 2 or -NMe 2 ), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups.
- R 7 is selected from hydroxamic acid, hydrazinocarbonyl, amino (e.g., -NH 2 ), amido (e.g., -C(0)NH 2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0) 2 OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt) 2 ), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido).
- R 7 is hydroxamic acid.
- A is aryl or heteroaryl
- Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- n is 1 , 2, 3, 4 or 5; each R 2 is independently selected from alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, fluoro, bromo, iodo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
- R 7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
- A is aryl (e.g., phenyl).
- A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole).
- R is cycloalkylene, such as cyclopropylene. In some embodiments, R, is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, Ri is a bond. In some embodiments, n is 0. In some embodiments, n is 1 or 2.
- each R 2 is independently selected from alkyl (e.g., methyl), hydroxyalkyl (e.g., -CH 2 OH), alkoxy (e.g., methoxy), sulfhydryl, fluoro, bromo, carboxy, nitro, amino (e.g., -NH 2 or -NMe 2 ), formyl, aryl (e.g;, phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups.
- alkyl e.g., methyl
- hydroxyalkyl e.g., -CH 2 OH
- alkoxy e.g., methoxy
- sulfhydryl fluoro, bromo, carboxy, nitro, amino (e.g., -NH 2 or -NMe 2 ), formyl, aryl (e.g;, phenyl), haloalkyl (e.g., triflu
- R 7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., - C(0)OMe or -C(O)OEt), amino (e.g., -NH 2 ), amido (e.g., -C(0)NH 2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0) 2 OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt) 2 ), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido).
- R 7 is carboxy.
- R 7 is hydroxamic acid.
- A is selected from imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran and carbazole;
- Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- R 7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
- A is imidazole, thiophene or furan.
- Ri is heteroalkylene, such as -0-CH 2 - or -S-CH 2 -.
- R-i is cycloalkylene, such as cyclopropylene.
- R is heterocycloalkylene, such as oxetane or aziridine.
- Ri is a bond.
- n is 0. In some embodiments, n is 1 or 2.
- each R 2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH 2 OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH 2 or -NMe 2 ), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups.
- R 7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., -C(0)OMe or -C(O)OEt), amino (e.g., -NH 2 ), amido (e.g., -C(0)NH 2 or -C(O)NHMe), sulfonic acid, sulfonate-(e.g., - S(0) 2 OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt) 2 ), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido).
- R 7 is carboxy.
- R 7 is hydroxamic acid.
- A is aryl or heteroaryl
- alkylene is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond
- n 2, 3, 4 or 5;
- each R 2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and R 7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
- A is aryl (e.g., phenyl).
- A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole).
- R-i is C 2 -C 3 alkylene (e.g., C 2 -C 3 alkenylene or C 2 -C 3 alkynylene.
- R n is heteroalkylene, such as -O-CH2- or -S-CH2-.
- R- ⁇ is cycloalkylene, such as cyclopropylene.
- R ⁇ is heterocycloalkylene, such as oxetane or aziridine.
- Ri is a bond.
- n is 2.
- each R 2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH 2 OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH2 or -NMe 2 ), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups.
- R 7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., -C(0)OMe or -C(O)OEt), amino (e.g., -NH 2 ), amido (e.g., -C(0)NH 2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0) 2 OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt) 2 ), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido).
- R 7 is carboxy.
- R 7 is hydroxamic acid.
- the compounds described herein include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds may have the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 3 C- or 14 C-enriched carbon.
- a compound described herein can be in the form of a salt, e.g., a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt includes salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, J. Pharma. Science 1977, 66: 1-19).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- the present invention may also provide compounds that are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds described herein.
- prodrugs for carboxylic acid compounds of the invention include a variety of esters.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Compounds that may be used in the methods described herein may be synthesized using a variety of methods.
- Compounds that may be used in the methods described herein include phenylpropanoids, which are plant-derived organic compounds synthesized from phenylalanine.
- Phenylpropanoid derivatives can be made by adding or removing substituents using methods known to those of skill in the art. As shown in the Examples, phenylpropanoid derivatives such as those disclosed herein can be synthesized de novo or by modifying naturally-occurring compounds.
- ethyl cinnamates A2 are transformed to cyclopropanyl esters A7.
- the latter can be further converted to cyclopropanyl hydroxamatates A8 by TFA deprotectiori and reacting with hydroxylamine, or to the corresponding alcohols A9 by LAH reduction and TFA de-protection.
- the analogs with other heterocycles, such as indolyl, thionaphthyl, naphthyl, and other groups can be synthesized in the similar ways.
- the ethyl sulfonates D1 can be cleaved with tetra-n-butylammonium iodide (n-Bu4NI), and further deprotection with TFA affords the frans-2-arylethenylsulfonic acids D2.
- n-Bu4NI tetra-n-butylammonium iodide
- TFA tetra-n-butylammonium iodide
- cinnamic acids are converted into the corresponding methyl esters.
- the latter can be further transformed into hydroxamic acids by treating with hydroxylamine under basic condition.
- the hydroxamic acids can be obtained directly from the corresponding carboxylic acids.
- the corresponding amides can be obtained from the methyl esters.
- the esters can readily reduced by LiAIH 4 /AICI 3 system, resulting in cinnamyl alcohols.
- hydrazides can be obtained from cinnamic acids by treating with HOBt and EDC followed by hydrazine.
- benzaldehyde can reacted with ethyl diethylphosphoryl-methanesulfonate to generate ethyl frans-2-arylethenylsulfonates (Niimi et al. 2001 ) ( Figure 27).
- the resulting ethyl sulfonates can be cleaved with tetra-n- butylammonium iodide (n-Bu 4 NI), affording the frans-2-arylethenylsulfonic acids.
- Phthalimide potassium salt can be alkylated with allyl chloride in DMF to produce N-allylphthalimide. Under the Heck reaction conditions (Patel et al. 1977), N-allylphthalimide reacted with aryl bromide to give N-cinnamyl phthalimide. Upon treatment with hydrazine, cinnamyl amine was obtained from N-cinnamyl phthalimide ( Figure 28).
- Activity assays may be carried out on intact bacteria or on isolated bacterial components.
- receptor portions of the GacS/GacA-type system or HrpX/HrpY- type system may be reconstituted in vitro, e.g. in membrane microsomes, or as isolated, soluble protein components.
- the assay includes measurement of binding affinity of a test compound to the GacS-type or HrpX-type polypeptide.
- the assays may also be conducted on genetically-engineered bacteria in which the GacS/GacA-type system or HrpX/HrpY-type system is coupled to a reporter.
- a test compound can be screened by contacting the compound with an appropriately engineered bacterium so that the binding and/or activation of the GacS/GacA pathway by the compound will be directly reported without the need to assay a downstream target or effector such as a component of the Rsm pathway or T3SS system.
- the reporter in the genetically-engineered bacterium could be linked to any number of known fluorescent or colorimetric assays, e.g. green fluorescent protein (GFP), to make possible rapid screening of large numbers of compounds.
- GFP green fluorescent protein
- Various assays may be used to test the efficacy of the compounds, such as any of the assays described herein, including without limitation promoter-probe bioreporter assays, cell sorting (FACS), pectinase activity assays, qRT-PCR analysis, analysis of the phosphorylation of GacA or HrpY, leaf maceraction assays, growth kinetics assays, plate assays, analysis of pellicle formation, analysis of exoenzyme production, and spectrophotometric quantification assays.
- promoter-probe bioreporter assays include cell sorting (FACS), pectinase activity assays, qRT-PCR analysis, analysis of the phosphorylation of GacA or HrpY, leaf maceraction assays, growth kinetics assays, plate assays, analysis of pellicle formation, analysis of exoenzyme production, and spectrophotometric quantification assays.
- Assays may be performed using Dickeya dadantii or any other suitable bacterial species or strain having a GacS/GacA-type system, a HrpX/HrpY-type system, an Rsm-type system, and/or a T3SS-type system.
- Leaf maceraction assays may be carried out using leaves from any of a variety of plants, including African violet, Chinese cabbage, or witloof chicory leaves.
- PCR polymerase-chain reaction
- electrophoretic mobility-based methods such as Southern and Northern blotting may be used, among other techniques.
- the bacterium can be any one of a number of virulent bacterial species or strains, including those bacterial species or strains having at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a Rsm-type system, and/or a T3SS-type system.
- the suitable bacterial species or strains include without limitation Pseudomonas spp., E/w/n/a-related strains, Azotobacter vinelandii, Vibrio cholarae, Salmonella enterica, and Escherichia coli strains.
- the bacterium may be a Pseudomonas spp. including P. aureofaciens, P.
- the bacterium may be an Env/n/a-related strain including Dickeya dadantii, Erwinia carotovora (also known as Pectobacterium carotovorum), Erwinia atroseptica ('also known as Pectobacterium atrosepticum), and Erwinia amylovora.
- Dickeya dadantii is a member of the Enterobacteriaceae family, which includes the plant pathogens Pectobacterium carotovorum and Erwinia amylovora as well as animal and human pathogens such as E. coli, Salmonella spp., and Yersinia spp (such as Yersinia pseudotuberculosi, Yersinia enterocolitica and Yersinia pestis).
- Bacteria may further include Acidovorax spp. (such as Acidovorax avenae), Aeromonas spp.
- spp. such as Aeromonas hydrophila, Aeromonas veronii and Aeromonas salmonicida
- Bordetella spp. such as Bordetella pertussis
- Bradyrhizobium spp. such as Bradyrhizobium japonicum and Bradyrhizobium liaoningense
- Burkholderia spp. such as Burkholderia pseudomallei
- Candidatus spp. Cellvibrio spp.
- Chlamydia spp. such as Chlamydia trachomatis and Chlamydia pneumoniae
- Chromobacterium spp. such as Chromobacterium violaceum
- Citrobacter spp. such as Citrobacter rodentium
- Cupriavidus spp. Desulfovibrio spp., Dickeya spp.
- Edwardsiella spp. such as Edwardsiella tarda and Edwardsiella ictalun
- Erwinia spp. such as Erwinia chrysanthemi
- Escherichia spp. Hahella spp. (such as Hahella chejuensis), Hamiltonella spp.
- Ralstonia spp. such as Ralstonia solanacearum
- Rhizobium spp. such as Rhizobium sp. Strain NGR234
- Salmonella spp. such as Salmonella typhimurium and Salmonella enterica
- Shewanella spp. Shigella spp.
- Xanthomonas spp. such as Shigella flexneri, Sinorhizobium spp. (such as Sinorhizobium fredii), Sodalis spp., Vibrio spp. (such as Vibrio cholerae and Vrtwro parahaemolyticus), and Xanthomonas spp. (such as Xanthomonas campestris, Xanthomonas axonopodis, Xanthomonas oryzae, Xanthomonas fuscans subsp. Fuscan, Xanthomonas campestris pv. campestris, Xanthomonas campestns pv. citri, anthomonas campestris pv. oryzae, and Xanthomonas campestris pv. vesicatoria).
- results of the assays may be evaluated in accordance with the methods described herein and according to the knowledge of one skilled in the art to determine whether the compound that is tested reduces bacterial virulence. Those compounds that demonstrate activity in reducing bacterial virulence in the assays may then be used as antimicrobial compounds, for example as described herein.
- the invention may provide a method of screening a compound for an ability to reduce virulence of a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system.
- the method comprises contacting the bacterium with a compound described herein and detecting at least one of: (i) a change in a component of at least one of the GacS/GacA-type system, the HrpX/HrpY-type system, the T3SS-type system, and the Rsm-type system of the bacterium, and (ii) a change in host pathology.
- those analogs that show effective reduction may be tested for use in reducing virulence in bacteria that are associated with a subject such as a plant or an animal, including a human.
- the bacteria may be on the surface of the subject or within the subject or otherwise associated with the subject.
- Active compounds may be used in a method to treat a subject having a bacterial infection comprising administering to the subject an effective amount of a composition comprising the compound (see Examples). Active compounds may also be applied to a surface to reduce virulence of bacteria associated with the surface.
- the invention may provide a method of treating a subject having a bacterium associated therewith, the bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system.
- the method comprises administering to the subject a composition comprising an effective amount of a compound described herein.
- the invention may provide a method of reducing virulence of a bacterium on a surface comprising a bacterium having at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system.
- the method comprises contacting the surface with a composition comprising an effective amount of a compound described herein.
- the invention may provide a pharmaceutical composition comprising ah effective amount of a compound described herein, and a pharmaceutically- acceptable carrier or diluent.
- the active compounds, compositions containing the active compounds, and methods of using the same may be used with any plant including those having an appropriate TCSTS-containing bacterium associated therewith, including a bacterium having a GacS/GacA-type system or a HrpX/HrpY-type system. These plants may include cultivated, domesticated, or wild plants, including annual crops and longer-term crops such as trees. Agriculturally relevant annual crops include, without limitation, corn, soy, wheat, barley, oats, rice, sorghum, rye, alfalfa, tobacco, and sunflower.
- the compounds, compositions, and methods may be used either on terrestrial plants or on aquatic plants, including freshwater and marine-dwelling plants.
- the compounds may be formulated in compositions such as a liquid suitable for application by spraying or other mode of application; dust; granules; oil; or solid (e.g. as a spike).
- the composition may be produced in a concentrated form, including a concentrated liquid, powder, solid, or other form, which may be reconstituted prior to use.
- WP wettable powders
- SP water-soluble powders
- EW emulsifiable concentrates
- CS capsule suspensions
- DP dusting powders
- solutions which can be mixed with oils (OL) seed-dressing agents
- GR granules in the form of microgranules, spray granules, coated granules and adsorption granules, granules for broadcasting and soil application
- SG water-soluble granules
- WG water- dispersible granules
- ULV formulations microcapsules and waxes.
- Combinations with other active substances such as herbicides, fungicides or insecticides, as well as fertilizers and/or growth regulators, may also be prepared on the basis of these formulations, for example in the form of a ready-mix or as a tank mix.
- the active compound combinations according to the invention can either be a mixed formulation of the two components which are then diluted with water and applied in a customary manner, or they can be prepared as so-called tank mixes by joint dilution, with water, of the separately formulated components.
- Wettable powders are preparations which are uniformly dispersible in water and which, besides the active compound, also contain wetting agents, for example polyoxethylated alkylphenols, polyoxethylated fatty alcohols or fatty amines, alkane- or alkylbenzenesulfonates, and dispersing agents, for example sodium ligninsulfonate, sodium 2,2'-dinaphthylmethane-6,6'-disulfonate, sodium dibutylnaphthalenesulfonate, or alternatively sodium oleylmethyltaurinate, in addition to a diluent or inert substance.
- wetting agents for example polyoxethylated alkylphenols, polyoxethylated fatty alcohols or fatty amines, alkane- or alkylbenzenesulfonates
- dispersing agents for example sodium ligninsulfonate, sodium 2,2'-dinap
- Emulsifiable concentrates may be prepared by dissolving the active compound in an organic solvent, for example butanol, cyclohexanone, dimethylformamide, xylene and also higher-boiling aromatic compounds or hydrocarbons, with the addition of one or more emulsifiers.
- organic solvent for example butanol, cyclohexanone, dimethylformamide, xylene and also higher-boiling aromatic compounds or hydrocarbons.
- emulsifiers which may be used are: calcium salts of an alkylarylsulfonic acid, such as Ca dodecylbenzenesulfonate, or non-ionic emulsifiers, such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide/ethylene oxide condensation products, alkyl polyethers, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters or polyoxyethylene sorbitol esters.
- alkylarylsulfonic acid such as Ca dodecylbenzenesulfonate
- non-ionic emulsifiers such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide/ethylene oxide condensation products, alkyl polyethers, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid est
- Dusting agents may be obtained by grinding the active compound with finely divided solid substances, for example talc or natural clays, such as kaolin, bentonite, pyrophillite or diatomaceous earth.
- finely divided solid substances for example talc or natural clays, such as kaolin, bentonite, pyrophillite or diatomaceous earth.
- Granules may be produced either by spraying the active substance onto adsorptive, granulated inert material or by applying active substance concentrates onto the surface of carriers, such as sand, kaolinites or of granulated inert material, by means of binders, for example polyvinyl alcohol, sodium polyacrylate or, alternatively, mineral oils. Suitable active substances may also be granulated in the manner which is conventional for the production of fertilizer granules, if desired in a mixture with fertilizers.
- carriers such as sand, kaolinites or of granulated inert material
- binders for example polyvinyl alcohol, sodium polyacrylate or, alternatively, mineral oils.
- Suitable active substances may also be granulated in the manner which is conventional for the production of fertilizer granules, if desired in a mixture with fertilizers.
- the concentration of active compound in wettable powders may be, for example, about 10 to about 95% by weight, the remainder to 100% by weight is composed of conventional formulation components.
- the concentration of active compound may be about 1 to about 85% by weight, preferably about 5 to about 80% by weight.
- Formulations in the form of dusts usually contain about 1 to about 25% by weight, mostly about 5 to about 20% by weight of active compound, sprayable solutions about 0.2 to about 25% by weight, preferably about 2 to about 20% by weight, of active compound.
- the active compound content depends partly on whether the active compound is liquid or solid and on which granulation auxiliaries and fillers are used.
- the content in water-dispersible granules is generally between about 10 and about 90% by weight.
- the active compound formulations mentioned contain, if appropriate, the adhesives, wetting agents, dispersing agents, emulsifiers, penetrants, solvents, fillers or carriers which are conventional in each case.
- the formulations may be diluted, if appropriate, in a customary manner, for example using water in the case of wettable powders, emulsifiable concentrates, dispersions and water-dispersible granules. Preparations in the form of dusts, granules for soil application and/or broadcasting, and also sprayable solutions are usually not further diluted with other inert substances before use.
- the application rate required for the compositions varies with the external conditions, such as, inter alia, temperature, humidity, and the nature of the compound and composition used.
- compositions may be applied to different parts of the plant, including leaves, stems, roots, buds, fruits, frill, stump, bark, and roots, as well as to soil in the vicinity of a plant (e.g., the rhizosphere).
- Methods of application may include spraying, irrigating, dusting, and spreading or broadcasting of granules, powders, or other solid or liquid forms.
- composition may be applied to leaf surfaces, stems of plants including agricultural crops, and irrigated into soil to protect root systems from human and other pathogens (including, for example, E. coli 0157:1-17 on lettuce, spinach) which may be present as contaminants from exposure to animal waste.
- pathogens including, for example, E. coli 0157:1-17 on lettuce, spinach
- composition may be applied to the surfaces of stored crops (including without limitation onions, potatoes, grains, squash, melons) to reduce post-harvest infection and contamination by plant, animal, and human pathogens.
- stored crops including without limitation onions, potatoes, grains, squash, melons
- the composition may be applied to leaf surfaces, stems, fruits, and other portions of plants intended for consumption by animals including humans, either for fresh consumption or consumption following cooking or other preparation.
- the composition may be applied at various stages including while the plant is still in the ground; post-harvest; and prior to, during, or after shipping. Application of the composition may reduce post-harvest infection and contamination by plant, animal, and human pathogens.
- composition may be applied once or in repeated applications. Applications may be repeated any number of times daily, weekly, monthly, or annually. Applications may be repeated about 1 to about 100 times per day, week, month, or year, as needed.
- Applying a composition comprising an active compound may reduce virulence of bacteria associated with the plant.
- the active compound or a pharmaceutical composition comprising the active compound may be administered to an animal subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g.
- vaginal parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly. Additional modes of administration may include adding the active compound and/or a composition comprising the active compound to a food or beverage, including a water supply for an animal, to supply the active compound as part of the animal's diet.
- the subject may include, without limitation, a eukaryote, an animal, a vertebrate animal, a bird, a reptile, an insect, a mammal, a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), ovine (e.g., a sheep), bovine (e.g., a cow), a primate such as a monkey (e.g. marmoset, baboon) or an ape (e.g. gorilla, chimpanzee, orangutan, gibbon), or a human.
- a rodent e.g., a guinea pig, a hamster, a rat, a mouse
- canine e.g., a dog
- feline e.
- the active compound may be presented as a pharmaceutical composition (e.g., formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically-acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilizers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
- a pharmaceutical composition e.g., formulation
- the active compound may be presented as a pharmaceutical composition (e.g., formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically-acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilizers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
- the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilizers, or other materials, as described herein.
- Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations may be prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, lozenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, electuaries, or aerosols.
- Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
- a tablet may be made by conventional means, e.g., compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); and preservatives (e.g., methyl p-hydroxybenzoate, propy
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile.
- Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil.
- a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents.
- a formulation may be added to a conventional bandage, e.g. to a gauze portion that contacts the wound, as an antimicrobial agent.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active compound in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.
- Formulations suitable for nasal administration, wherein the carrier is a solid include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer include aqueous or oily solutions of the active compound.
- Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurized pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- Formulations suitable for topical administration via the skin include ointments, creams, and emulsions.
- the active compound When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active compounds may be formulated in a cream with an oil-in-water cream base.
- the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1 ,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
- the topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
- an emulsifier otherwise known as an emulgent
- a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
- the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Suitable emulgents and emulsion stabilizers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate.
- the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain antioxidants, buffers, preservatives, stabilizers, bacteriostats in addition to the active compound, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
- aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain antioxidants, buffers, preservatives, stabilizers, bacteriostats in addition to the active compound, and solutes which render the formulation isotonic with the blood of the intended recipient
- aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or
- Suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
- concentration of the active compound in the solution is from about 1 ng/ml to about 1 pg/ml, although other concentrations are possible and are encompassed within the invention.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or more organs.
- appropriate dosages of the active compounds, and compositions comprising the active compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight, condition, general health, and prior medical history of the patient.
- the amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration in vivo can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
- a suitable dose of the active compound is in the range of about 100 pg to about 250 mg per kilogram body weight of the subject per day.
- the active compound is a salt, an ester, prodrug, or the like
- the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
- the composition may be administered once, on a continuous basis (e.g. by an intravenous drip), or on a periodic/intermittent basis, including about once per hour, about once per two hours, about once per four hours, about once per eight hours, about once per twelve hours, about once per day, about once per two days, about once per three days, about twice per week, about once per week, and about once per month.
- the composition may be administered until a desired reduction of symptoms is achieved, which may be taken as an indication that bacterial virulence has been reduced.
- Treatment of an animal subject with an active compound, or a composition comprising an active compound may reduce virulence of bacteria associated with the animal subject.
- the active compounds may be applied to surfaces to reduce the virulence of bacteria on the surfaces.
- the active compounds may be formulated in compositions suitable for application to surfaces, including as a gel, powder, liquid, concentrate, spray, or other suitable compositions known to those skilled in the art.
- the composition may be applied to surfaces in residential, commercial, medical, industrial, agricultural, and other settings, to reduce virulence of bacteria associated with the surfaces.
- the composition may be applied to surfaces including without limitation those in bathrooms; kitchens and other food storing or preparation areas; medical facilities including operating rooms and hospital rooms; laundry facilities including laundered articles; restaurant facilities including kitchens and food storage areas; refrigerators and freezers; dishwashing facilities; factories; slaughterhouses; and grocery stores.
- the active compounds may be incorporated into or applied on packaging, e.g. for medical items or food products, to reduce virulence of bacteria associated therewith.
- the active compound and/or a composition comprising the active compound may be used to reduce or inhibit biofilm formation in medical, industrial, and other equipment, where a biofilm is defined as an aggregation of microorganisms on a solid substrate.
- the active compound may be applied to external and internal surfaces of the equipment, including pipes and tubing, to reduce or inhibit bacterial virulence and biofilm formation.
- the composition may be sprayed, dusted, spread, rubbed, painted, mopped, soaked, or otherwise applied on surfaces.
- the composition may be applied once or may be repeated on a periodic basis. Periodic application may be about 1 to about 100 times per day, week, month, or year, as needed.
- Applying a composition to a surface comprising an active compound may reduce virulence of bacteria on or associated with the surface.
- the bacterial strains and plasmids used in this study are listed in Table 1.
- E. coli was grown in LB broth at 37°C and D. dadantii was grown in minimal Aw -inducing medium (MM) at 28°C.
- Antibiotics g/ml used were: ampicillin, 100; chloramphenicol, 50; kanamycin, 50; spectinomycin, 50.
- Primers used for Polymerase Chain Reaction (PCR) in this report are also listed in Table 1. Chinese cabbage purchased in a grocery store and African violet, without visible symptom from pathogen infection were used in this study.
- aAp R ampicillin resistance
- Cm chloramphenicol resistance
- Km R kanamycin resistance
- Sp R spectinomycin resistance.
- FACS analysis of promoter activity of dspE, hrpA, hrpL, hrpN, and hrpS was carried out as described (Peng et al., 2006). Briefly, the wild-type Ech3937 and the mutant strains carrying the promoter reporter plasmid were grown on LB broth at 28°C overnight and transferred to appropriate media. For FACS analysis, samples were collected by centrifugation, washed with 1X phosphate buffer saline (PBS) at 13,000 rpm for 1 min, and re-suspended in 1X PBS to ca 10 6 CFU/ml prior to . being run in a FACS Calibur flow cytometer (BD Biosciences, CA). Three replicates were performed for each treatment.
- PBS 1X phosphate buffer saline
- RNA from the bacterial cells was isolated by using the TRI reagent method (Sigma, MO) and treated with Turbo DNA-free DNase kits (Ambion, TX) as described (Peng ef al., 2006).
- An iScript cDNA Synthesis Kit (Bio-Rad, CA) was used to synthesize cDNA from 0.5 pg of treated total RNA.
- the Real Master Mix (Eppendorf, Westbury, NY) was used for qRT-PCR reaction to quantify the cDNA level of target genes in different samples. The rplU was used as the endogenous control for data analysis.
- Ech3937 Ech3937 cells carrying plasmid pdspE
- the expression of dspE was further induced in MM supplemented with Chinese cabbage juice in comparison with the bacterial cells grown in MM alone.
- low promoter activities of dspE were observed in hrpL mutant Ech131 carrying pdspE grown in MM and MM supplemented with Chinese cabbage (Table 2), suggesting that HrpL is essential for the expression of dspE under inducing conditions.
- dspE promoter activities in the wild-type Ech3937 and hrpL mutant Ech131 were compared after 12 h of culture in LB, MM, and MM supplemented with plant juice.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
- alues (Mean Fluorescence Intensity) are representative of two experiments. Three replicates were used in this experiment. The values are the average with the standard deviation.
- T3SS genes Plant juice induced the expression of T3SS genes of Ech3937, suggesting the existence of compounds in plant tissues that activate the T3SS regulon.
- Phenolic compounds constitute an important class of organic substances produced by plants.
- the phenolic compound SA is a signaling molecule that plays a role in host defenses.
- OCA and TCA are the biosynthetic precursors of SA and are also reported to induce the expression of defense-related genes in plants.
- OCA, TCA, and SA were examined to elucidate their effects on the expression of T3SS genes.
- the expression of the T3SS gene hrpN was examined in MM and MM supplemented with OCA, TCA, and SA, at concentrations of 0.05, 0.1 , and 0.2 mM, respectively.
- Figures 2A and 2B show the promoter activities of hrpN in Dickeya dadantii 3937 (Ech3937) grown in MM and MM supplemented with 0.05, 0.1 , and 0.2 mM OCA, TCA, and SA at 12 h ( Figure 2A) and 24 h ( Figure 2B) post-inoculation.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA). The growth of Ech3937 in MM supplemented with different concentrations of OCA, TCA and SA was recorded.
- the concentration of the phenolic compound f-cinnamic acid (TCA) in healthy potato leaves is approximately 0.5 ⁇ and levels in the leaves can rise to approximately 10 uM after exposure to a cell-free culture filtrate (CF) of E. c. carotovora.
- CF cell-free culture filtrate
- hrpN was examined using concentrations of TCA comparable to levels found in plants. Ech3937 (phrpN) was grown in MM supplemented with 0.2, 0.5, 5, and 10 ⁇ of TCA, respectively.
- MM Minimum medium
- TCA f-cinnamic acid
- SA salicylic acid
- hrpN ' ⁇ promoter activities of hrpN were measured at 12 and 24 h of growing in the media.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Three replicates were used in this experiment. The value (Mean Fluorescence Intensity) is present as the average of three replicates with standard deviation.
- FIG. 3 shows the promoter activities of hrpA, hrpN, hrpL, and hrpS in Dickeya dadantii 3937 (Ech3937) and hrpL mutant WPP96 grown in MM and MM supplemented with 0.1 mM OCA 12 h post-grown.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA).
- lines labeled "1" stand for the GFP expression control base level of the Ech3937 containing pPROBE-AT vector; lines labeled “2” stand for the promoter activity of hrpS, hrpL, hrpA and hrpN in Ech3937 in MM; lines labeled “3” stand for the promoter activity of Ech3937 in MM supplemented with 0.1 mM OCA; lines labeled "4" stand for the promoter activity of hrpL mutant WPP96 in MM; lines labeled "5" stand for the promoter activity of hrpL mutant WPP96 in MM supplemented with 0.1 mM OCA. Values are representative of at least two experiments.
- the mrp whose protein product has an ATPase conserved domain (2e-06), was used as a reference gene in this study. A slightly higher mrp expression was observed in Ech3937 ⁇ pmrp) when the bacterial cells were grown in MM and MM supplemented with 0.1 mM OCA and TCA, respectively (Table 4).
- Ech3937 (pPROBE-AT) 1.9 ⁇ 0 2.0 ⁇ 0 1.9 ⁇ 0 a
- the promoter activities were compared at 12 h of growing in the media.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
- alues are representative of three experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation.
- the relative mRNA level of hrpY, hrpS, hrpL, dspE, and hrpA of Ech3937 grown in MM and MM supplemented with OCA was examined by qRT-PCR. Compared with MM alone, a significantly higher amount of dspE and hrpA mRNA was observed in Ech3937 supplemented with OCA ( Figure 4).
- T3SS genes dspE, hrpA, and hrpN were reduced in an iaaM mutant Ech138; iaaM encodes an enzyme in the pathway for indole-3-acetic acid (lAA) biosynthesis.
- lAA indole-3-acetic acid
- Ech3937 (pPROBE-AT) 1.9 ⁇ 0 2.0 ⁇ 0 1.9 ⁇ 0 2.0 ⁇ 0 1.8 ⁇ 0 1.9 ⁇ 0
- the promoter activities were compared at 6, 12, and 24 h of bacterial growth.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
- Ech3937 gacA plays a role in regulating the expression of T3SS genes by a post- transcriptional regulation of hrpL through the Gac-Rsm regulatory pathway (Yang, S., Q. Peng, Q. Zhang, X. Yi, C. J. Choi, R. M. Reedy, A. O. Charkowski, and C.-H. Yang. 2008.
- HrpL appears to be involved in the induction of T3SS gene expression by the phenolic acids OCA and TCA, as the addition of OCA or TCA did not induce the T3SS gene expression (hrpA and hrpN) in the hrpL mutant background (Table 4).
- OCA and TCA were regulated through HrpX/Y-HrpS-HrpL, experiments were performed to investigate whether OCA and TCA were able to induce the expression of T3SS genes in the absence of hrpX, hrpY, and hrpS, respectively.
- FIG. 5 shows levels of expression of hrpN of Dickeya dadantii 3937 (Ech3937), hrpS mutant WPP90, hrpX mutant WPP67, hrpY mutant WPP92 in MM, MM supplemented with 0.1 mM OCA (MMOCA), and MM supplemented with 0.1 mM TCA (MMTCA).
- Ech3937 (pAT) is the wild-type containing the pPROBE-AT vector.
- the promoter activities were compared at 12 h of growth in the media.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
- Values (Mean Fluorescence Intensity; MFI) are a representative of three experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
- SD standard deviation
- kanamycin 50 Mg/ml
- rifampicin 100 pg/ml
- ampicillin 100 pg/ml
- spectinomycin 50 g/ml.
- the gacA deletion mutant was constructed by a crossover PCR mutagenesis approach as described (Yang, C. H., Gavilanes-Ruiz, M., Okinaka, Y., Vedel, R., Berthuy, I., Boccara, M., Chen, J. W., Perna, N. T., and Keen, N. T. 2002.
- hrp genes of Erwinia chrysanthemi 3937 are important virulence factors. Mol.
- the primer pair used for pelL promoter in this study is PpelL_F, 5'ATG CGG TAA TGC GGG GAT3' (SEQ ID NO:23) and PpelL_R, 5'GGC CAG AAC TGA TGT ACT GT3' (SEQ ID NO:24), which produces a 609-bp pelL promoter region sequence of Ech-Rif.
- the inserted DNA was further subcloned into the Xba ⁇ ISac ⁇ sites of the promoter-probe vector pPROBE- AT (Table 6).
- a plasmid pCLgacA containing a full-length gacA in plasmid pCL1920 also was constructed using the primer set gacAco_F, 5'GCC AAT GTT TCG GGT GTA G3' (SEQ ID NO:25) and gacAco_R, 5'CAT CGA TCT GCC GGA TAC TTT3' (SEQ ID NO:26).
- the GFP reporter in combination with the FACS-based approach has been used to evaluate gene activity in several bacteria at the single-cell level. Because the gfp gene in the pPROBE-AT contains its own ribosome binding site, the stability of gfp mRNA should not be interfered by RsmA when a promoter-containing DNA region of Ech3937 is cloned into the reporter vector.
- Ech-Rif and Ech137 carrying GFP reporter plasmid constructs were washed three times with 1 ⁇ phosphate-buffered saline (PBS) buffer (8.0 g of NaCI, 0.2 g of KCI, 1.44 g of Na 2 HP0 4 , and 0.24 g of KH 2 P0 4 per liter, pH 7.2 to 7.4) and diluted to approximately 106 CFU/ml before analysis.
- PBS phosphate-buffered saline
- Bacterial cells were identified based on forward and side light scatter properties and electronically gated for analysis. The promoter activity was determined by FACS (Becton Dickinson, San Jose, CA, U.S.A.) and the flow cytometry results were analyzed using Cell Quest software (BD Biosciences, San Jose, CA, U.S.A.).
- Wild-type Ech-Rif and the gacA mutant Ech137 were grown in MM with glucose as carbon source (Yang et al. 2007).
- Total RNA from the bacteria was isolated by using TRI reagent method (Sigma-Aldrich, St. Louis, MO) and treated with Turbo DNA-free DNase kits (Ambion, Austin, TX, U.S.A.).
- An iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, U.S.A.) was used to synthesize cDNA from 0.5 pg of treated total RNA.
- the Real Master Mix (Eppendorf, Westbury, NY, U.S.A.) was used for real-time PCR reaction to quantify the cDNA level of hrpL, rsmA, rsmB, rsmC, and rplU in different samples.
- the rplU was used as the endogenous control for data analysis.
- the primer pairs used in this study were RplUsF, 5' GCG GCA AAA TCA AGG CTG AAG TCG 3' (SEQ ID NO:27) and RplUsR, 5' CGG TGG CCA GCC TGC TTA CGG TAG 3' (SEQ ID NO:28) for ⁇ /U; HrpLsF, 5' GAT GAT GCT GCT GGA TGC CGA TGT 3' (SEQ ID NO:29) and HrpLsR, 5' TGC ATC AAC AGC CTG GCG GAG ATA 3' (SEQ ID NO:30) for hrpL rsmAf, 5' TTT TGA CTC GTC GAG TTG GCG AAA 3' (SEQ ID NO:31 ) and rsmAr, 5' GCG CGT TAA CAC CGA TAC GAA CCT 3' (SEQ ID NO:32) for rsmA; rsmBf, 5' AGA GGG ATC
- pellicle formation assay bacterial strains were grown in SOBG broth at 28'C as described (Yap et al. 2005). Due to the slow formation of pellicle in Ech137, 10-day-old pellicles from Ech-Rif and Ech137 were used for SEM observation. The samples of pellicle were fixed in 2% glutaraldehyde in PBS buffer (pH 7.0) for 2 h and post-fixed in 1 % osmium tetroxide in the same buffer for 1 h. After dehydration in the graded series of ethanol, specimens were infiltrated with polyethylene glycol (PEG). Cross sections of the pellicles were cut using an ultramicrotome.
- PEG polyethylene glycol
- wild-type bacterial cells and gacA mutant Ech137 cells were syringe-infiltrated in the middle of each symmetric side of the same leaf with approximately 50 ⁇ of a bacterial suspension at 106 CFU/ml.
- Phosphate buffer 50 mM, pH 7.4 was used to suspend the bacterial cells.
- Three replicate plants with a total of at least 12 leaves were inoculated.
- the pathogenicity of the bacterium was evaluated as described (Franza, T., Sauvage, C, and Expert, D. 1999. Iron regulation and pathogenicity in Erwinia chrysanthemi 3937: Role of the fur repressor protein. Mol. Plant-Microbe Interact.
- a volume of a 50 ⁇ of the bacterial suspension with an optical density at 600 nm of 0.01 was inoculated into the front edge of the African violet leaf.
- 12 plants were inoculated. Inoculated plants were kept in growth chambers at 28*C, 95% relative humidity, and a photoperiod of 16 h.
- Development of symptoms induced by bacterial strains in African violet plants was considered as systemic when at least one leaf and its petiole were macerated. Progression of the symptoms was scored daily for 12 days.
- Pel production was the ratio of the optical density at 230 nm unit to the log unit of the bacterial concentration (U/log [CFU/cm 2 ]).
- Three replicate plants with a total of six leaves per plant were used in each sampling time for the in planta Pel production and bacterial growth kinetics assays.
- Ech3937 is capable of forming a biofilm and pellicle in SOBG broth.
- a spontaneous rifampicin-resistant derivative of Ech3937, Ech-Rif was used as a wild-type in this study (Table 6).
- a gacA deletion mutant Ech137 of Ech-Rif was constructed and confirmed by DNA sequencing analysis. The gacA gene of Ech137 was deleted with only 20 bp of the gacA open reading frame remaining. No significant difference in growth between Ech-Rif and the gacA mutant Ech137 was observed in M9 minimal medium (MM).
- Ech-Rif formed biofilm-pellicle in SOBG broth grown for 2 days at 28 ⁇ .
- Figure 6A shows biofilm and pellicle formation in SOBG broth (Yap et al. 2005).
- Figure 6A(a) shows biofilm and pellicle formed in wild-type Ech-Rif in SOBG cultures grown for 3 days at 28 ⁇ .
- Figure 6A(b) shows delayed biof ilm and pellicle formation in Ech137, the gacA mutant in SOBG cultures grown for 3 days at 28 .
- F igure 6A(c) shows the gacA gene expressed on plasmid pCLgacA restored biofilm and pellicle formation to the gacA mutant Ech 137 in SOBG cultures grown for 3 days at 28 ⁇ .
- F igure 6B shows cross sections of the pellicle observed with scanning electron microscopy at different magnifications.
- Figure 6B(a1 ) shows Ech-Rif;
- Figure 6B(b1 ) shows Ech137;
- Figure 6B(a2) shows Ech-Rif;
- Figure 6B(b2) shows Ech137.
- the size bars in the micrographs in Figure 6B(a1) and Figure 6B(b1 ) are 1 mm, while in Figure 6B(a2) and Figure 6B(b2) the size bars are 100 ⁇ .
- FIG. 8 shows spectrophotometric quantification of pectate lyase (Pel) activity (U/optical density at 600 nm [OD600]) in Ech-Rif, gacA mutant Ech137, and the complementary strain Ech137 (pCLgacA) grown in minimal medium supplemented with 1 % polygalacturonate at 36 h. Values are a representative of two experiments. Three replicates were used in this experiment; the value is present as average of three replicates and the standard deviation.
- EXAMPLE 6 GacA regulates the expression of pe/ and T3SS genes
- PelD has higher activity on nonmethylated pectins and PelL prefers partially methylated pectins.
- the promoter regions of pelD and pe/L, respectively, were cloned into pPROBE-AT to produce pPelD and pPelL (Table 6).
- the Ech-Rif and Ech137 cells carrying these GFP promoter plasmids were grown in MM-supplemented 1 % PGA and the fluorescence intensity of the bacterial cells was measured with an FACS.
- the fluorescence intensity collected by FACS was analyzed in a four-decade log scale using CellQuest Pro software from Becton Dickinson, and the gene expression profiles were analyzed as i) total, the average GFP fluorescence intensity of total bacterial cells; ii) GFP+ mean, average GFP fluorescence intensity of GFP expressing bacterial cells; and iii) GFP+%, the percentage of GFP-expressing bacterial cells of the total bacterial cells.
- the promoter activities of pe/D and pelL of Ech-Rif and Ech137 were examined.
- Figure 9 shows expression of pe/D and pelL in Ech-Rif (black line with black filling) and gacA mutant Ech137 (gray line) grown in minimal medium supplemented with 1% polygalacturonate (MMP).
- MMP polygalacturonate
- the promoter activities were compared after 12 and 24 h of culture in the medium MMP.
- Green fluorescent protein (GFP) intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA, U.S.A.).
- the gray line with gray filling stands for the GFP expression control base level of the Ech-Rif containing pPROBE-AT vector without insert. Values are a representative of two experiments.
- the Ech-Rif cells carrying pPelD at 12 and 24 h were expressed at a mean fluorescence intensity (MFI) of 190 ⁇ 17 and 459 ⁇ 73, while the Ech137 cells carrying pPelD at 12 and 24 h were expressed with an MFI of 52 ⁇ 3 and 324 ⁇ 11.
- MFI mean fluorescence intensity
- the pelL promoter activity in the Ech-Rif cells was approximately 50% greater than that in the gacA mutant Ech137 cells.
- the MFI values of Ech-Rif (pPelL) were 31 ⁇ 0.1 and 28 ⁇ 0 at 12 and 24 h postgrown, respectively (Figure 9).
- the MFI values of Ech137 (pPelL) were 19 ⁇ 1 and 22 ⁇ 1 at 12 and 24 h ( Figure 9).
- Promoter activities were compared after 8 and 12 h of culture in the minimal medium. Values represent total green fluorescent protein intensity and are a representative of two experiments. Three replicates were used in this experiment The value is present as average of three replicates and the. standard deviation.
- EXAMPLE 7 The Gac-Rsm regulatory network controls Pel and T3SS gene expression
- Rsm is a novel type of post-transcriptional regulatory system that plays a critical role in gene expression.
- the relative mRNA level of rsmC, rsmB, and rsmA was examined by qRT-PCR.
- the qRT-PCR data were analyzed using the Relative Expression Software Tool as described by Pfaffl and associates (Pfaffl et al. 2002).
- Figure 10A shows relative levels of rsmA, rsmB, rsmC, and hrpL mRNA in gacA mutant Ech137 compared with wild-type Ech-Rif grown for 6 or 12 h in a minimal medium. Three replicates were used in each experiment and the values are presented as the average of the three replicates and the standard deviation. Compared with wild-type, a lower amount of rsmB mRNA was observed in Ech137. Wild-type Ech-Rif produced approximately 10-fold more rsmB mRNA than gacA mutant Ech137 at 6 h and 24-fold more at 12 h, with a P value less than 0.05. No significant differences in amount of rsmC and rsmA mRNA were observed between Ech-Rif and Ech137 (with a P value range from 0.74 to 1 ) ( Figure 10A).
- Figure 10B shows relative levels of gacA and rsmB mRNA in gacA mutant Ech137 and gacA mutant complemented strain Ech137 (pCLgacA) compared with wild-type Ech-Rif grown for 12 h in a minimal medium.
- the amount of mRNA was examined by realtime polymerase chain reaction assay and analyzed by Relative Expression Software Tool. The normalized value of mRNA for wild-type was 1.0. Three replicates were used in each experiment and the values are presented as the average of the three replicates and the standard deviation. No detectable mRNA of gacA was observed in Ech137 by qRT-PCR ( Figure 10B).
- the gacA and rsmB expression of Ech137 was restored by introducing the plasmid pCLgacA into the mutant.
- the relative mRNA amounts of gacA and rsmB of Ech137 are approximately 180 and 150% of the Ech-Rif ( Figure 10B).
- the higher amounts of gacA and rsmB mRNAs in Ech137 (pCLgacA) compared with Ech-Rif may be due to the copy number effect of the plasmid.
- EXAMPLE 8 GacA influences the expression of Pel and T3SS genes in planta
- GFP* mean 78.2 + 17.0 40.1 + 0.7 54.4 + 12.2 15.8 + 15.2
- GFP Greco fluorescent protein
- GacA affects multiple phenotypes contributing to pathogenesis
- a local maceration assay was carried out with Ech-Rif, Ech137, and the complemented strain Ech137 (pCLgacA) in the African violet cv. Gauguin as previously described (Yang et al. 2002).
- Figure 11 shows local maceration lesions caused by a, Ech-Rif; b, gacA mutant Ech137; and c, complemented strain Ech137 (pCLgacA).
- Bacterial cells were inoculated in the middle of each half side of the same leaf.
- Gauguin (Saintpaulia ionantha). Leaves of African violet were inoculated with a 50- ⁇ bacterial suspension at a concentration of 10 6 CFU/ml. Six leaves from six replicate plants were used at each sampling time for each bacterial strain, the value is present as average of three replicates and the standard deviation; concentration of Ech-Rif (solid diamonds) and Ech137 (solid triangles). The spectrophotometric quantification was carried out as described to measure the pectinase (Pel) activity in the inoculaled leaves from the same sample for population kinetics; Pel production of Ech-Rif (open diamonds) and Ech137 (open triangles).
- a systemic invasion assay (Franza et al. 1999) was further applied to investigate the role of GacA of the bacterium in S. ionantha.
- Ech-Rif and Ech137 12 plants (one leaf per plant) were inoculated. Response was considered as systemic when at least one leaf and its petiole were macerated. Values are a representative of two experiments. Eight days after inoculation, 11 of the 12 plants inoculated with Ech-Rif developed systemic invasion symptoms ( Figure 13). In contrast, the Ech137 showed a reduced ability to develop a systemic invasion in the plant host; only one plant developed a systemic invasion with the gacA mutant 16 days postinoculation.
- GFP intensity which is a measurement of hrpA promoter activity, was measured by flow cytometry.
- the TCA analogs p-coumaric acid (PCA) and cinnamyl alcohol were discovered to be inhibitors of the expression of hrpA (Table 9).
- Table 9 The expression of hrpA of Dickeya dadantii 3937 (Ech3937) in MM and MM supplemented with different isomers and analogs of f-cinnamic acid.
- MM aMinimum medium
- MM aMinimum medium
- MM supplemented with 0.1 mM of different compounds.
- bEch3937 cells carrying GFP reporter phrpA was used in this study.
- the promoter activities were compared at 6, 12, and 24 h of bacterial growth.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
- Values (Mean Fluorescence Intensity) of GFP are a representative of three experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
- FIGS. 16A and 16B show the promoter activities of hrpA in Dickeya dadantii 3937 (Ech3937) grown in minimum medium (MM) and MM supplemented with different amount of p-coumaric acid (PCA) at 12 h ( Figure 16A) and 24 h ( Figure 16B) post- inoculation.
- GFP intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA).
- FIG. 14 shows the relative mRNA level of hrpS, hrpL, dspE, hrpA, hrpN, and rsmB of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) supplemented with 0.1 mM p-coumaric acid (PCA) compared to those in MM without PCA.
- the amount of mRNA was determined by qRT-PCR. Three replicates were used in this experiment. The p-value was calculated using Relative Expression Software Tool as described by Pfaffl et al. (2002).
- the promoter activities were compared at 12 and 24 h of bacterial growth in p-coumaric acid (PCA).
- PCA p-coumaric acid
- b GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values (Mean Fluorescence Intensity) are a representative of two experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
- GacS/GacA also induced the production of pectate lyase of Ech3937.
- PCA pectate lyase
- Figure 17 shows pectate lyase (Pel) production of Dickeya dadantii 3937 (Ech3937) grown in minimal medium (MM) and MM supplemented with 0.1 mM of p-coumaric acid (PCA) at 12 h examined by plate assays as described (Mats.umoto et al. 2003). Values are a representative of two experiments. Three replicates were used in this experiment.
- the T3SS of Ech3937 which belongs to Group I T3SS of phytobacteria, is primarily regulated by a HrpX/Y-HrpS-HrpL pathway.
- the two-component system HrpX/HrpY activates the gene encoding HrpS, which is required for expression of hrpL.
- HrpL an alternative sigma factor, further activates expression of genes encoding the T3SS apparatus and its secreted substrates.
- Figure 15 shows HrpN protein expression of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) and MM supplemented with 0.1 mM of p-Coumaric acid (PCA).
- Lane 1 of Figure 15 shows a HrpN overexpression strain.
- Lane 2 shows Ech3937 grown in MM supplemented with 0.1 mM PCA.
- Lane 3 shows Ech3937 grown in MM.
- Lane 4 shows Ech3937 grown in MM supplemented with 0.01 mM PCA. Compared with MM alone, a lower amount of HrpN was observed in Ech3937 grown in MM supplemented with 0.1 mM of PCA ( Figure 15).
- Table 11 shows HrpN protein expression of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) and MM supplemented with 0.1 mM of p-Coumaric acid (PCA).
- Lane 1 of Figure 15 shows a HrpN over
- hrpA and hrpN of wild-type Dickeya dadantii 3937 (Ech3937) and hrpX (WPP67), hrpY (WPP92), hrpS (WPP90) and hrpL (WPP96) mutants in minimum medium (MM) and MM supplemented with 0.1 mM PCA (MMPCA).
- the promoter activities were compared at 12 and 24 h of bacterial growth in p-Coumaric acid (PCA).
- PCA p-Coumaric acid
- bGFP intensity was determined on gated populations of bacterial cells by flow cytometry.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
- Values (Mean Fluorescence Intensity) are a representative of two experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
- Method A A mixture of cinnamic acid (25 mmol) and concentrated H 2 S0 4 (0.1 ml_) in anhydrous MeOH (25 mL) was refluxed at 803 ⁇ 4 (bath temperature) for 16 h. After the excess MeOH was removed by a rotary evaporator, the residue was treated with H 2 0 (50 mL), and the resulting mixture was extracted with EtOAc (3 ⁇ 50 mL). The combined extracts were washed with H 2 0 (50 mL) and brine (50 mL), and dried (anhydrous Na 2 S0 4 ).
- Method B To a stirred mixture of cinnamic acid (7 mmol) and diisopropylethylamine (DIEA) (2.45 mL, 17 mmol) in anhydrous DMF (20 ml_) was added HBTU (2.92g, 7.7 mmol) at room temperature, followed by adding a solution of hydroxylamine hydrochloride (0.98g, 14 mmol) and DBU (2.13g, 14 mmol) in anhydrous DMF (8 mL), and then the whole reaction mixture was stirred at room temperature for 1 h.
- DIEA diisopropylethylamine
- PCA was converted into its methyl ester 101 by refluxing in methanol in the presence of sulfonic acid.
- Compound 101 was transformed to amide 102 by reacting with ammonia.
- a solution of methyl cinnamate (28 mmol) and 7 M ammonia in MeOH (30 mL) was sealed in a 100 mL thick-wall round bottom flashed, and heated at 90 with stirring for 72 h, resulting in a brown solution. After the solvent was removed by a rotary evaporator, the crude products were purified by flash silica gel chromatography (eluting with 2-10% MeOH in DCM) to afford cinnamamide.
- Compound 102 was a yellow solid, obtained at 30% yield. Identity was confirmed by 1 H NMR (300 MHz, CD 3 OD).
- the reaction mixture was stirred at -78 ⁇ for 3CC, at 0 * C for additional 1 h, then allowed to warm to ambient temperature, and with stirring for additional 30 min.
- the reaction mixture was rechilled to 0 w ith an ice bath, and treated with saturated NaHC0 3 (40 mL).
- Aryl bromide (10 mmol), N-allylphthalimide (1.93 g, 10.3 mol, 1.03 equiv) and triethylamine (2.78 mL, 20 mmol, 2 equiv) were placed in a 50 mL three-necked round bottom flask, palladium acetate (23 mg, 0.1 mmol, 0.01 equiv) and tri-O-tolylphosphine (61 mg, 0.2 mmol, 0.02 equiv) were added to the flask under the flash of argon, and the whole mixture was heated at 100 ⁇ (bath temperature) unde r argon and with stirring for 16 h.
- N-cinnamyl phthalimide (3 mmol) was mixed with 65% hydrazine hydrate (6 mmol, 2 equiv) and MeOH (10 mL), and the mixture was heated at 70 for 2 h. After the solvent was removed by a rotary evaporator, the solid residue was treated with 1 N NaOH (30 mL), and the resulting mixture was extracted with EtOAc (4x50 mL) and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 5-20% MeOH in DCM) to give cinnamyl amine.
- the minimal inhibitory concentration of the compounds on hrpA was measured by supplement compounds at various concentrations, and the reporter plasmid phrpA was used to measure the effects of these compounds on hrpA expression.
- Compounds 101 , 102, 104, 105, 106, 113, 116, 125, 126, and 127 showed inhibitory effect on hrpA expression at a concentration of 100 ⁇ .
- Compound 103 showed inhibitory effect on hrpA expression at a concentration of 10 ⁇ .
- hrpA encodes the T3SS pilus required for protein translocation into plant cells.
- the reporter plasmid phrpA was used to measure the effects of these compounds on hrpA expression.
- the reporter plasmid phrpA encodes a transcriptional fusion of the hrpA promoter controlling expression of green fluorescent protein (gfp).
- the expression level of hrpA of these bacterial cells was measured by measuring GFP intensity of gated populations of the bacterial cells by flow cytometry and analyzed with Cell Quest software (BD Biosciences, San Jose, CA). The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Compounds were assayed two different times (12 and 24 h of bacterial growth) with T3SS minimal media (MM) as the control treatment for each set of experiment. Results are shown in Table 13 and Table 14. Values presented in Table 14 are mean fluorescence intensity of GFP, representative of two experiments, presented as the average of three replicates with standard deviation (SD).
- Compound 101 showed weak inhibitory activity comparing to PCA (data not shown). However, 102 did not show any inhibitory activity against T3SS gene expression (data not shown).
- Compound 104 showed potent inhibitory activity. Similarly, allylic alcohol 126 was also a potent inhibitor of T3SS gene expression.
- Table 13 The eight compounds listed below showed inhibitory effect on T3SS hrpA expression, using the reporter plasmid, phrpA.
- Phenolic compound (Trial 1) Mean Fluorescence Intensity of GFP
- Phenolic compound (Trail 2) Mean Fluorescence Intensity of GFP
- MM aT3SS-inducing minimal medium
- Table 14 The hrpA expression of D. dadantii 3937 in MM and MM supplemented with different isomers and analogs of PCA, TCA, and OCA.
- the fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values presented in Table 16 are mean fluorescence intensity values, representative of two experiments, and presented as the average of three replicates with standard deviation (SD). Table 15. Strains and plasmids used
- NMR ( 1 H, 13 C and 32 P) spectra were measured on either a Varian Mercury 300 or Inova 400 spectrometer using TMS as the internal standard.
- Electrospray ionization mass spectrometry (ESI-MS) was performed on an Agilent 1100 Series LC/MSD Trap Spectrometer with a Daly conversion dynode detector. Ionization was achieved in the positive or negative ion mode by application of +5 or -5 kV at the entrance to the capillary.
- Thin-layer chromatography (TLC) was performed on precoated silica gel 60 F25 plates (Merck, 0.25 mm, purchased from Sigma-Aldrich Company).
- Phthalimide potassium salt was alkylated with allyl chloride in DMF to produce N- allylphthalimide. Under the Heck reaction conditions (Patel et al. 1977), N-allylphthalimide reacted with aryl bromide to give N-cinnamyl phthalimide. Upon treatment with hydrazine, cinnamyl amine was obtained from N-cinnamyl phthalimide ( Figure 28).
- Method A A mixture of cinnamic acid (25 mmol) and concentrated H 2 S0 4 (0.1 ml) in anhydrous MeOH (25 ml) was refluxed at 80 ⁇ (bath temperature) for 16 h. After the excess MeOH was removed by a rotary evaporator, the residue was treated with H 2 0 (50 ml), and the resulting mixture was extracted with EtOAc (3x50 ml). The combined extracts were washed with H 2 0 (50 ml) and brine (50 ml), and dried (anhydrous Na 2 S0 4 ). The solvent was evaporated to dryness, and the crude products were purified by flash silica gel chromatography (eluting with 10-60% hexane in EtOAc) to afford methyl cinnamate.
- Method B To a stirred mixture of cinnamic acid (7 mmol) and diisopropylethylamine (DIEA) (2.45 ml, 17 mmol) in anhydrous DMF (20 ml) was added HBTU (2.92 g, 7.7 mmol) at room temperature, followed by adding a solution of hydroxylamine hydrochloride (0.98 g, 14 mmol) and DBU (2.13 g, 14 mmol) in anhydrous DMF (8 ml), and then the whole reaction mixture was stirred at room temperature for 1 h.
- DIEA diisopropylethylamine
- TSOI trimethylsulfoxonium iodide
- 60% NaH 4 g, 100 mmol, 2.6 eq
- anhydrous DMSO 120 ml
- a solution of frans-4-methoxycinnamate (7.91 g, 38.4 mmol) in anhydrous DMSO (50 ml) was added dropwise within 10 min to the resulting suspension at room temperature, and the entire mixture was stirred at room temperature for 18 h.
- reaction mixture was cooled with an ice bath, and quenched with brine (250 ml).
- the resulting mixture was extracted with ether (5 100 ml), washed with brine (2x60 ml), and dried.
- the solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 2-10% EtOAc in hexane) to afford 100 (1.6 g, 19% yield) as white solid.
- Aryl bromide (10 mmol), N-allylphthalimide (1.93 g, 10.3 mol, 1.03 equiv) and triethylamine (2.78 ml, 20 mmol, 2 equiv) were placed in a 50 ml three-necked round bottom flask, palladium acetate (23 mg, 0.1 mmol, 0.01 equiv) and tri-O-tolylphosphine (61 mg, 0.2 mmol, 0.02 equiv) were added to the flask under the flash of argon, and the whole mixture was heated at 100 (bath temperature) under argon and with stirring for 16 h.
- N-cinnamyl phthalimide (3 mmol) was mixed with 65% hydrazine hydrate (6 mmol, 2 equiv) and MeOH (10 ml), and the mixture was heated at 70 * C for 2 h. After the solvent was removed by a rotary evaporator, the solid residue was treated with 1 N NaOH (30 ml), and the resulting mixture was extracted with EtOAc (4x50 ml) and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 5-20% MeOH in DCM) to give cinnamyl amine.
- Bacterial strains Bacterial strains, plasmids, and growth conditions.
- Bacterial strains and plasmids used in this study are listed in the table in Fig. 31. Wild-type Pseudomonas strains were routinely grown in King's B (KB) medium at 28 ⁇ (King 1954), and E. coli strains were routinely grown in Luria-Bertani (LB) broth at 37"C. For induction of T3SS genes, DC3000 was grown in HIM supplemented with 10 mM fructose as previously described (Huynh et al. 1989).
- the promoter-probe plasmid was constructed as follows.
- the hrpA promoter region was amplified by PCR using phrpAF and phrpAR primers incorporating SamHI and EcoRI restriction sites, respectively.
- a 496-bp DNA fragment encoding the hrpA promoter was digested with SamHI and EcoRI and cloned into pPROBE-NT digested with the same enzymes. This construct was mobilized into DC3000 by conjugation using E. coli S17-1 K-pir as the donor strain.
- DC3000 was cultured in KB medium overnight at 28 ⁇ and subcultured in HIM medium supplemented with DMSO or with 250 ⁇ TCA for 9 h.
- Total bacterial RNA was isolated using RNeasy Mini Kit (QIAGEN, Valencia, CA) and treated with Turbo DNA-free DNase kit (Ambion, Austin, TX).
- cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) from 0.8 g of total RNA.
- the Real Master Mix SYBR ROX (5 PRIME, Gaithersburg, MD) was used for real-time PCR reactions to quantify the cDNA level of target genes in different samples.
- HrpW protein level was determined by immunoblot using anti-HrpW antibody provided by Dr. Alan Collmer (Cornell University, Ithaca, NY). Sample preparation was performed as previously described with modifications (Yuan and He 1996). Wild-type DC3000 was grown overnight in King's B medium at 28"C. The culture was washed with ⁇ -inducing medium (HIM) and resuspended in 40 ml of the same medium to an optical density (OD) at 600 nm of 0.1. To determine the effect of TCA on the HrpW protein level, TCA dissolved in DMSO was added to the culture at the final concentration of 250 ⁇ and the culture was grown with moderate shaking at 28 * C .
- HIM ⁇ -inducing medium
- OD optical density
- DMSO phosphate buffered saline
- Pelleted cells were resuspended in 1 ⁇ sample buffer (2% w/v sodium dodecyl sulfate, 2% v/v glycerol, 2 mM ⁇ - mercaptoethanol, 50 mM Tris-HCI [pH6.8], and 0.01 % w/v bromophenol blue) and heat- treated at 98 for 10 min using Dry Bath Incubator (Fisher Scientific, Pittsburgh, PA). The supernatant proteins were concentrated 100-fold with Amicon Ultra-4 Centrifugal Filter Unit (30 kDa cut-off) (Millipore, Billerica, MA) and mixed with the same volume of 2 * sample buffer and heat-treated. Cell pellets were similarly heat-treated.
- sample buffer 2% w/v sodium dodecyl sulfate, 2% v/v glycerol, 2 mM ⁇ - mercaptoethanol, 50 mM Tris-HCI [pH6.8], and 0.01
- TCA inhibits gene expression of T3SS hrpA but not bacterial growth
- DC3000 carrying phrpA was cultured in HIM and HIM supplemented with 25 ⁇ , 50 ⁇ , 100 ⁇ , 250 ⁇ , or 500 ⁇ of TCA.
- Promoter activity was measured at 6 h and 9 h as mentioned above using flow cytometry.
- Bacterial growth was determined by withdrawing samples of each culture and spot-plating serial dilutions onto King's B agar (King et al. 1954) in tandem with promoter activity assays. Colonies were counted after 48 h of incubation at 28'C.
- DC3000 mutations in genes which encode components of the T3SS result in the inability to elicit HR in non-hosts (Collmer et al. 2000). Since TCA represses expression of hrpA (a major component of the T3SS) in vitro, the ability of TCA to suppress HR in planta was examined.
- DC3000 (OD 600 0.1 ) with 25 ⁇ , 50 ⁇ , 100 ⁇ , 250 ⁇ , or 500 ⁇ of TCA in DMSO was injected into leaves of tobacco (Nicotiana tabacum cv. Xanthi). Concentrations of DMSO which correspond to similar amounts of TCA were also injected into the tobacco plants as negative controls.
- Tobacco leaves were assessed for HR symptoms 18 hours post-infiltration. No visible signs of tissue damage or HR were observed when DMSO or TCA was separately infiltrated into the tobacco leaves (data not shown). When bacterial cells were infiltrated into plants in combination with 250 ⁇ of TCA, elicitation of HR by DC3000 was completely suppressed (Fig. 34A). 100 ⁇ of TCA was unable to completely block HR, but the symptoms were slightly less severe than those seen when either 50 ⁇ or 25 ⁇ was infiltrated with bacterial cells into tobacco leaves.
- TCA not only inhibits expression of the hrpA gene encoding the major structural component of the T3SS pilus, but also functions in planta to suppress the ability of DC3000 to elicit HR on a non-host. This effect is most likely due to lack of a functional T3SS.
- TCA analogs (104) were chosen as a negative control to evaluate the specificity of TCA to inhibit T3SS in planta.
- EXAMPLE 16 Effect of TCA on HrpW of DC3000.
- the T3SS is responsible for the translocation of virulence and accessory proteins which contribute to disease in plants (Lindeberg et al. 2006).
- HrpW is a T3SS-secreted harpin capable of eliciting HR on tobacco (Charkowski et al. 1998).
- the amount of hrpW mRNA and HrpW protein levels in the DC3000 cells grown in TCA can serve as an indicator of the HR response in tobacco plants by the bacterium (Wei et al. 2000).
- Real-time PCR was performed to examine the effect of TCA on hrpW expression.
- HrpW protein was detected at similar levels of intensity when DC3000 was grown in HIM or in HIM with DMSO (TCA solvent), which suggests that the concentrations of DMSO used in this study did not cause alteration of HrpW production in the bacterium.
- TCA prevents DC3000 from causing disease in tomato.
- TCA specifically blocks the action of T3SS by inhibiting its expression.
- the effects of TCA on virulence in tomato plants were examined. Lycopersicon esculentum cv.
- Moneymaker plants were dip-inoculated with a negative control treatment (dH 2 0 with 0.02% Silwet L-77 and DMSO), a positive control treatment (DC3000 in dH 2 0 with 0.02% Silwet L-77 and DMSO), or with a chemical treatment (DC3000 in dH 2 0 with 0.02% Silwet L-77 and 250 ⁇ TCA) as described in the methods.
- DSI disease severity index
- EXAMPLE 18 Screening for Inhibitors/lnducers of the T3SS of P. aeruginosa
- a promoter-probe vector pPROBE-AT containing the promoterless green fluorescent protein (gfp) gene was used to construct an exoS promoter-g/ plasmid reporter, pATexoS.
- PA01 containing pATexoS was cultured in T3SS-inducing medium containing dimethyl sulfoxide (DMSO; solvent of chemical compounds), or supplemented with 250 ⁇ of each compound, and promoter activity was assessed at 6 h by measuring GFP intensity using flow cytometry. 101 compounds (58 synthesized and 43 commercially available) were screened.
- DMSO dimethyl sulfoxide
- EXAMPLE 19 Evaluation of the dose-dependent effects of compounds on exoS expression and bacterial growth.
- aeruginosa T3 inducer 103 shares its structure with less-functional 132 (no hydroxyl group on the phenol ring) and nonfunctional 137 (the hydroxyl group on the carbonyl-nitrogen group was replaced with a methyl group), indicating that of these two functional groups, one enhances the effect of the compound and the other is crucial for its induction activity, respectively (Table 18).
- Wild-type Erwinia amylovora 273 was used in this study.
- the promoter-probe plasmid phrpA was constructed as follows. The hrpA promoter region of Erwinia amylovora 273 was amplified and cloned into pPROBE-NT to produce PhrpA. Plasmid PhrpA was electroporated into Erwinia amylovora 273. Expression of hrpA was analyzed using a FACS Calibur flow cytometer (BD Biosciences, CA).
- Wild-type Erwinia amylovora 273 containing phrpA was cultured in a rtrp-inducing medium (HIM) containing dimethyl sulfoxide (DMSO; solvent of chemical compounds), or HIM supplemented with 100 ⁇ of each compound, and promoter activity was assessed at 6 h and 9 h by measuring GFP intensity using flow cytometry (Table 19).
- HIM rtrp-inducing medium
- DMSO dimethyl sulfoxide
- Ea273 Erwinia amylovora 273 carrying pPROBE-NT (vector control)
- Ea273 Erwinia amylovora 273 carrying phrpA
- HIM hrp inducing medium
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.
Description
METHODS OF REDUCING VIRULENCE IN BACTERIA
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001 ] This application claims priority to U.S. Provisional Application No. 61/305,027, filed on February 16, 2010, and U.S. Provisional Application No. 61/332,385, filed on May 7, 2010, each of which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under EF-0332163 awarded by the National Science Foundation. The United States government has certain rights in the invention.
FIELD OF THE INVENTION
[0003] The present invention relates to methods and compounds for controlling virulence in bacteria, methods of identifying further compounds for controlling virulence in bacteria, and methods, compounds, and compositions for treating subjects with bacterial infections to reduce virulence of bacteria in said subjects.
BACKGROUND
[0004] GacS/GacA is a two component signal transduction system ("TCSTS") that is widely distributed in many bacteria to respond to environmental stimuli and adapt to different environmental conditions. GacS is a putative histidine kinase sensor and GacA is the response regulator. The homologs of the TCSTS of GacS/GacA have been reported in a variety of Gram-negative bacteria, including E. coli (BarA/UvrY), Pectobacterium spp., S. typhimurium (BarA/SirA), Pseudomonas spp. (GacS/GacA), Legionella pneumophila (LetS/LetA) and Vibrio species.
[0005] GacS/GacA and homologous systems regulate many virulence factors including, but not limited to, regulatory RNA, quorum sensing ("QS") signals, type III secretion system ("T3SS") genes, pectate lyases, proteases, biofilm formation, and toxins. For example, in D. dadantii, the GacS/GacA system is located at the top of a regulatory cascade and functions as a central regulator by controlling an assortment of transcriptional and posttranscriptional factors. Mainly, the influence of the GacS/GacA system on pectinase production and T3SS gene expression is channeled through a regulatory RNA system, the Rsm system, by activating rsmB which binds to and inhibits the T3SS mRNA decay effect of RsmA.
[0006] In addition to the GacS/GacA-RsmA-rsmS-ftrpZ. regulatory pathway, the T3SS of Dickeya dadantii, which belongs to Group I T3SS of phytobacteria, is regulated by a HrpX/Y- HrpS-HrpL pathway. The two-component system HrpX HrpY activates the gene encoding HrpS, which is required for expression of hrpL. HrpL, an alternative sigma factor, further
activates expression of genes encoding the T3SS apparatus and its secreted products. Thus, the GacS/GacA and HrpX/HrpY TCSTS systems both exert a regulatory effect in D. dadantii, in particular through the T3SS system.
SUMMARY OF THE INVENTION
[0007] In one embodiment, the invention may provide a method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein, such as compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI) and Formula (VII) described herein.
In another embodiment, the invention may provide a compound selected from the
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 shows a regulatory network of type III secretion system (T3SS) regulatory pathways of Dickeya dadantii 3937 (Ech3937).
[0010] Figures 2A and 2B show the promoter activities of hrpN in Dickeya dadantii 3937
(Ech3937) using FACS analysis at 12 h (Figure 2A) and 24 h (Figure 2B).
[0011] Figure 3 shows the promoter activities of hrpA, hrpN, hrpL, and hrpS in Dickeya dadantii 3937 (Ech3937) and hrpL mutant WPP96 using FACS analysis.
[0012] Figure 4 shows the relative mRNA level of hrpY, hrpS, hrpL, dspE, hrpA, rsmB, and gacA of Dickeya dadantii 3937 (Ech3937) using quantitative RT-PCR (qRT-PCR).
[0013] Figure 5 shows the promoter activity of hrpN of Dickeya dadantii 3937 (Ech3937), hrpS mutant WPP90, hrpX mutant WPP67, hrpY mutant WPP92, and Ech3937 (pAT) using
FACS analysis.
[0014] Figure 6A shows biofilm and pellicle formation in SOBG broth.
[0015] Figure 6B shows cross sections of the pellicle observed with scanning electron microscopy at different magnifications.
[0016] Figure 7 shows pectate lyase (Pel), protease (Prt), and cellulase (Cel) production of wild-type Ech-Rif, gacA mutant Ech137, and gacA mutant complemented strain Ech137 (pCLgacA) examined by plate assays.
[0017] Figure 8 shows spectrophotometric quantification of pectate lyase (Pel) activity for Ech-Rif, gacA mutant Ech137, and the complementary strain Ech137 (pCLgacA).
[0018] Figure 9 shows promoter activity of pelD and pelL in Ech-Rif (black line with black filling) and gacA mutant Ech137 (gray line).
[0019] Figure 10A shows relative levels of rsmA, rsmB, rsmC, and hrpL mRNA in gacA mutant Ech137 compared with wild-type Ech-Rif grown for 6 or 12 h in a minimal medium.
[0020] Figure 10B shows relative levels of gacA and rsmB mRNA in gacA mutant Ech137 and gacA mutant complemented strain Ech137 (pCLgacA) compared with wild-type Ech-Rif grown for 12 h in a minimal medium.
[0021] Figure 11 shows local maceration lesions caused by a, Ech-Rif; b, gacA mutant Ech137; and c, complemented strain Ech137 (pCLgacA).
[0022] Figure 12 shows the bacterial population and pectinase activity of Ech-Rif (solid diamonds) and Ech137 (solid triangles) determined by plate assay and spectrophotometric quantification, respectively.
[0023] Figure 13 shows the development of systemic symptoms caused by Ech-Rif and Ech137 strains in African violet cv. Gauguin (Saintpaulia ionantha) plants.
[0024] Figure 14 shows the relative mRNA level of hrpS, hrpL, dspE, hrpA, hrpN, and rsmB of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) supplemented with 0.1 mM p-coumaric acid (PCA) compared to those in MM without PCA.
[0025] Figure 15 shows HrpN protein expression of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) and MM supplemented with p-Coumaric acid (PCA).
[0026] Figures 16A and 16B show the promoter activities of hrpA in Dickeya dadantii
3937 (Ech3937) grown in minimum medium (MM) and MM supplemented with different amount of p-coumaric acid (PCA) at 12 h (Figure 16A) and 24 h (Figure 16B).
[0027] Figure 17 shows pectate lyase (Pel) production of Dickeya dadantii 3937
(Ech3937) grown in minimal medium (MM) and MM supplemented with 0.1 mM of p- coumaric acid (PCA) at 12 h.
[0028] Figure 18 shows a scheme for synthesis of various compounds.
[0029] Figure 19 shows a scheme for synthesis of various compounds.
[0030] Figure 20 shows a scheme for synthesis of various compounds.
[0031] Figure 21 shows a scheme for synthesis of various compounds.
[0032] Figure 22 are graphs of the effect of different concentrations of compound 103 on hrpA expression.
[0033] Figure 23 shows a Northern blot for rsmB RNA of bacterial cells cultured in media supplemented with compound 103.
[0034] Figure 24 shows a scheme for synthesis of various compounds.
[0035] Figure 25 shows a scheme for synthesis of various compounds.
[0036] Figure 26 shows a scheme for synthesis of various compounds.
[0037] Figure 27 shows a scheme for synthesis of various compounds.
[0038] Figure 28 shows a scheme for synthesis of various compounds.
[0039] Figure 29 shows a scheme for synthesis of various compounds.
[0040] Figure 30 shows a scheme for synthesis of various compounds.
[0041 ] Figure 31 shows a Table of Bacterial strains, plasmids, and primers used in this study.
[0042] Figure 32 shows the compounds screened for Pseudomonas syringae pv. tomato DC3000 (DC3000) hrpA inducers and inhibitors. Expression of DC3000 hrpA in HIM or HIM supplemented with different compounds.
[0043] Figure 33 shows a hrpA promoter activity and growth of Pseudomonas syringae pv. tomato DC3000 carrying GFP reporter plasmid phrpA grown in HIM supplemented with different concentrations of TCA at (A) 6 h and (B) 9 h of growth.
[0044] Figure 34 shows: (A) Tobacco leaves (N. tabacum cv. Xanthi) were infiltrated with Pseudomonas syringae pv. tomato DC3000 (DC3000) (OD600= 0.1 ) or DC3000 (OD600= 0.1 ) supplemented with different concentrations of the T3SS inhibitor TCA. 1. 25 μΜ. 2. 50 μΜ. 3. 100 μΜ. 4. 250 μΜ. 5. 500 μΜ. 6. to 10. : DC3000 alone. (Β) Tobacco leaves were infiltrated with DC3000 (OD60o= 0.1 ) or DC3000 (OD600= 0.1 ) supplemented with different concentrations of 104. 1. 25 μΜ. 2. 50 μΜ. 3. 100 μΜ. 4. 250 μΜ. 5. 500 μΜ. 6. to 10. : DC3000 alone.
[0045] Figure 35 shows an HrpW immunoblot analysis was performed using anti-HrpW polyclonal antibody. Samples were taken at two different time points; 9 h and 12 h after subculturing cells into HIM medium. Chemiluminescent signals were detected by 6 min and 8 min exposure for cytoplasmic and supernatant fractions, respectively. Lane 1 , Pseudomonas syringae pv. tomato DC3000 (DC3000) in HIM; lane 2, DC3000 in HIM supplemented with DMSO; lane 3, DC3000 in HIM supplemented with 250 μΜ TCA.
[0046] Figure 36 shows: Bacterial suspension of Pseudomonas syringae pv. tomato DC3000 (DC3000) was diluted to 6* 105 CFU/ml in dH20 and 0.02% Silwet L-77 for dip- inoculation. (A) DC3000 supplemented with 250 μΜ of 001. No lesions of bacterial speck were observed in tomato plants treated with TCA. (B) DC3000 alone.
[0047] Figure 37 shows the effects of compounds on exoS expression and bacterial growth. Gray lines represent the exoS expression levels of the cells treated with DMSO.
[0048] Figure 38 shows an evaluation of the dose-dependent effect of compounds on exoS expression. Dose-dependent effect of (A) T3 inhibitors or (B) T3 inducers on exoS expression. X-axis represents the relative exoS expression level (compound/DMSO). Black lines represent asymptotic lines for the DMSO-treated samples.
[0049] Figure 39 shows an evaluation of the dose-dependent effect of compounds on P. aeruginosa growth. Dose-dependent effect of (A) T3 inhibitors or (B) T3 inducers on P. aeruginosa growth. X-axis represents the relative cell density (compound/DMSO). Black- lines represent asymptotic lines for the DMSO-treated samples.
[0050] Figure 40 shows an evaluation of the dose-dependent effect of compounds on exoS expression and cell populations. X-axis, MFI (mean fluorescence intensity); Y-axis, cell number; Z-axis, concentration of the compound.
[0051] Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limited.
DETAILED DESCRIPTION OF THE INVENTION
[0052] A regulatory role for the two-component system GacS/GacA on the type III secretion system ("T3SS") of Dickeya dadantii 3937 (Ech3937) has been demonstrated to channel through a regulator of secondary metabolism (Rsm) system. Rsm is a novel type of post-transcriptional regulatory system that plays a critical role in gene expression. RsmA is a small RNA-binding protein that acts by lowering the half-life of the target mRNA. rsmB is an untranslated regulatory RNA that binds RsmA and inhibits its activity by forming an inactive ribonucleoprotein complex. In Ech3937, GacS/GacA upregulates hrpL mRNA through a post-transcriptional regulation by enhancing the rsmB RNA level, which binds to RsmA and inhibits the hrpL mRNA decay effect of RsmA (Figure 1 ).
[0053] Figure 1 shows a regulatory network of type III secretion system (T3SS) of Dickeya dadantii 3937 (Ech3937). Lines with a (+) symbol designate positive regulation, and the line with a (-) symbol indicates negative regulation. The T3SS of Ech3937 is regulated by the HrpX/HrpY-HrpS-HrpL and GacS/GacA-rsmS-HrpL regulatory pathways. The two- component system HrpX/HrpY activates the gene encoding a o54-enhancer HrpS, which is
required for expression of an alternative sigma factor, hrpL. HrpL further activates expression of genes encoding the T3SS apparatus and its secreted products.
[0054] The T3SS contributes to bacterial virulence within a host. A gacA deletion mutant of Dickeya dadantii (Erwinia chrysanthemi 3937) was found to exhibit diminished production of pectate lyase, protease, and cellulose, enzymes that normally lead to loss of structural integrity of plant cell walls. Diminished production of enzymes that attack the plant cell walls leads to diminished bacterial virulence.
[0055] Several compounds, including o-coumaric acid ("OCA") and ί-cinnamic acid ("TCA"), have been identified as inducers of the GacS/GacA regulatory system. Induction of the GacS/GacA system in turn affects the Rsm system, which further affects the expression of T3SS genes, including pectinase genes.
[0056] In further studies the inventors have screened compounds, including i-cinnamic acid, o-coumaric acid, m-coumaric acid, p-coumaric acid, hydrocinnamic acid, phenoxyacetic acid, frans-2-phenylcyclopropane-1-carboxylic acid, frans-3-(3-pyridyl) acrylic acid, trans-3- indoleacrylic acid, 2-methylcinnamic acid, 2-chlorocinnamic acid, methyl frans-cinnamate, and cinnamyl alcohol. Two compounds, p-coumaric acid (PCA) and cinnamyl alcohol, were found to reduce induction of virulence in Dickeya dadantii. Without being limited as to theory, PCA appears to reduce virulence through the HrpX/HrpY system (see Figure 1 , Example 10).
[0057] Based on the discovery that OCA, TCA, PCA, and cinnamyl alcohol can regulate (i.e. promote or reduce) bacterial virulence, further screening was conducted in order to identify compounds that reduce bacterial virulence. Various compounds were synthesized and screened for their ability to reduce bacterial virulence. The synthesized compounds were tested for an ability to reduce virulence of bacteria having a two-component signal transduction system such as a GacS/GacA system (or a homolog of the GacS/GacA system), a HrpX/HrpY system (or a homolog of the HrpX/HrpY system), an Rsm system (or homolog), and/or a T3SS system (or homolog).
[0058] The compounds produced for testing include compounds referred to herein as "phenylpropanoid derivatives." A description of phenylpropanoid derivatives generally is found in U.S. Patent Application No. 12/595,148, filed October 8, 2009, and incorporated herein by reference in its entirety.
Definitions
[0059] Each of the groups defined below may be substituted with one or more of the moieties defined herein.
[0060] Alkyl: The term "alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from
1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, cycloalkyenyl, cylcoalkynyl, etc., discussed below.
[0061] In the context of alkyl groups, the prefixes (e.g., C^, Ci_7, Ci.2o> C2.7, C3.7, etc.) denote the number of carbon atoms, or range of number of carbon atoms. For example, the term "C^ alkyl" as used herein, pertains to an alkyl group having from 1 to 4 carbon atoms. Examples of groups of alkyl groups include
alkyl ("lower alkyl"), C1-7 alkyl, C1-2o alkyl and Ci-3o alkyl. Note that the first prefix may vary according to other limitations; for example, for unsaturated alkyl groups, the first prefix must be at least 2; for cyclic and branched alkyl groups, the first prefix must be at least 3; etc.
[0062] Examples of saturated alkyl groups include, but are not limited to, methyl (Ci), ethyl (C2), propyl (C3), butyl (C4), pentyl (C5), hexyl (C6), heptyl (C7), octyl (C8), nonyl (C9), decyl (C10), undecyl (C ), dodecyl (C12), tridecyl (C13), tetradecyl (C14), pentadecyl (Ci5), and eicodecyl (C20).
[0063] Examples of saturated linear alkyl groups include, but are not limited to, methyl (d), ethyl (C2), n-propyl (C3), n-butyl (C4), n-pentyl (amyl) (C5), n-hexyl (C6), and n-heptyl (C7).
[0064] Examples of saturated branched alkyl groups include iso-propyl (C3), iso-butyl (C4), sec-butyl (C ), tert-butyl (C4), iso-pentyl (C5), and neo-pentyl (C5).
[0065] Alkenyl: The term "alkenyl" as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds. Examples of groups of alkenyl groups include C2-4 alkenyl, C2.7 alkenyl, C2.20 alkenyl.
[0066] Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH2), 1-propenyl (-CH=CH-CH3), 2-propenyl (allyl, -CH-CH=CH2), isopropenyl (1-methylvinyl, -C(CH3)=CH2), butenyl (C4), pentenyl (C5), and hexenyl (C6).
[0067] Alkynyl: The term "alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds. Examples of groups of alkynyl groups include C2 alkynyl, C2.7 alkynyl, C2.2o alkynyl.
[0068] Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C≡CH) and 2-propynyl (propargyl, -CH2-C≡CH).
[0069] Cycloalkyl: The term "cycloalkyl" as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound, which carbocyclic ring may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated), which moiety has from 3 to 20 carbon atoms (unless otherwise specified), including from 3 to 20 ring atoms. Thus, the term "cycloalkyl" includes the sub-classes
cycloalkyenyl and cycloalkynyl. Preferably, each ring has from 3 to 7 ring atoms. Examples of groups of cycloalkyl groups include C3.3o cycloalkyl, C3.2o cycloalkyl, C3.i0 cycloalkyl, C3.7 cycloalkyl.
[0070] Examples of cycloalkyl groups include, but are not limited to, those derived from: saturated monocyclic hydrocarbon compounds (cyclopropane (C3), cyclobutane (C4), cyclopentane (C5), cyclohexane (C6), cycloheptane (C7), methylcyclopropane (C4), dimethylcyclopropane (C5), methylcyclobutane (C5), dimethylcyclobutane (C6), methylcyclopentane (C6), dimethylcyclopentane (C7), methylcyclohexane (C7), dimethylcyclohexane (C8), menthane (C10)); unsaturated monocyclic hydrocarbon compounds (cyclopropene (C3), cyclobutene (C4), cyclopentene (C5), cyclohexene (C6), methylcyclopropene (C ), dimethylcyclopropene (C5), methylcyclobutene (C5), dimethylcyclobutene (C6), methylcyclopentene (C6), dimethylcyclopentene (C ), methylcyclohexene (C7), dimethylcyclohexene (C8)); saturated polycyclic hydrocarbon compounds (thujane (Ci0), carane (C10), pinane (C 0), bornane (Cio), norcarane (C7), norpinane (C7), norbomane (C7), adamantane (Ci0), decalin (decahydronaphthalene) (Ci0)); unsaturated polycyclic hydrocarbon compounds (camphene (Ci0), limonene (C10), pinene (Cio)); and polycyclic hydrocarbon compounds having an aromatic ring (indene (C9), indane (e.g., 2,3-dihydro-1 H-indene) (C9), tetraline (1 ,2,3,4-tetrahydronaphthalene) (C10), acenaphthene (C 2), fluorene (Ci3), phenalene (C13), acephenanthrene (C15), aceanthrene (C 6), cholanthrene (C20)).
[0071] Hydroxyalkyl: The term "hydroxyalkyl" as used herein pertains to an alkyl group in which a hydrogen atom has been replaced with a hydroxyl group.
[0072] Heterocyclyl: The term "heterocyclyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.
[0073] In this context, the prefixes (e.g., C3.2o, C3.7, 05-6, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C5^ heterocyclyl" as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms. Examples of groups of heterocyclyl groups include C3-30 heterocyclyl, C3.20 heterocyclyl, Cs.20 heterocyclyl, C3-i5 heterocyclyl, Cs-is heterocyclyl, C3- 2 heterocyclyl, C5.i2 heterocyclyl, C3.i0 heterocyclyl, C5.10 heterocyclyl, C3.7 heterocyclyl, C$.7 heterocyclyl, and heterocyclyl.
[0074] Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from: aziridine (C3), azetidine (C4), pyrrolidine (tetrahydropyrrole) (C5), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C5), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole)
(C5), piperidine (C6), dihydropyridine (C6), tetrahydropyridine (C6), azepine (C7); Οΰ oxirane (C3), oxetane (C4), oxolane (tetrahydrofuran) (C5), oxole (dihydrofuran) (C5), oxane (tetrahydropyran) (C6), dihydropyran (C6), pyran (C6), oxepin (C7); Sv thiirane (C3), thietane (C4), thiolane (tetrahydrothiophene) (C5), thiane (tetrahydrothiopyran) (C6), thiepane (C7); 02: dioxolane (C5), dioxane (C6), and dioxepane (C7); 03: trioxane (C6); N2: imidazolidine (C5), pyrazolidine (diazolidine) (C5), imidazoline (C5), pyrazoline (dihydropyrazole) (C5), piperazine (C6); NiO, tetrahydrooxazole (C5), dihydrooxazole (C5), tetrahydroisoxazole (C5), dihydroisoxazole (C5), morpholine (C6), tetrahydrooxazine (C6), dihydrooxazine (C6), oxazine (C6); NiS,: thiazoline (C5), thiazolidine (C5), thiomorpholine (C6); N20^. oxadiazine (C6); O1S1: oxathiole (C5) and oxathiane (thioxane) (C6); and
oxathiazine (C6).
[0075] Examples of substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C5), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C6), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.
[0076] Aryl: The term "aryl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified). Preferably, each ring has from 5 to 7 ring atoms.
[0077] In this context, the prefixes (e.g. C3.20, C5.7, C5-6, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C5-6 aryl" as used herein, pertains to an aryl group having 5 or 6 ring atoms. Examples of groups of aryl groups include C3.30 aryl, C3.2o aryl, C5-20 aryl, C5- 5 aryl, C5-i2 aryl, C5-io aryl, Cs- aryl, C5^ aryl, C5 aryl, and C6 aryl.
[0078] The ring atoms may be all carbon atoms, as in "carboaryl groups". Examples of carboaryl groups include C3.20 carboaryl, C5.20 carboaryl, Cs-is carboaryl, C5-12 carboaryl, C5.10 carboaryl, C5.7 carboaryl, C5-3 carboaryl and C6 carboaryl.
[0079] Examples of carboaryl groups include, but are not limited to, those derived from benzene (i.e., phenyl) (C6), naphthalene (C 0), azulene (C10), anthracene (Ci4), phenanthrene (C14), naphthacene (C18), and pyrene (C16).
[0080] Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g., 2,3-dihydro- 1 H-indene) (C9), indene (C9), isoindene (C9), tetraline (1 ,2,3,4-tetrahydronaphthalene (C 0), acenaphthene (Ci2), fluorene (C 3), phenalene (Ci3), acephenanthrene (C15), and aceanthrene (C16).
[0081] Alternatively, the ring atoms may include one or more heteroatoms, as in "heteroaryl groups". Examples of heteroaryl groups include C3.20 heteroaryl, CS-M heteroaryl,
C5.15 heteroaryl, Cs.12 heteroaryl, C5.10 heteroaryl, C5-7 heteroaryl,^ heteroaryl, C5 heteroaryl, and C6 heteroaryl.
[0082] Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from: pyrrole (azole) (C5), pyridine (azine) (C6); 0Ί: furan (oxole) (C5); S,: thiophene (thiole) (C5); Ν,Ο·, oxazole (C5), isoxazole (C5), isoxazine (C6); N20^\ oxadiazole (furazan) (C5); N3O1: oxatriazole (C5); NTSI: thiazole (C5), isothiazole (C5); N2: imidazole (1 ,3-diazole) (C5), pyrazole (1 ,2-diazole) (C5), pyridazine (1 ,2-diazine) (C6), pyrimidine (1 ,3-diazine) (C6) (e.g., cytosine, thymine, uracil), pyrazine (1 ,4-diazine) (C6); N3: triazole (C5), triazine (C6); and N4: tetrazole (C5).
[0083] Examples of heteroaryl groups which comprise fused rings, include,' but are not limited to: C9 heteroaryl groups (with 2 fused rings) derived from benzofuran (O^), isobenzofuran (O1), indole (N^, isoindole (N^, indolizine ( ^, indoline (N^, isoindoline (N^, purine (N4) (e.g., adenine, guanine), benzimidazole (N2), indazole (N2), benzoxazole (NTCM), benzisoxazole (NiOi), benzodioxole (02), benzofurazan (N2Oi), benzotriazole (N3), benzothiofuran (Si), benzothiazole (NTSI), benzothiadiazole (N2S); Ci0 heteroaryl groups (with 2 fused rings) derived from chromene (ΟΊ), isochromene (ΟΊ), chroman (O,), isochroman (O^, benzodioxan (02), quinoline (N^, isoquinoline (N,), quinolizine (N^, benzoxazine (N^), benzodiazine (N2), pyridopyridine (N2), quinoxaline (N2), quinazoline (N2), cinnoline (N2), phthalazine (N2), naphthyridine (N2), pteridine (N4); Cn heteroaryl groups (with 2 fused rings) derived from benzodiazepine (N2); C13 heteroaryl groups (with 3 fused rings) derived from carbazole (Ni), dibenzofuran (CM), dibenzothiophene (Si), carboline (N2), perimidine (N2), pyridoindole (N2); and C14 heteroaryl groups (with 3 fused rings) derived from acridine (Ni), xanthene (O^, thioxanthene (S^, oxanthrene (02), phenoxathiin
phenothiazine thianthrene (S2), phenanthridine (N^, phenanthroline (N2), phenazine (N2).
[0084] Heteroaryl groups which have a nitrogen ring atom in the form of an -NH- group may be N-substituted, that is, as -NR-. For example, pyrrole may be N-methyl substituted, to give N-methylpyrrole. Examples of N-substituents include, but are not limited to C1.7 alkyl, C3.20 heterocyclyl, C5.2o aryl, and acyl groups.
[0085] Heterocyclic groups (including heteroaryl groups) which have a nitrogen ring atom in the form of an -N= group may be substituted in the form of an N-oxide, that is, as -N(—>0)= (also denoted -N+(→0")=). For example, quinoline may be substituted to give quinoline N-oxide; pyridine to give pyridine N-oxide; benzofurazan to give benzofurazan N- oxide (also known as benzofuroxan).
[0086] Cyclic groups may additionally bear one or more oxo (=0) groups on ring carbon atoms.
[0087] The above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below.
[0088] Halo: -F, -CI, -Br, and -I.
[0089] Hydroxy: -OH.
[0090] Ether: -OR, wherein R is an ether substituent, for example, a C1-7 alkyl group (also referred to as a alkoxy group, discussed below), a C3-20 heterocyclyl group (also referred to as a C3.2o heterocyclyloxy group), or a C5.20 aryl group (also referred to as a C5.20 aryloxy group), preferably a C -7alkyl group.
[0091] Alkoxy: -OR, wherein R is an alkyl group, for example, a 01-7 alkyl group. Examples of C alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec- butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).
[0092] Acetal: -CH(OR)2, wherein each R is independently an acetal substituents, for example, a C -7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a C1-7 alkyl group, or, in the case of a "cyclic" acetal group, R and R2, taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups include, but are not limited to, -CH(OMe)2, -CH(OEt)2, and -CH(OMe)(OEt).
[0093] Hemiacetal: -CH(OH)(OR), wherein R is a hemiacetal substituent, for example, a Ci- alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a C1- alkyl group. Examples of hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and - CH(OH)(OEt).
[0094] Ketal: -CR(OR)2, where each R is defined as for acetals, and each R is independently a ketal substituent other than hydrogen, for example, a d.7 alkyl group, a C3-20 heterocyclyl group, or a C5.20 aryl group, preferably a C1-7 alkyl group. Examples ketal groups include, but are not limited to, -C(Me)(OMe)2, -C(Me)(OEt)2, -C(Me)(OMe)(OEt), - C(Et)(OMe)2, -C(Et)(OEt)2, and -C(Et)(OMe)(OEt).
[0095] Hemiketal: -CR(OH)(OR), where R is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C -7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a Ci- alkyl group. Examples of hemiacetal groups include, but are not limited to, -C(Me)(OH)(OMe), -C(Et)(OH)(OMe), -C(Me)(OH)(OEt), and -C(Et)(OH)(OEt).
[0096] Oxo (keto, -one): =0.
[0097] Thione (thioketone): =S.
[0098] Imino (imine): =NR, wherein R is an imino substituent, for example, hydrogen, C1.7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably hydrogen or a C1-7
alkyl group. Examples of ester groups include, but are not limited to, =NH, =NMe, =NEt, and =NPh.
[0099] Formyl (carbaldehyde, carboxaldehyde): -C(=0)H.
[00100] Acyl (keto): -C(=0)R, wherein R is an acyl substituent, for example, a C1-7 alkyl group (also referred to as C .7 alkylacyl or C,.7 alkanoyl), a C3-2o heterocyclyl group (also referred to as C3.2o heterocyclylacyl), a C5.2o aryl group (also referred to as C5.2o arylacyl), preferably a C1.7 alkyl group or a halo. Examples of acyl groups include, but are not limited to, -C(=0)CH3 (acetyl), -C(=0)CH2CH3 (propionyl), -C(=0)C(CH3)3 (t-butyryl), -C(=0)Ph
(benzoyl, phenone), -C(=0)CI.
[00101] Carboxy (carboxylic acid): -C(=0)OH.
[00102] Thiocarboxy (thiocarboxylic acid): -C(=S)SH.
[00103] Thiolocarboxy (thiolocarboxylic acid): -C(=0)SH.
[00104] Thionocarboxy (thionocarboxylic acid): -C(=S)OH.
[00105] Imidic acid: -C(=NH)OH.
[00106] Hydroxamic acid: -C(=NOH)OH.
[00107] Ester (carboxylate, carboxylic acid ester, oxycarbonyl): -C(=0)OR, wherein R is an ester substituent, for example, a C1-7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a C1.7 alkyl group. Examples of ester groups include, but are not limited to, -C(=0)OCH3, -C(=0)OCH2CH3, -C(=0)OC(CH3)3, and -C(=0)OPh.
[00108] Acyloxy (reverse ester): -OC(=0)R, wherein R is an acyloxy substituent, for example, a C1.7 alkyl group, a C3.20 heterocyclyl group, or a C^o aryl group, preferably a C1-7 alkyl group. Examples of acyloxy groups include, but are not limited to, -OC(=0)CH3 (acetoxy), -OC(=0)CH2CH3, -OC(=0)C(CH3)3l -OC(=0)Ph, and -OC(=0)CH2Ph.
[00109] Oxycarboyloxy: -OC(=0)OR, wherein R is an ester substituent, for example, a C1-7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a Ci.7 alkyl group. Examples of ester groups include, but are not limited to, -OC(=0)OCH3, -OC(=0)OCH2CH3, -OC(=0)OC(CH3)3, and -OC(=0)OPh.
[00110] Amino: -NR2, wherein each R is independently an amino substituent, for example, hydrogen, a C1-7 alkyl group (also referred to as Ci_7 alkylamino or di-C1-7 alkylamino), a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably H or a C1-7 alkyl group, or, in the case of a "cyclic" amino group, both R's, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups may be primary (-NH2), secondary (-NHR), or tertiary (-NHR2), and in cationic form, may be quaternary (-+NR3). Examples of amino groups include, but are not limited to, -NH2, -NHCH3, -NHC(CH3)2, -N(CH3)2, -N(CH2CH3)2, and -NHPh. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.
[00111] Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): -C(=0)NR2, wherein each R is independently an amino substituent, as defined for amino groups. Examples of amido groups include, but are not limited to, -C(=0)NH2, -C(=0)NHCH3, -C(=0)N(CH3)2, -C(=0)NHCH2CH3, and -C(=0)N(CH2CH3)2, as well as amido groups in which both R's, together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.
[00112] Thioamido (thiocarbamyl): -C(=S)NR2, wherein each R is independently an amino substituent, as defined for amino groups. Examples of amido groups include, but are not limited to, -C(=S)NH2, -C(=S)NHCH3, -C(=S)N(CH3)2, and -C(=S)NHCH2CH3.
[00113] Acylamido (acylamino): -NR10C(=O)R11, wherein R10 is an amide substituent, for example, hydrogen, a C-\.7 alkyl group, a C3.2o heterocyclyl group, or a C5.20 aryl group, preferably hydrogen or a alkyl group, and R 1 is an acyl substituent, for example, a Ci-7 alkyl group, a C3-20 heterocyclyl group, or a C5-2oaryl group, preferably hydrogen or a C†.7 alkyl group. Examples of acylamide groups include, but are not limited to, -NHC(=0)CH3 , -NHC(=0)CH2CH3, and -NHC(=0)Ph. R 0 and R1 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:
succinimidyl maleimidyl phthalimidyl
[00114] Aminocarbonyloxy: -OC(=0)NR2, wherein each R is independently an amino substituent, as defined for amino groups. Examples of aminocarbonyloxy groups include, but are not limited to, -OC(=0)NH2, -OC(=0)NHMe, -OC(=0)NMe2, and -OC(=0)NEt2.
[00115] Ureido: -N(R12)CONR2 wherein each R is independently an amino substituent, as defined for amino groups, and R12 is a ureido substituent, for example, hydrogen, a C1-7 alkyl group, a C3.20 heterocyclyl group, or a Cs^o aryl group, preferably hydrogen or a alkyl group. Examples of ureido groups include, but are not limited to, -NHCONH2, -NHCONHMe, -NHCONHEt, -NHCONMe2, -NHCONEt2, -NMeCONH2, -NMeCONHMe, -NMeCONHEt, - NMeCONMe2, and -NMeCONEt2.
[00116] Guanidino: -NH-C(=NH)NH2.
[00117] Imino: =NR, wherein R is an imino substituent, for example, for example, hydrogen, a C -7 alkyl group, a C3.20 heterocyclyl group, or a C^o aryl group, preferably H or a C1-7alk l group. Examples of imino groups include, but are not limited to, =NH, =NMe, and =NEt.
[00118] Amidine (amidino): -C(=NR)NR2, wherein each R is independently an amidine substituent, for example, hydrogen, a C1.7 alkyl group, a C3.2o heterocyclyl group, or a C5.20 aryl group, preferably H or a C1.7 alkyl group. Examples of amidine groups include, but are not limited to, -C(=NH)NH2, -C(=NH)NMe2, and -C(=NMe)NMe2.
[00119] Nitro: -N02.
[00120] Nitroso: -NO.
[00121] Azido: -N3.
[00122] Cyano (nitrile, carbonitrile): -CN.
[00123] Isocyano: -NC.
[00124] Cyanato: -OCN.
[00125] Isocyanato: -NCO.
[00126] Thiocyano (thiocyanato): -SCN.
[00127] Isothiocyano (isothiocyanato): -NCS.
[00128] Sulfhydryl (thiol, mercapto): -SH.
[00129] Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a C alkyl group (also referred to as a Cwalkylthio group), a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a C1-7 alkyl group. Examples of C1-7 alkylthio groups include, but are not limited to, -SCH3 and -SCH2CH3.
[00130] Disulfide: -SS-R, wherein R is a disulfide substituent, for example, a C1.7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group, preferably a C1.7 alkyl group (also referred to herein as C -7 alkyl disulfide). Examples of C1.7 alkyl disulfide groups include, but are not limited to, -SSCH3 and -SSCH2CH3.
[00131] Sulfine (sulfinyl, sulfoxide): -S(=0)R, wherein R is a sulfine substituent, for example, a alkyl group, a C3.20 heterocyclyl group, or a C5.2o aryl group, preferably a C1.7 alkyl group. Examples of sulfine groups include, but are not limited to, -S(=0)CH3 and -S(=0)CH2CH3.
[00132] Sulfone (sulfonyl): -S(=0)2R, wherein R is a sulfone substituent, for example, a Ci.7 alkyl group, a C3.2o heterocyclyl group, or a C5.2o aryl group, preferably a C1-7 alkyl group, including, for example, a fluorinated or perfluorinated Ci_7 alkyl group. Examples of sulfone groups include, but are not limited to, -S(=0)2CH3 (methanesulfonyl, mesyl), -S(=0)2CF3 (triflyl), -S(=0)2CH2CH3 (esyl), -S(=0)2C4F9 (nonaflyl), -S(=0)2CH2CF3 (tresyl), -S(=0)2CH2CH2NH2 (tauryl), -S(=0)2Ph (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-1-ylsulfonate (dansyl).
[00133] Sulfinic acid (sulfino): -S(=0)OH, -S02H.
[00134] Sulfonic acid (sulfo): -S(=0)2OH, -S03H.
[00135] Sulfinate (sulfinic acid ester): -S(=0)OR; wherein R is a sulfinate substituent, for example, a Ci-7 alkyl group, a C3-20 heterocyclyl group, or a C5.20 aryl group, preferably a Ci_7 alkyl group. Examples of sulfinate groups include, but are not limited to, -S(=0)OCH3 (methoxysulfinyl; methyl sulfinate) and -S(=0)OCH2CH3 (ethoxysulfinyl; ethyl sulfinate).
[00136] Sulfonate (sulfonic acid ester): -S(=0)2OR, wherein R is a sulfonate substituent, for example, a alkyl group, a C3-20 heterocyclyl group, or a C5.20 aryl group, preferably a C1-7 alkyl group. Examples of sulfonate groups include, but are not limited to, -S(=0)20CH3 (methoxysulfonyl; methyl sulfonate) and -S(=0)2OCH2CH3 (ethoxysulfonyl; ethyl sulfonate).
[00137] Sulfinyloxy: -OS(=0)R, wherein R is a sulfinyloxy substituent, for example, a alkyl group, a C3.2o heterocyclyl group, or a C5.2o aryl group, preferably a C1-7 alkyl group. Examples of sulfinyloxy groups include, but are not limited to, -OS(=0)CH3 and -OS(=0)CH2CH3.
[00138] Sulfonyloxy: -OS(=0)2R, wherein R is a sulfonyloxy substituent, for example, a Ci.7 alkyl group, a C3.2o heterocyclyl group, or a C5.2o aryl group, preferably a C1-7 alkyl group. Examples of sulfonyloxy groups include, but are not limited to, -OS(=0)2CH3 (mesylate) and -OS(=0)2CH2CH3 (esylate).
[00139] Sulfate: -OS(=0)2OR; wherein R is a sulfate substituent, for example, a C -7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a alkyl group. Examples of sulfate groups include, but are not limited to, -OS(=0)2OCH3 and -SO(=0)2OCH2CH3.
[00140] Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): -S(=0)NR2, wherein each R is independently an amino substituent, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, -S(=0)NH2, -S(=0)NH(CH3), -S(=0)N(CH3)2, -S(=0)NH(CH2CH3), -S(=0)N(CH2CH3)2, and -S(=0)NHPh.
[00141] Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): -S(=0)2NR2, wherein each R is independently an amino substituent, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, -S(=0)2NH2, -S(=0)2NH(CH3), -S(=0)2N(CH3)2, -S(=0)2NH(CH2CH3), -S(=0)2N(CH2CH3)2, and -S(=0)2NHPh.
[00142] Sulfamino: -NRS(=0)2OH, wherein R is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, but are not limited to, -NHS(=0)2OH and -N(CH3)S(=0)2OH.
[00143] Sulfonamino: -NR13S(=0)2R, wherein R13 is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a Ci.7 alkyl group, a C3-20 heterocyclyl group, or a C5.20 aryl group, preferably a C,.7 alkyl group. Examples of sulfonamino groups include, but are not limited to, -NHS(=0)2CH3 and -N(CH3)S(=0)2C6H5.
[00144] Sulfinamino: -NR13S(=0)R, wherein R13 is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for example, a Ci_7 alkyl group, a C3.20 heterocyclyl group, or a C5-20 aryl group, preferably a C1.7 alkyl group. Examples of sulfinamino groups include, but are not limited to, -NHS(=0)CH3 and -N(CH3)S(=0)C6H5.
[00145] Silyl: -SiR3, wherein each R is independently a silyl substituent, for example, H, a Ci.7 alkyl group, a C3.2o heterocyclyl group, or a C5.2o aryl group, preferably a Ci-7 alkyl group.
[00146] Phosphino (phosphine): -PR2, wherein each R is independently a phosphino substituent, for example, -H, a C1.7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably -H, a Ci-7 alkyl group, or a C5.2o aryl group. Examples of phosphino groups include, but are not limited to, -PH2, -P(CH3)2, -P(CH2CH3)2, -P(t-Bu)2, and -P(Ph)2.
[00147] Phospho: -P(=0)2.
[00148] Phosphinyl (phosphine oxide): -P(=0)R2, wherein each R is independently a phosphinyl substituent, for example, a C -7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably a C -7 alkyl group or a C5.20 aryl group. Examples of phosphinyl groups include, but are not limited to, -P(=0)(CH3)2, -P(=0)(CH2CH3)2, -P(=0)(t-Bu)2, and -P(=0)(Ph)2.
[00149] Phosphonic acid (phosphono): -P(=0)(OH)2.
[00150] Phosphonate (phosphono ester): -P(=0)(OR)2, wherein each R is independently a phosphonate substituent, for example, -H, a Ci-7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably -H, a C1-7 alkyl group, or a C5.20 aryl group. Examples of phosphonate groups include, but are not limited to, -P(=0)(OCH3)2, -P(=0)(OCH2CH3)2, -P(=0)(0-t-Bu)2, and -P(=0)(OPh)2.
[00151] Phosphoric acid (phosphonooxy): -OP(=0)(OH)2.
[00152] Phosphate (phosphonooxy ester): -OP(=0)(OR)2, wherein each R is independently a phosphate substituent, for example, -H, a Ci-7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably -H, a Ci-7 alkyl group, or a C5.20 aryl group. Examples of phosphate groups include, but are not limited to, -OP(=0)(OCH3)2, -OP(=0)(OCH2CH3)2, -OP(=0)(0-t-Bu)2, and -OP(=0)(OPh)2.
[00153] Phosphorous acid: -OP(OH)2.
[00154] Phosphite: -OP(OR)2, wherein each R is independently a phosphite substituent, for example, -H, a C -7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably -H, a C1-7 alkyl group, or a C^o aryl group. Examples of phosphite groups include, but are not limited to, -OP(OCH3)2, -OP(OCH2CH3)2, -OP(0-t-Bu)2, and -OP(OPh)2.
[00155] Phosphoramidite: -OP(OR)-NR2, wherein each R is independently a phosphoramidite substituent, for example, -H, a (optionally substituted) C1-7 alkyl group, a C3.20 heterocyclyl group, or a C5.20 aryl group, preferably -H, a Ci.7 alkyl group, or a C5-20 aryl
group. Examples of phosphoramidite groups include, but are not limited to, -OP(OCH2CH3)- N(CH3)2, -OP(OCH2CH3)-N(i-Pr)2, and -OP(OCH2CH2CN)-N(i-Pr)2.
[00156] Phosphoramidate: -OP(=0)(OR)-NR2l wherein each R is independently a phosphoramidate substituent, for example, -H, a (optionally substituted) C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group, preferably -H, a Ci-7 alkyl group, or a C5-20 aryl group. Examples of phosphoramidate groups include, but are not limited to, -OP(=0)(OCH2CH3)-N(CH3)2, -OP(=0)(OCH2CH3)-N(i-Pr)2, and -OP(=0)(OCH2CH2CN)-N(i- Pr)2.
[00157] The term "alkylene", as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 1 to 12 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated. Thus, the term "alkylene" includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.
[00158] Examples of linear saturated alkylene groups include, but are not limited to, -(CH2)n- where n is an integer from 3 to 12, for example, -CH2CH2CH2- (propylene), -CH2CH2CH2CH2- (butylene), -CH2CH2CH2CH2CH2- (pentylene) and -CH2CH2CH2CH- 2CH2CH2CH2- (heptylene).
[00159] Examples of branched saturated alkylene groups include, but are not limited to, -CH(CH3)CH2-, -CH(CH3)CH2CH2-, -CH(CH3)CH2CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH(CH3)CH2CH2-, -CH(CH2CH3)-, -CH(CH2CH3)CH2-, and -CH2CH(CH2CH3)CH2-.
[00160] Examples of linear partially unsaturated alkylene groups (alkenylene, and alkynylene groups) include, but are not limited to, -CH=CH-CH2-, -CH2-CH=CH2-, -CH=CH-CH2-CH2-, -CH=CH-CH2-CH2-CH2-, -CH=CH-CH=CH-, -CH=CH-CH=CH-CH2-, - CH=CH-CH=CH-CH2-CH2-, -CH=CH-CH2-CH=CH-, -CH=CH-CH2-CH2-CH=CH-, and -CH2- C≡C-CH2-.
[00161] Examples of branched partially unsaturated alkylene groups (alkenylene and alkynylene groups) include, but are not limited to, -C(CH3)=CH-, -C(CH3)=CH-CH2-, -CH=CH-CH(CH3)- and -C≡C-CH(CH3)-.
[00162] Examples of alicyclic saturated alkylene groups (cycloalkylenes) include, but are not limited to, cyclopropylene (e.g. cycloprop-1 ,2-ylene), cyclobutylene (e.g. cyclobut-1 ,2- ylene), cyclopentylene (e.g. cyclopent-1 ,3-ylene), and cyclohexylene (e.g. cyclohex-1 ,4-ylene).
[00163] Examples of alicyclic partially unsaturated alkylene groups (cycloalkylenes) include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1 ,3-ylene), cyclohexenylene (e.g. 2-cyclohexen-1 ,4-ylene; 3-cyclohexen-1 ,2-ylene; 2,5-cyclohexadien- 1 ,4-ylene).
[00164] The term "C1-3 alkylene" as used herein, is an alkylene as defined above group and having from 1 to 3 carbon atoms. Alkylene includes cyclopropylene groups.
[00165] The term "heteroalkylene", as used herein, pertains to an alkylene group in which at least one carbon atom has been replaced with a heteroatom such as O, S or NR, wherein R is hydrogen, a Ci_7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group, preferably H or a C .7 alkyl group . Examples of heteroalkylene groups include, but are not limited to, - O-CH2-, -NH-CH2-, -S-CH2-, -O-CH2-CH2-, -S-CH2-CH2-, -NH-CH2-CH2-, -CH2-0-CH2-, -CH2- S-CH2- and -CH2-NH-CH2-. Heteroalkylene groups also include cyclic heteroalkylene (heterocycloalkylene) groups, examples of which include, but are not limited to, oxirane, oxetane, aziridine and azetidine rings from which two hydrogen atoms are removed.
[00166] The term "GacS/GacA-type system" refers to the signal transduction system in D. dadantii as well as homologous systems in other bacteria (e.g. E. coli (BarA UvrY), Pectobacterium spp., S. typhimurium (BarA/SirA), Pseudomonas spp. (GacS/GacA), and Legionella pneumophila (LetS/LetA), Vibrio species) that have a similar structure and function to the GacS/GacA system of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria. Similarly, "GacA-type polypeptide" and "GacS-type polypeptide" refer to the respective polypeptides in D. dadantii as well as homologous polypeptides having similar structure and function in other bacteria.
[00167] The term "HrpX/HrpY-type system" refers to the signal transduction system in D. dadantii as well as homologous systems in other bacteria that have a similar structure and function to the HrpX/HrpY system of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria. Similarly, "HrpY-type polypeptide" and "HrpX-type polypeptide" refer to the respective polypeptides in D. dadantii as well as homologous polypeptides having similar structure and function in other bacteria.
[00168] The term "Rsm-type system" refers to the regulator of secondary metabolism (Rsm) system of D. dadantii as well as homologous systems in other bacteria that have a similar structure and function to the Rsm system of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria.
[00169] The term "T3SS-type system" refers to the type III secretion system (T3SS) of D. dadantii as well as homologous systems in other bacteria that have a similar structure and function to the T3SS of D. dadantii, even though the homologous regulatory system may be known by a different name in other bacteria.
[00170] As used herein, the terms "reducing" or "reduced" are used relative to an untreated sample or other suitable control. For example, "reducing expression" of a polynucleotide in a bacterium in response to contacting the bacterium with a test compound means lowering the amount of expression of the polynucleotide (e.g. lowering the amount of polynucleotide-encoded mRNA or protein formed) relative to the level of expression of the
polynucleotide in the same bacterium under control conditions. The control conditions may include exposing the bacterium to the same conditions without contacting the bacterium with the test compound.
[00171] "Reducing virulence" in a bacterium refers to altering expression of genes associated with virulence, including regulators of virulence. Reducing virulence also refers to physical and biochemical manifestations of virulence including those manifestations associated with any step of the bacterial life cycle when it is associated with a host, including without limitation the adherence, invasion, replication, evasion of host defenses, and transmittal to a new host. Reduced bacterial virulence may be manifested in the form of reduced symptoms in a host, and thus may be detected by monitoring the host for a reduced reaction to the bacteria associated therewith. Reduced virulence may arise as a result of either inhibition or stimulation of a two-component regulatory system such as a GacS/GacA- type system or a HrpX/HrpY-type system, which could lead to increases or decreases of polynucleotide and polypeptide production. For example, reduced virulence may be associated with increase production of a repressor, reduced production of a transcription factor, or increased production of enzymes or toxins. Regulation of bacterial virulence may lead to alterations in the production of pectinase, exoprotease, syringomycin, syringolin, alginate, tolaasin, siderophores, pyocyanin, cyanide, lipase, type III secretion system (T3SS) genes, cholera toxin, polyhydroxybutyrate, or a polynucleotide controlled by a GacS/GacA- type system or a HrpX/HrpY-type system in a Gram negative bacterium. A reduction in virulence may be at least about a 1 % reduction, at least about a 10% reduction, at least about a 20% reduction, at least about a 30% reduction, at least about a 40% reduction, at least about a 50% reduction, at least about a 60% reduction, at least about a 70% reduction, at least about a 80% reduction, at least about a 90% reduction, or at least about a 100% reduction of virulence, as measured by any assay described herein or known to those of skill in the art, when measured against a suitable control.
[00172] "Components" of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS- type system, and a Rsm-type system include without limitation polynucleotides and polypeptides that are part of the respective systems (including genes arid gene products of the named operons) as well as polynucleotides, polypeptides, and other molecules that regulate the systems including genes and gene products that are upstream or downstream of the system. "Components" also includes molecules that are products of the genes or gene products of the systems as well as genes or gene products that generate posttranslational modifications of polynucleotides or polypeptides of the systems. A "regulator" is a component that changes (increases or decreases) an expression or activity level of a component. A "repressor" is a component that decreases an expression or activity level of a component, arising from either an increase or a decrease in the amount or activity
level of the repressor. An "effector" is a component that puts into effect the activity of the system, e.g. exoenzymes of the T3SS-type system are nonlimiting examples of effectors. A component is "associated with virulence" if a change in an amount or activity of the component leads, directly or indirectly, to an increase or reduction in some aspect of bacterial virulence.
[00173] A "phenylpropanoid-type inhibitory compound" as used herein includes phenylpropanoid compounds, such as p-coumaric acid or cinnamyl alcohol, that reduce bacterial virulence. In addition, "phenylpropanoid-type inhibitory compound" also includes phenylpropanoid derivative that have been found to be "active compounds," i.e. compounds that have shown through screening to have bacterial virulence-reducing activity.
[00174] A bacterium is "associated with" (or "associated therewith") a host or subject such as a plant or animal (including a human) when the bacterium is in or on the host or subject. For a plant host or subject, an associated bacterium can be on a plant part such as a root, stem, leaf, flower, or fruit of the plant, or in the soil adjacent to the roots or base of the stem. For an animal host or subject,, an associated bacterium can be on the outer surface of the animal or on an inner surface such as an intestinal surface, or the associated bacterium can be within the animal, e.g. in a tissue or fluid of the animal or any other internal portion of the animal.
[00175] "Treating" or "treatment," as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human, an animal (e.g. in veterinary applications), or plants, in which some desired therapeutic effect is achieved, for example, the reduction of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e. prophylaxis) is also included. "Treating" and "treatment" also refer to reducing the symptoms associated with the condition that is being treated.
[00176] "Effective amount," when used herein in the context of contacting a bacterium associated with a plant with a compound described herein, refers to an amount of a compound that can be therapeutically effective to inhibit, prevent or treat the symptoms of particular disease, disorder, or side effect, particularly those associated with bacterial virulence. An effective amount of the active compound may be used alone or as part of a composition as described herein. In various embodiments, an effective amount of active compound in the composition may be from about 0.1 μg/g to about 0.9 g/g, about 1 pg/g to about 100 mg/g, about 10 pg/g to about 10 mg/g, and about 100 pg/g to about 1 mg/g. The amount of active compound applied to a surface (e.g. soil, stem, or a leaf) may be about 0.1 pg/sq.ft., about 1 pg/sq.ft., about 10 pg/sq.ft., about 100 pg/sq.ft., about 1 mg/sq.ft., about 10 mg/sq.ft., about 100 mg/sq.ft., about 1 g/sq.ft., about 10 g/sq.ft., or about 100 g/sq.ft.
[00177] "Effective amount," when used herein in the context of contacting a bacterium associated with an animal (e.g., a human) with a compound described herein, refers to an amount of a compound that can be therapeutically effective to inhibit, prevent or treat the symptoms of particular disease, disorder, or side effect, particularly those associated with bacterial virulence. Thus, an effective amount of the active compound may be used alone or as part of a composition as described herein to treat an animal subject having a bacterium associated therewith in order to reduce the virulence of the bacterium. The composition may be prepared as appropriate for oral, topical, pulmonary, parenteral, or other route of administration. The concentration of active compound in the composition may be from about 0.1 pg/g to about 0.9 g/g, about 1 pg/g to about 100 mg/g, about 10 pg/g to about 10 mg/g, and about 100 pg/g to about 1 mg/g. When administered internally (e.g. parenterally or orally), the dose to the subject may be about 0.1 pg/kg body weight to about 1.0 g/kg body weight, about 1 pg/kg body weight to about 100 mg/kg body weight, about 10 pg/kg body weight to about 10 mg/kg body weight, and about 100 pg/kg body weight to about 1 mg/kg body weight.
[00178] "Effective amount," when used herein in the context of contacting a bacterium associated with a surface with a compound described herein, refers to an amount of the active compound that can be effective to reduce virulence of a bacterium associated with a surface when the compound, or a composition comprising the compound, is administered to a surface that includes the bacterium. An effective amount of the active compound may be used alone or as part of a composition as described herein. In various embodiments, an effective amount of the active compound in the composition may be from about 0.1 pg/g to about 0.9 g/g, about 1 pg/g to about 100 mg/g, about 10 pg/g to about 10 mg/g, and about 100 pg/g to about 1 mg/g. The amount of active compound applied to a surface may be about 0.1 pg/sq.ft., about 1 pg/sq.ft., about 10 pg/sq.ft., about 100 pg/sq.ft., about 1 mg/sq.ft., about 10 mg/sq.ft., about 100 mg/sq.ft., about 1 g/sq.ft., about 10 g/sq.ft., or about 100 g/sq.ft.
[00179] The term "pharmaceutically acceptable" as used herein pertains to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g., human or other animal) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[00180] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they optionally encompass substituents resulting from writing the structure from right to left, e.g., -CH20- optionally also recites -OCH2-.
Compounds
[00181] Compounds that may be used in the methods described herein include compounds of formula (I):
R2. R3. R4, R5, and R6 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyi, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, alkylamino, formyl and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyi, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonate, substituted or unsubstituted bicyclic heteroaromatic, and carboxamide groups.
or a salt thereof.
[00182] In some embodiments, in the compound of formula (I):
Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
R2, R5, and R6 are each independently selected from hydrogen, hydroxy, hydroxyalkyi, alkoxy, alkyl, alkenyl, alkynyl, halo, carboxy, and amino groups;
R3 is selected from hydrogen, hydroxy, hydroxyalkyi and alkoxy groups;
R is selected from hydrogen, alkyl, alkenyl, alkynyl, halo, hydroxy, hydroxyalkyi and alkoxy groups; and
R7 is selected from hydroxy, hydroxyalkyi, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonate, substituted or unsubstituted bicyclic heteroaromatic, and carboxamide groups.
[00183] In some embodiments, Ri is C2-C3 alkylene (e.g., C2-C3 alkenylene or C2-C3 alkynylene. In some embodiments, Ri is heteroalkylene, such as -0-CH2- or -S-CH2-. In some embodiments, Ri is cycloalkenylene, such as cyclopropylene. In some embodiments, R, is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, is a bond. In some embodiments, R4 is alkoxy (e.g., methoxy) or hydroxy. In some embodiments, R7 is hydroxamic acid, allylic alcohol, hydroxy, carboxy, alkoxy (e.g., methoxy), or ester (e.g., C02Et). In some embodiments, R7 is hydroxamic acid.
[00185] Compounds that may be used in the methods described herein include compounds of formula (II):
wherein A is aryl or heteroaryl;
Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 0, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, alkylamino, formyl and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonate, substituted or unsubstituted bicyclic heteroaromatic, and carboxamide groups.
[00186] In some embodiments, A is aryl (e.g., phenyl or naphthyl). In some embodiments, A is heteroaryl (e.g., thiophene, furan, indole, pyridyl, imidazole, benzofuran, benzothiofuran, quinoline or carbazole.) In some embodiments Ri is C2-C3 alkylene (e.g., C2- C3 alkenylene or C2-C3 alkynylene). In some embodiments, is heteroalkylene, such as - O-CH2- or -S-CH2-. In some embodiments, R, is cycloalkenylene, such as cyclopropylene. In some embodiments, Ri is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, Ri is a bond. In some embodiments, n is at least 1. In some embodiments, at least one R2 is alkoxy (e.g., methoxy) or hydroxy. In some embodiments, R7 is hydroxamic acid, allylic alcohol, hydroxy, carboxy, alkoxy (e.g., methoxy), or ester (e.g., C02Et).
[00187] In some embodiments, the compound is compound 127:
[00188] Compounds that may be used in the methods described herein include compounds of formula (III):
wherein:
A is aryl or heteroaryl;
Ri is selected from oxygen, sulfur and a bond;
n is 0, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, fomnyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
[00189] In some embodiments, A is aryl (e.g., phenyl). In some embodiments, A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole). In some embodiments, is a bond. In some embodiments, n is 0. In some embodiments, n is 1 or 2. In some embodiments, each R2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH2OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH2 or -NMe2), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups. In some embodiments, R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., -C(0)OMe or -C(O)OEt), amino (e.g., -NH2), amido (e.g., -C(0)NH2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0)2OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt)2), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido). In some embodiments, R7 is carboxy. In some embodiments, R7 is hydroxamic acid.
[00190] Compounds that may be used in the methods described herein include compounds of formula (IV):
wherein:
A is aryl or heteroaryl;
is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 0, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
[00191] In some embodiments, A is aryl (e.g., phenyl). In some embodiments, A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole). In some embodiments, Ri is alkylene such as a C2-C3 alkylene (e.g., -CH=CH-, -CH2-CH2-, -CH=CH-CH2- or -C≡C-). In some embodiments, Ri is heteroalkylene, such as -0-CH2- or -S-CH2-. In some embodiments, R, is cycloalkylene, such as cyclopropylene. In some embodiments, R^ is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, R^ is a bond. In some embodiments, n is 0. In some embodiments, n is 1 or 2. In some embodiments, each R2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH2OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH2 or -NMe2), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups. In some embodiments, R7 is selected from hydroxamic acid, hydrazinocarbonyl, amino (e.g., -NH2), amido (e.g., -C(0)NH2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0)2OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt)2), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido). In some embodiments, R7 is hydroxamic acid.
[00192] Compounds that may be used in the methods described herein include compounds of formula (V):
wherein:
A is aryl or heteroaryl;
Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, fluoro, bromo, iodo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
[00193] In some embodiments, A is aryl (e.g., phenyl). In some embodiments, A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole). In some embodiments, R, is alkylene such as a C2-C3 alkylene (e.g., -CH=CH-, -CH2-CH2-, -CH=CH-CH2- or -C≡C-). In some embodiments, is heteroalkylene, such as -0-CH2- or -S-CH2-. In some embodiments, R, is cycloalkylene, such as cyclopropylene. In some embodiments, R, is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, Ri is a bond. In some embodiments, n is 0. In some embodiments, n is 1 or 2. In some embodiments, each R2 is independently selected from alkyl (e.g., methyl), hydroxyalkyl (e.g., -CH2OH), alkoxy (e.g., methoxy), sulfhydryl, fluoro, bromo, carboxy, nitro, amino (e.g., -NH2 or -NMe2), formyl, aryl (e.g;, phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups. In some embodiments, R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., - C(0)OMe or -C(O)OEt), amino (e.g., -NH2), amido (e.g., -C(0)NH2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0)2OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt)2), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido). In some embodiments, R7 is carboxy. In some embodiments, R7 is hydroxamic acid.
[00194] Compounds that may be used in the methods described herein include compounds of formula (VI):
wherein:
A is selected from imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran and carbazole;
Ri is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 0, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
[00195] In some embodiments, A is imidazole, thiophene or furan. In some embodiments, Ri is alkylene such as a C2-C3 alkylene (e.g., -CH=CH-, -CH2-CH2-, -CH=CH- CH2- or -C≡C-). In some embodiments, Ri is heteroalkylene, such as -0-CH2- or -S-CH2-. In some embodiments, R-i is cycloalkylene, such as cyclopropylene. In some embodiments, R, is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, Ri is a bond. In some embodiments, n is 0. In some embodiments, n is 1 or 2. In some embodiments, each R2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH2OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH2 or -NMe2), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups. In some embodiments, R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., -C(0)OMe or -C(O)OEt), amino (e.g., -NH2), amido (e.g., -C(0)NH2 or -C(O)NHMe), sulfonic acid, sulfonate-(e.g., - S(0)2OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt)2), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido). In some embodiments, R7 is carboxy. In some embodiments, R7 is hydroxamic acid.
[00196] Compounds that may be used in the methods described herein include compounds of formula (VII):
wherein:
A is aryl or heteroaryl;
is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
[00197] In some embodiments, A is aryl (e.g., phenyl). In some embodiments, A is heteroaryl (e.g., indole, pyridyl, imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran or carbazole). In some embodiments, R-i is C2-C3 alkylene (e.g., C2-C3 alkenylene or C2-C3 alkynylene. In some embodiments, Rn is heteroalkylene, such as -O-CH2- or -S-CH2-. In some embodiments, R-\ is cycloalkylene, such as cyclopropylene. In some embodiments, R^ is heterocycloalkylene, such as oxetane or aziridine. In some embodiments, Ri is a bond. In some embodiments, n is 2. In some embodiments, each R2 is independently selected from alkyl (e.g., methyl), hydroxy, hydroxyalkyl (e.g., -CH2OH), alkoxy (e.g., methoxy), sulfhydryl, halo (e.g., fluoro, chloro or bromo), carboxy, nitro, amino (e.g., -NH2 or -NMe2), formyl, aryl (e.g., phenyl), haloalkyl (e.g., trifluoromethyl), ester and amido groups. In some embodiments, R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester (e.g., -C(0)OMe or -C(O)OEt), amino (e.g., -NH2), amido (e.g., -C(0)NH2 or -C(O)NHMe), sulfonic acid, sulfonate (e.g., -S(0)2OEt), phosphonic acid, phosphonate (e.g., -P(0)(OEt)2), and substituted or unsubstituted bicyclic heteroaromatic groups (e.g., phthalimido). In some embodiments, R7 is carboxy. In some embodiments, R7 is hydroxamic acid.
Compounds that may be used in the methods described herein also include the
or salts thereof.
[00199] Combinations of the substituent groups described above for Formula (I), (II), (III), (IV), (V), (VI) and (VII) are also contemplated as part of this disclosure.
[00200] The compounds described herein include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds may have the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 3C- or 14C-enriched carbon.
[00201] A compound described herein can be in the form of a salt, e.g., a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" includes salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, J. Pharma. Science 1977, 66: 1-19). Certain specific compounds of the present invention contain both basic and acidic
functionalities that allow the compounds to be converted into either base or acid addition salts.
[00202] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
[00203] In addition to salt forms, the present invention may also provide compounds that are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds described herein. For instance, prodrugs for carboxylic acid compounds of the invention include a variety of esters. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
Synthesis of Compounds
[00204] Compounds that may be used in the methods described herein may be synthesized using a variety of methods. Compounds that may be used in the methods described herein include phenylpropanoids, which are plant-derived organic compounds synthesized from phenylalanine. Phenylpropanoid derivatives can be made by adding or removing substituents using methods known to those of skill in the art. As shown in the Examples, phenylpropanoid derivatives such as those disclosed herein can be synthesized de novo or by modifying naturally-occurring compounds.
[00205] The synthetic routes for the compounds are described in the schemes presented in Figures 18-22 and 24-30. In Figure 18, aryl bromides A1 are reacted with ethyl acrylate to give ethyl frans-cinnamates A2 under the Heck reaction conditions (Patel, B. A., et al. J. Org. Chem. 1977, 42: 3903-3907). After removing the protecting group by trifluoroacetic acid (TFA), the ester was displaced by hydroxylamine to result in hydroxamates A3 with hydroxy, hydroxythio, amino and other groups in phenyl group, respectively. Basic hydrolysis of esters A2 followed by TFA deprotection affords cinnamic acid derivatives A4. The carboxyl group in A4 can be reduced by diborane, resulting in cinnamyl alcohols A5. By following the reported procedure (Zhang, X., et al. J. Org. Chem. 2002, 67: 9471-9474), hydrazides A6 can be obtained from acids A4 by treating with HOBt and hydrazine. Under the Corey- Chaykovsky cyclopropanation reaction conditions (TMSOI, NaH, DMSO) (Corey, E. J., Chaykovsky, M. J. Am. Chem. Soc. 1965, 87: 1353-1364), ethyl cinnamates A2 are
transformed to cyclopropanyl esters A7. The latter can be further converted to cyclopropanyl hydroxamatates A8 by TFA deprotectiori and reacting with hydroxylamine, or to the corresponding alcohols A9 by LAH reduction and TFA de-protection. The analogs with other heterocycles, such as indolyl, thionaphthyl, naphthyl, and other groups can be synthesized in the similar ways.
[00206] As shown in Figure 19, benzaldehydes B1 react with ethyl chloroacetate to afford ethyl oxiranecarboxylates B2 in the presence of sodium ethoxide (Li, S. W., et al. Bioorg. Chem. 1998, 26: 45-50). Conversion of B2 to 3-aryl oxiranecarboxylic acids B4 will be accomplished by deprotection with TFA followed by basic hydrolysis (Figure 19).
[00207] As shown in Figure 20, Knoevenagel reaction of benzaldehydes B1 with diethylphosphonoacetic acid leads to the formation of diethyl frans-2-arylvinylphosphonates C1 (Krawczyk, H., Albrecht, L. Synthesis 2005, 17: 2887-2896). Upon treatment with trimethylsilyl bromide (TMSBr) and TFA, the phosphonates C1 can be converted to trans-2- arylvinylphosphoric acids C3 (Figure 20). In the similar way, frans-2-(indol-3- yl)vinylphosphoric acids C4 can be obtained from the corresponding indol-3-aldehydes.
[00208] As shown in Figure 21 , In the presence of n-butyllithium, benzaldehydes B1 are reacted with ethyl diethylphosphoryl-methanesulfonate to generate ethyl trans-2- arylethenylsulfonates D1 (Niimi, T., et al. J. Med. Chem. 2001 , 44: 4737-4740) (Figure 21 ). The ethyl sulfonates D1 can be cleaved with tetra-n-butylammonium iodide (n-Bu4NI), and further deprotection with TFA affords the frans-2-arylethenylsulfonic acids D2. Corey- Chaykovsky cyclopropanation reaction of D1 produces cyclopropanyl sulfonates D3, and the corresponding sulfonic acids D4 will be obtained from D3 after treating with n-Bu4 I and TFA.
[00209] In Figure 24, cinnamic acids are converted into the corresponding methyl esters. The latter can be further transformed into hydroxamic acids by treating with hydroxylamine under basic condition. When the substituent in the phenyl group is halo, methyl, methoxy, or other groups which will not form amide/ester, the hydroxamic acids can be obtained directly from the corresponding carboxylic acids. By refluxing with ammonia in methanol, the corresponding amides can be obtained from the methyl esters. The esters can readily reduced by LiAIH4/AICI3 system, resulting in cinnamyl alcohols. By employing the reported procedure (Zhang et al. 2002), hydrazides can be obtained from cinnamic acids by treating with HOBt and EDC followed by hydrazine.
[00210] Under the Corey-Chaykovsky cyclopropanation reaction conditions (Corey and Chaykovsky, 1965), ethyl 4-methoxycinnamate was transformed into cyclopropanyl ester (100). Upon hydrolysis, acid 105 was obtained. Demethylation of 100 with borane tribromide gave 106. The latter was further hydrolyzed with lithium hydroxide to afford the corresponding carboxylic acid 107 (Figure 25).
[00211] Knoevenagel reaction (Krawczyk and Albrecht 2005) of 4-hydroxybenzaldehydes with diethylphosphonoacetic acid leads to the formation of diethyl trans-2- arylvinylphosphonates 114. Upon treatment with trimethylsilyl bromide (TMSBr), the phosphonate was converted into vinylphosphoric acid 115 (Figure 26). In the similar way, other frans-2-arylvinylphosphoric acids can be obtained from the corresponding arylaldehydes.
[00212] In the presence of n-butyllithium, benzaldehyde can reacted with ethyl diethylphosphoryl-methanesulfonate to generate ethyl frans-2-arylethenylsulfonates (Niimi et al. 2001 ) (Figure 27). The resulting ethyl sulfonates can be cleaved with tetra-n- butylammonium iodide (n-Bu4NI), affording the frans-2-arylethenylsulfonic acids.
[00213] Phthalimide potassium salt can be alkylated with allyl chloride in DMF to produce N-allylphthalimide. Under the Heck reaction conditions (Patel et al. 1977), N-allylphthalimide reacted with aryl bromide to give N-cinnamyl phthalimide. Upon treatment with hydrazine, cinnamyl amine was obtained from N-cinnamyl phthalimide (Figure 28).
[00214] As can be appreciated by the skilled artisan, alternative methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991 ); L. Fieser and M. Fieser, Fieser and Fieser"s Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
Activity of Compounds
[00215] Activity assays may be carried out on intact bacteria or on isolated bacterial components. For example, receptor portions of the GacS/GacA-type system or HrpX/HrpY- type system may be reconstituted in vitro, e.g. in membrane microsomes, or as isolated, soluble protein components. In one embodiment, the assay includes measurement of binding affinity of a test compound to the GacS-type or HrpX-type polypeptide.
[00216] The assays may also be conducted on genetically-engineered bacteria in which the GacS/GacA-type system or HrpX/HrpY-type system is coupled to a reporter. Thus, a test compound can be screened by contacting the compound with an appropriately engineered bacterium so that the binding and/or activation of the GacS/GacA pathway by the compound will be directly reported without the need to assay a downstream target or
effector such as a component of the Rsm pathway or T3SS system. The reporter in the genetically-engineered bacterium could be linked to any number of known fluorescent or colorimetric assays, e.g. green fluorescent protein (GFP), to make possible rapid screening of large numbers of compounds.
[00217] Various assays may be used to test the efficacy of the compounds, such as any of the assays described herein, including without limitation promoter-probe bioreporter assays, cell sorting (FACS), pectinase activity assays, qRT-PCR analysis, analysis of the phosphorylation of GacA or HrpY, leaf maceraction assays, growth kinetics assays, plate assays, analysis of pellicle formation, analysis of exoenzyme production, and spectrophotometric quantification assays. Assays may be performed using Dickeya dadantii or any other suitable bacterial species or strain having a GacS/GacA-type system, a HrpX/HrpY-type system, an Rsm-type system, and/or a T3SS-type system. Leaf maceraction assays may be carried out using leaves from any of a variety of plants, including African violet, Chinese cabbage, or witloof chicory leaves.
[00218] In addition to the methods described herein, additional methods known to those skilled in the art may be employed as needed in screening and assaying the synthesized compounds. For example, to detect and measure amounts of polypeptides, methods such as SDS-PAGE gel electrophoresis, Western blotting, and enzyme-linked immunoassays (ELISA) may be used, among other techniques. To detect and measure polynucleotides, polymerase-chain reaction (PCR) as well as electrophoretic mobility-based methods such as Southern and Northern blotting may be used, among other techniques.
[00219] The bacterium can be any one of a number of virulent bacterial species or strains, including those bacterial species or strains having at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a Rsm-type system, and/or a T3SS-type system. The suitable bacterial species or strains include without limitation Pseudomonas spp., E/w/n/a-related strains, Azotobacter vinelandii, Vibrio cholarae, Salmonella enterica, and Escherichia coli strains. The bacterium may be a Pseudomonas spp. including P. aureofaciens, P. chlororaphis, P. fluoresce ns, P. marginalis, Pseudomonas syringae, P. tolaasii, P. viridiflava, and P. aeruginosa. The bacterium may be an Env/n/a-related strain including Dickeya dadantii, Erwinia carotovora (also known as Pectobacterium carotovorum), Erwinia atroseptica ('also known as Pectobacterium atrosepticum), and Erwinia amylovora. Dickeya dadantii is a member of the Enterobacteriaceae family, which includes the plant pathogens Pectobacterium carotovorum and Erwinia amylovora as well as animal and human pathogens such as E. coli, Salmonella spp., and Yersinia spp (such as Yersinia pseudotuberculosi, Yersinia enterocolitica and Yersinia pestis). Bacteria may further include Acidovorax spp. (such as Acidovorax avenae), Aeromonas spp. (such as Aeromonas hydrophila, Aeromonas veronii and Aeromonas salmonicida), Bordetella spp. (such as
Bordetella pertussis), Bradyrhizobium spp. (such as Bradyrhizobium japonicum and Bradyrhizobium liaoningense), Burkholderia spp. (such as Burkholderia pseudomallei), Candidatus spp., Cellvibrio spp., Chlamydia spp. (such as Chlamydia trachomatis and Chlamydia pneumoniae), Chlamydophilia spp. (such as Chlamydophilia psittaci and Chlamydophilia pneumoniae), Chromobacterium spp. (such as Chromobacterium violaceum), Citrobacter spp. (such as Citrobacter rodentium), Cupriavidus spp., Desulfovibrio spp., Dickeya spp., Edwardsiella spp. (such as Edwardsiella tarda and Edwardsiella ictalun), Erwinia spp. (such as Erwinia chrysanthemi), Escherichia spp., Hahella spp. (such as Hahella chejuensis), Hamiltonella spp. (such as Hamiltonella defensa), Lawsonia spp. (such as Lawsonia intracellulars), Mesorhizobium spp. (such as Mesorhizobium /of/), Pantoea spp. (such as Pantoea agglomerans), Pectobacterium spp. (such as Pectobacterium wasabiae), Photobacterium spp., Photorhabdus spp. (such as Photorhabdus asymbiotic, Photorhabdus temperata and Photorhabdus luminescens), Proteus spp. (such as Proteus mirabilis), Providencia spp., Pseudomonas spp. (such as Pseudomonas aeruginosa, Pseudomonas syringae pv. glycinea, Pseudomonas syringae pv. tomato, and Pseudomonas syringae pv. syringae), Ralstonia spp. (such as Ralstonia solanacearum), Rhizobium spp., (such as Rhizobium sp. Strain NGR234), Salmonella spp. (such as Salmonella typhimurium and Salmonella enterica), Shewanella spp., Shigella spp. (such as Shigella flexneri), Sinorhizobium spp. (such as Sinorhizobium fredii), Sodalis spp., Vibrio spp. (such as Vibrio cholerae and Vrtwro parahaemolyticus), and Xanthomonas spp. (such as Xanthomonas campestris, Xanthomonas axonopodis, Xanthomonas oryzae, Xanthomonas fuscans subsp. Fuscan, Xanthomonas campestris pv. campestris, Xanthomonas campestns pv. citri, anthomonas campestris pv. oryzae, and Xanthomonas campestris pv. vesicatoria).
[00220] The results of the assays may be evaluated in accordance with the methods described herein and according to the knowledge of one skilled in the art to determine whether the compound that is tested reduces bacterial virulence. Those compounds that demonstrate activity in reducing bacterial virulence in the assays may then be used as antimicrobial compounds, for example as described herein.
[00221] Accordingly, the invention may provide a method of screening a compound for an ability to reduce virulence of a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system. The method comprises contacting the bacterium with a compound described herein and detecting at least one of: (i) a change in a component of at least one of the GacS/GacA-type system, the HrpX/HrpY-type system, the T3SS-type system, and the Rsm-type system of the bacterium, and (ii) a change in host pathology.
Methods of Use
[00222] After the compounds have been screened for their efficacy in reducing induction of virulence, those analogs that show effective reduction (also called "active compounds") may be tested for use in reducing virulence in bacteria that are associated with a subject such as a plant or an animal, including a human. The bacteria may be on the surface of the subject or within the subject or otherwise associated with the subject. Active compounds may be used in a method to treat a subject having a bacterial infection comprising administering to the subject an effective amount of a composition comprising the compound (see Examples). Active compounds may also be applied to a surface to reduce virulence of bacteria associated with the surface.
[00223] Accordingly, in one embodiment, the invention may provide a method of treating a subject having a bacterium associated therewith, the bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system. The method comprises administering to the subject a composition comprising an effective amount of a compound described herein.
[00224] In another embodiment, the invention may provide a method of reducing virulence of a bacterium on a surface comprising a bacterium having at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system. The method comprises contacting the surface with a composition comprising an effective amount of a compound described herein.
[00225] In another embodiment, the invention may provide a pharmaceutical composition comprising ah effective amount of a compound described herein, and a pharmaceutically- acceptable carrier or diluent.
Use on Plants
[00226] The active compounds, compositions containing the active compounds, and methods of using the same, may be used with any plant including those having an appropriate TCSTS-containing bacterium associated therewith, including a bacterium having a GacS/GacA-type system or a HrpX/HrpY-type system. These plants may include cultivated, domesticated, or wild plants, including annual crops and longer-term crops such as trees. Agriculturally relevant annual crops include, without limitation, corn, soy, wheat, barley, oats, rice, sorghum, rye, alfalfa, tobacco, and sunflower. The compounds, compositions, and methods may be used either on terrestrial plants or on aquatic plants, including freshwater and marine-dwelling plants.
[00227] For application on plants, the compounds may be formulated in compositions such as a liquid suitable for application by spraying or other mode of application; dust; granules; oil; or solid (e.g. as a spike). The composition may be produced in a concentrated
form, including a concentrated liquid, powder, solid, or other form, which may be reconstituted prior to use.
[00228] The following are suitable as possible formulations: wettable powders (WP), water-soluble powders (SP), emulsifiable concentrates (EC), aqueous solutions or concentrates, emulsions (EW), sprayable solutions, capsule suspensions (CS), dispersions on an oil or water base, suspoemulsions, suspension concentrates (SC), dusting powders (DP), solutions which can be mixed with oils (OL), seed-dressing agents, granules (GR) in the form of microgranules, spray granules, coated granules and adsorption granules, granules for broadcasting and soil application, water-soluble granules (SG), water- dispersible granules (WG), ULV formulations, microcapsules and waxes.
[00229] These individual types of formulations are known in principle and are described, for example, in: Winnacker-Kuchler, "Chemische Technologie [Chemical Technology]", Volume 7, C. Hauser Verlag Munich, 4th Ed. 1986; van Valkenburg, "Pesticides Formulations", Marcel Dekker N.Y., 2nd Ed. 1972-73; K. Martens, "Spray Drying Handbook", 3rd Ed. 979, G. Goodwin Ltd. London.
[00230] The formulation auxiliaries required, such as inert materials, surfactants, solvents and other additives are likewise known and are described, for example, in: Watkins, "Handbook of Insecticide Dust Diluents and Carriers", 2nd Ed., Darland Books, Caldwell N.J.; H. V. Olphen, "Introduction to Clay Colloid Chemistry"; 2nd Ed., J. Wiley & Sons, N.Y., Marsden, "Solvents Guide", 2nd Ed., Interscience, N.Y. 1950; McCutcheon's, "Detergents and Emulsifiers Annual", MC Publ. Corp., Ridgewood N.J.; Sisley and Wood, "Encyclopedia of Surface Active Agents", Chem. Publ. Co. Inc., N.Y. 1964; Schonfeldt, "Grenzflachenaktive Athylenoxidaddukte [Surface-active Ethylene Oxide Adducts]", Wiss. Verlagsgesell., Stuttgart 1976; and Winnacker-Kuchler, "Chemische Technologie [Chemical Technology]", Volume 7, C. Hauser Verlag Munich, 4th Ed. 1986.
[00231] Combinations with other active substances such as herbicides, fungicides or insecticides, as well as fertilizers and/or growth regulators, may also be prepared on the basis of these formulations, for example in the form of a ready-mix or as a tank mix.
[00232] The active compound combinations according to the invention can either be a mixed formulation of the two components which are then diluted with water and applied in a customary manner, or they can be prepared as so-called tank mixes by joint dilution, with water, of the separately formulated components.
[00233] Wettable powders are preparations which are uniformly dispersible in water and which, besides the active compound, also contain wetting agents, for example polyoxethylated alkylphenols, polyoxethylated fatty alcohols or fatty amines, alkane- or alkylbenzenesulfonates, and dispersing agents, for example sodium ligninsulfonate, sodium
2,2'-dinaphthylmethane-6,6'-disulfonate, sodium dibutylnaphthalenesulfonate, or alternatively sodium oleylmethyltaurinate, in addition to a diluent or inert substance.
[00234] Emulsifiable concentrates may be prepared by dissolving the active compound in an organic solvent, for example butanol, cyclohexanone, dimethylformamide, xylene and also higher-boiling aromatic compounds or hydrocarbons, with the addition of one or more emulsifiers. Examples of emulsifiers which may be used are: calcium salts of an alkylarylsulfonic acid, such as Ca dodecylbenzenesulfonate, or non-ionic emulsifiers, such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide/ethylene oxide condensation products, alkyl polyethers, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters or polyoxyethylene sorbitol esters.
[00235] Dusting agents may be obtained by grinding the active compound with finely divided solid substances, for example talc or natural clays, such as kaolin, bentonite, pyrophillite or diatomaceous earth.
[00236] Granules may be produced either by spraying the active substance onto adsorptive, granulated inert material or by applying active substance concentrates onto the surface of carriers, such as sand, kaolinites or of granulated inert material, by means of binders, for example polyvinyl alcohol, sodium polyacrylate or, alternatively, mineral oils. Suitable active substances may also be granulated in the manner which is conventional for the production of fertilizer granules, if desired in a mixture with fertilizers.
[00237] In one embodiment, the concentration of active compound in wettable powders may be, for example, about 10 to about 95% by weight, the remainder to 100% by weight is composed of conventional formulation components. In the case of emulsifiable concentrates, the concentration of active compound may be about 1 to about 85% by weight, preferably about 5 to about 80% by weight. Formulations in the form of dusts usually contain about 1 to about 25% by weight, mostly about 5 to about 20% by weight of active compound, sprayable solutions about 0.2 to about 25% by weight, preferably about 2 to about 20% by weight, of active compound. In the case of granules, such as water-dispersible granules, the active compound content depends partly on whether the active compound is liquid or solid and on which granulation auxiliaries and fillers are used. The content in water-dispersible granules is generally between about 10 and about 90% by weight.
[00238] In addition, the active compound formulations mentioned contain, if appropriate, the adhesives, wetting agents, dispersing agents, emulsifiers, penetrants, solvents, fillers or carriers which are conventional in each case.
[00239] For use, the formulations, present in commercially-available form, may be diluted, if appropriate, in a customary manner, for example using water in the case of wettable powders, emulsifiable concentrates, dispersions and water-dispersible granules.
Preparations in the form of dusts, granules for soil application and/or broadcasting, and also sprayable solutions are usually not further diluted with other inert substances before use.
[00240] The application rate required for the compositions varies with the external conditions, such as, inter alia, temperature, humidity, and the nature of the compound and composition used.
[00241] Further information regarding formulation and application of compositions for agricultural use are disclosed in United States Patent 5,447,903, incorporated herein by reference.
[00242] The compositions may be applied to different parts of the plant, including leaves, stems, roots, buds, fruits, frill, stump, bark, and roots, as well as to soil in the vicinity of a plant (e.g., the rhizosphere). Methods of application may include spraying, irrigating, dusting, and spreading or broadcasting of granules, powders, or other solid or liquid forms.
[00243] The composition may be applied to leaf surfaces, stems of plants including agricultural crops, and irrigated into soil to protect root systems from human and other pathogens (including, for example, E. coli 0157:1-17 on lettuce, spinach) which may be present as contaminants from exposure to animal waste.
[00244] The composition may be applied to the surfaces of stored crops (including without limitation onions, potatoes, grains, squash, melons) to reduce post-harvest infection and contamination by plant, animal, and human pathogens.
[00245] The composition may be applied to leaf surfaces, stems, fruits, and other portions of plants intended for consumption by animals including humans, either for fresh consumption or consumption following cooking or other preparation. The composition may be applied at various stages including while the plant is still in the ground; post-harvest; and prior to, during, or after shipping. Application of the composition may reduce post-harvest infection and contamination by plant, animal, and human pathogens.
[00246] The composition may be applied once or in repeated applications. Applications may be repeated any number of times daily, weekly, monthly, or annually. Applications may be repeated about 1 to about 100 times per day, week, month, or year, as needed.
[00247] Applying a composition comprising an active compound may reduce virulence of bacteria associated with the plant.
Use in Animals including Humans
[00248] The active compound or a pharmaceutical composition comprising the active compound may be administered to an animal subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an
aerosol, e.g. through mouth or nose); rectal; vaginal; parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly. Additional modes of administration may include adding the active compound and/or a composition comprising the active compound to a food or beverage, including a water supply for an animal, to supply the active compound as part of the animal's diet.
[00249] The subject may include, without limitation, a eukaryote, an animal, a vertebrate animal, a bird, a reptile, an insect, a mammal, a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), ovine (e.g., a sheep), bovine (e.g., a cow), a primate such as a monkey (e.g. marmoset, baboon) or an ape (e.g. gorilla, chimpanzee, orangutan, gibbon), or a human.
[00250] While it is possible for the active compound to be administered alone, in some embodiments the active compound may be presented as a pharmaceutical composition (e.g., formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically-acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilizers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
[00251] Thus, the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilizers, or other materials, as described herein.
[00252] Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.
[00253] The formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations may be prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
[00254] Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, lozenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, electuaries, or aerosols.
[00255] Formulations suitable for oral administration (e.g., by ingestion) may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
[00256] A tablet may be made by conventional means, e.g., compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); and preservatives (e.g., methyl p-hydroxybenzoate, propyl p- hydroxybenzoate, sorbic acid). Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
[00257] Formulations suitable for topical administration (e.g., transdermal, intranasal, ocular, buccal, and sublingual) may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil. Alternatively, a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents. In addition, a formulation may be added to a conventional bandage, e.g. to a gauze portion that contacts the wound, as an antimicrobial agent.
[00258] Formulations suitable for topical administration in the mouth include lozenges comprising the active compound in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.
[00259] Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.
[00260] Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer, include aqueous or oily solutions of the active compound.
[00261] Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurized pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
[00262] Formulations suitable for topical administration via the skin include ointments, creams, and emulsions. When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active compounds may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1 ,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
[00263] When formulated as a topical emulsion, the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
[00264] Suitable emulgents and emulsion stabilizers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl
esters such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
[00265] Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
[00266] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.
[00267] Formulations suitable for parenteral administration (e.g., by injection, including cutaneous, subcutaneous, intramuscular, intravenous and intradermal), include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain antioxidants, buffers, preservatives, stabilizers, bacteriostats in addition to the active compound, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. Examples of suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection. Typically, the concentration of the active compound in the solution is from about 1 ng/ml to about 1 pg/ml, although other concentrations are possible and are encompassed within the invention. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or more organs.
[00268] It will be appreciated that appropriate dosages of the active compounds, and compositions comprising the active compounds, can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight,
condition, general health, and prior medical history of the patient. The amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
[00269] Administration in vivo can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
[00270] In general, a suitable dose of the active compound is in the range of about 100 pg to about 250 mg per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
[00271] Further information regarding formulation of and treatment with pharmaceutical compositions are disclosed in United States Patent 7,196,085, incorporated herein by reference.
[00272] The composition may be administered once, on a continuous basis (e.g. by an intravenous drip), or on a periodic/intermittent basis, including about once per hour, about once per two hours, about once per four hours, about once per eight hours, about once per twelve hours, about once per day, about once per two days, about once per three days, about twice per week, about once per week, and about once per month. The composition may be administered until a desired reduction of symptoms is achieved, which may be taken as an indication that bacterial virulence has been reduced.
[00273] Treatment of an animal subject with an active compound, or a composition comprising an active compound, may reduce virulence of bacteria associated with the animal subject.
Use on Surfaces
[00274] In one embodiment, the active compounds may be applied to surfaces to reduce the virulence of bacteria on the surfaces. The active compounds may be formulated in compositions suitable for application to surfaces, including as a gel, powder, liquid, concentrate, spray, or other suitable compositions known to those skilled in the art.
[00275] The composition may be applied to surfaces in residential, commercial, medical, industrial, agricultural, and other settings, to reduce virulence of bacteria associated with the surfaces. The composition may be applied to surfaces including without limitation those in
bathrooms; kitchens and other food storing or preparation areas; medical facilities including operating rooms and hospital rooms; laundry facilities including laundered articles; restaurant facilities including kitchens and food storage areas; refrigerators and freezers; dishwashing facilities; factories; slaughterhouses; and grocery stores. The active compounds may be incorporated into or applied on packaging, e.g. for medical items or food products, to reduce virulence of bacteria associated therewith.
[00276] In one embodiment, the active compound and/or a composition comprising the active compound may be used to reduce or inhibit biofilm formation in medical, industrial, and other equipment, where a biofilm is defined as an aggregation of microorganisms on a solid substrate. The active compound may be applied to external and internal surfaces of the equipment, including pipes and tubing, to reduce or inhibit bacterial virulence and biofilm formation.
[00277] The composition may be sprayed, dusted, spread, rubbed, painted, mopped, soaked, or otherwise applied on surfaces. The composition may be applied once or may be repeated on a periodic basis. Periodic application may be about 1 to about 100 times per day, week, month, or year, as needed.
[00278] Applying a composition to a surface comprising an active compound may reduce virulence of bacteria on or associated with the surface.
[00279] The following non-limiting Examples are intended to be purely illustrative, and show specific experiments that were carried out in accordance with embodiments of the invention.
EXAMPLES
[00280] The following methods apply to Examples 1-3:
Bacterial strains, plasmids. media and chemicals
[00281] The bacterial strains and plasmids used in this study are listed in Table 1. E. coli was grown in LB broth at 37°C and D. dadantii was grown in minimal Aw -inducing medium (MM) at 28°C. Antibiotics ( g/ml) used were: ampicillin, 100; chloramphenicol, 50; kanamycin, 50; spectinomycin, 50. Primers used for Polymerase Chain Reaction (PCR) in this report are also listed in Table 1. Chinese cabbage purchased in a grocery store and African violet, without visible symptom from pathogen infection were used in this study.
Table 1. Strains, plasmids, and DNA primers used in this study.
Strains, plasmids
Characters or sequences (5' to 3')" Reference or source and primers
Strains
A!acZYA-argF)U169 deoR recAl endAl Invitrogen, CA hsdRl 7 phoA supE44 thi-1 gyrA96 relA 1 X
E. coli TOP 10 F mcrA Amrr-hsdRMS-mcrBQ SQlacZAMi5 AlacX74 Invitrogen, CA
deoR recAl araD139 A(ara-leu)7679 galU galK rpsL
endA I nupC
D. dadantii
Ech3937 wild type, Saintpaulia (African violet) isolate Hugouvieux-Cotte-
Ech-Rif Ech3937 rifampicin resistant random mutant Pattat, N.
Echl31 AhrpL. kan; mR Yang et al., 2008
Echl 37 AgacAr.kan; mR Yang e/ o/., 2004
Echl38 AiaaMwkan; KmR Yang et al., 2008
WPP96 AA pZ,(A|.,85aa):: aadA; Sp /SmR Yang et al., 2007
WPP90 hrpSr.cat; Cm" Yap et al, 2005
WPP67 hrpXr.aadA; SpR/SmR Yap et al., 2005
WPP92 hrpY::kan; KmR Yap et al, 2005
Ech3937 (pAT) Ech3937 containing pPROBE-AT Yap et al, 2005
Ech3937 Ech3937 containing pdspE; ApR Peng et al, 2006
(pdspE) AhrpLv.kan containing pdspE; ApR KmR Yang et al., 2004
Echl31 (pdspE) Ech3937 containing phrpA; ApR Peng et al, 2006
Ech3937 WPP96 containing phrpA; Ap SpR This work
(phrpA) Ech3937 containing phrpN; ApR This work
WPP96 (phrpA) WPP96 containing phrpN; ApR SpR Yang et al., 2007
Ech3937 Ech3937 containing phrpL; ApR Yang et al., 2007
(phrpN) WPP96 containing phrpL; ApR SpR Yang et al, 2007
WPP96 (phrpN) Ech3937 containing phrpS; ApR Yang et al, 2007
Ech3937 (phrpL) WPP96 containing phrpS; ApR SpR This work
WPP96 (phrpL) Ech3937 containing pmrp; ApR This work
Ech3937 phrpS) Ech-Rif containing phrpA; ApR Peng et al, 2006
WPP96 (phrpS) Echl37 containing phrpA ApR mR Yang et al, 2008
Rch3937 (pmrp) Ech3937 containing phrpN; ApR Yang et al., 2008
Ech-Rif (ρΛ/ρ ) Echl38 containing phrpN; Ap Km8 Yang et al, 2007
Echl37 (p/ir/¾4) WPP90 containing phrpN; ApR SpR Yang et al, 2007
Ech3937 WPP67 containing phrpN; ApR SpR This work
(phrpN) WPP92 containing phrpN; ApR SpR This work
Echl38 (ρΛ Λ This work
WPP90 (phrpN)
hrpA_RTF C AGC AATGGCAGGC ATGCAG (SEQ ID NO: 13) Yang et al. , 2007 hrpA_RTR CTGGCCGTCGGTGATTGAGC (SEQ ID NO: 14) Yang et al., 2007 dspE_RTF G ATGGCGG AGCTG AAATCGTTC (S EQ ID NO: 15) Yang et al. , 2007 dspE_RTR CCTTGCCGGACCGCTTATCATT (SEQ ID NO: 16) Yang et al., 2007 rsmB_RTF AGAGGGATCGCCAGCAAGGATTGT (SEQ ID NO: 17) This work
rsmB RTR CGTTTGCAGCAGTCCCGCTACC (SEQ ID NO: 18) This work
aApR, ampicillin resistance; Cm", chloramphenicol resistance; KmR, kanamycin resistance; SpR, spectinomycin resistance.
Hugouvieux-Cotte-Pattat, N., Condemine, G., Nasser, W., and Reverchon, S. (1996) Regulation of pectinolysis in Erwinia chrysanthemi. Annu Rev Microbiol 50: 213-257.
Miller, W.G., Leveau, J.H.J., and Lindow, S.E. (2000) Improved gfp and inaZ broad-host- range promoter-probe vectors. Mol Plant-Microbe Interact 13: 1243-1250.
Miller, W.G., and Lindow, S.E. (1997) An improved GFP cloning cassette designed for prokaryotic transcriptional fusions. Gene 191: 149-153.
Peng, Q., Yang, S., Charkowski, A.O., Yap, M.N., Steeber, D.A., Keen, N.T., and Yang, C.H. (2006) Population behavior analysis of dspE and pelD regulation in Erwinia chrysanthemi 3937. Mol Plant-Microbe Interact 19: 451-457.
Yang, S., Q. Peng, Q. Zhang, X. Yi, C. J. Choi, R. M. Reedy, A. O. Charkowski, and C.-H. Yang. 2008. Dynamic regulation of GacA in type III secretion system, pectinase gene expression, pellicle formation, and pathogenicity of Dickeya dadantii. Mol. Plant-Microbe Interact. 21:133-142.
Yang, S., Zhang, Q., Guo, J., Charkowski, A.O., Glick, B.R., Ibekwe, A.M. er a/. (2007) Global effect of lndole-3-acetic acid (IAA) biosynthesis on multiple virulence factors of Erwinia chrysanthemi 3937. Appl Environ Microbiol 73: 1079-1088.
Yang, S., Perna, NT., Cooksey, D.A., Okinaka, Y., Lindow, S.E., Ibekwe, A.M. ef al. (2004) Genome-wide identification of plant-upregulated genes of Erwinia chrysanthemi 3937 using a GFP- based I ET leaf array. Mol Plant-Microbe Interact 17: 999-1008.
Yap, M.N., Yang, C.H., Barak, J.D., Jahn, C.E., and Charkowski, A.O. (2005) The Erwinia chrysanthemi type III secretion system is required for multicellular behavior. J Bacteriol 187: 639-648.
FACS analysis
[00282] FACS analysis of promoter activity of dspE, hrpA, hrpL, hrpN, and hrpS was carried out as described (Peng et al., 2006). Briefly, the wild-type Ech3937 and the mutant strains carrying the promoter reporter plasmid were grown on LB broth at 28°C overnight and transferred to appropriate media. For FACS analysis, samples were collected by centrifugation, washed with 1X phosphate buffer saline (PBS) at 13,000 rpm for 1 min, and re-suspended in 1X PBS to ca 106 CFU/ml prior to . being run in a FACS Calibur flow cytometer (BD Biosciences, CA). Three replicates were performed for each treatment.
qRT-PCR analysis
[00283] Bacterial strains were grown in MM. Total RNA from the bacterial cells was isolated by using the TRI reagent method (Sigma, MO) and treated with Turbo DNA-free DNase kits (Ambion, TX) as described (Peng ef al., 2006). An iScript cDNA Synthesis Kit (Bio-Rad, CA) was used to synthesize cDNA from 0.5 pg of treated total RNA. The Real Master Mix (Eppendorf, Westbury, NY) was used for qRT-PCR reaction to quantify the cDNA level of target genes in different samples. The rplU was used as the endogenous control for data analysis. qRT-PCR data were analyzed using Relative Expression Software Tool as described (Pfaffl, M.W., Horgan, G.W., and Dempfle, L. (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36.).
EXAMPLE 1 : T3SS gene expression induced by plant phenolic compounds
[00284] Screening of plant up-regulated genes in Ech3937 has demonstrated that dspE and hrpA were expressed in planta. In this study, the expression of dspE of Ech3937 was further compared in bacterial cells grown in a nutrient rich LB medium, a nutrient-limited medium (MM), and the MM supplemented with Chinese cabbage juice (10% V/V). For this purpose, a GFP reporter plasmid pdspE (pProbe-AT derivative with PCR fragment containing dspE promoter region) was used and cells cultured under different conditions were compared by flow cytometry. A higher total GFP intensity was observed in Ech3937 (pdspE) (Ech3937 cells carrying plasmid pdspE) grown in MM compared with the bacterial cells grown in LB (Table 2). The expression of dspE was further induced in MM supplemented with Chinese cabbage juice in comparison with the bacterial cells grown in MM alone. In addition, low promoter activities of dspE were observed in hrpL mutant Ech131 carrying pdspE grown in MM and MM supplemented with Chinese cabbage (Table 2), suggesting that HrpL is essential for the expression of dspE under inducing conditions.
Table 2. The expression of dspE of Dickeya dadantii 3937 (Ech3937) and the hrpL mutant Ech131 grown in LB, MM, and MM with Chinese cabbage juice (10% V/V) (MMJ).
Gene Promoter3 LB MM MMJ
Ech3937 (pdspE)b 3.2 ± 0.2 45 ± 1 161 ± 4
Ech131 (pdspE) 2.1 ± 0.2 2.1 ± 0.7 1.3 ± 0
Ech3937 (pProbe-AT) 1.9 ± 0.2 1.4 ± 0 1.2 ± 0
aThe dspE promoter activities in the wild-type Ech3937 and hrpL mutant Ech131 were compared after 12 h of culture in LB, MM, and MM supplemented with plant juice. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
alues (Mean Fluorescence Intensity) are representative of two experiments. Three replicates were used in this experiment. The values are the average with the standard deviation.
[00285] Plant juice induced the expression of T3SS genes of Ech3937, suggesting the existence of compounds in plant tissues that activate the T3SS regulon. Phenolic compounds constitute an important class of organic substances produced by plants. The phenolic compound SA is a signaling molecule that plays a role in host defenses. OCA and TCA are the biosynthetic precursors of SA and are also reported to induce the expression of defense-related genes in plants. OCA, TCA, and SA were examined to elucidate their effects on the expression of T3SS genes. The expression of the T3SS gene hrpN was examined in MM and MM supplemented with OCA, TCA, and SA, at concentrations of 0.05, 0.1 , and 0.2 mM, respectively. Figures 2A and 2B show the promoter activities of hrpN in Dickeya dadantii 3937 (Ech3937) grown in MM and MM supplemented with 0.05, 0.1 , and 0.2 mM OCA, TCA, and SA at 12 h (Figure 2A) and 24 h (Figure 2B) post-inoculation. GFP intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with
the Cell Quest software (BD Biosciences, San Jose, CA). The growth of Ech3937 in MM supplemented with different concentrations of OCA, TCA and SA was recorded. Compared with MM alone, the average GFP fluorescence intensity of bacterial cells of Ech3937 (phrpN) was increased approximately 4-fold when 0.05 mM of OCA and TCA were added to the medium (Figs. 2A, 2B). The addition of SA did not result in increased GFP fluorescence intensity of Ech3937 (Figs. 2A, 2B). No reduction of bacterial growth was observed when OCA, TCA, and SA were added into the MM (Figs. 2A, 2B).
[00286] The concentration of the phenolic compound f-cinnamic acid (TCA) in healthy potato leaves is approximately 0.5 μΜ and levels in the leaves can rise to approximately 10 uM after exposure to a cell-free culture filtrate (CF) of E. c. carotovora. To investigate whether the level of the phenolic compounds in plants is able to induce the expression of T3SS gene, the expression of hrpN was examined using concentrations of TCA comparable to levels found in plants. Ech3937 (phrpN) was grown in MM supplemented with 0.2, 0.5, 5, and 10 μΜ of TCA, respectively. Compared with Ech3937 (phrpN) in MM alone, a 1 .5- to 1.8-fold increase of GFP intensity was observed in the bacterial cells grown in MM supplemented with 0.2 and 0.5 μΜ TCA (Table 3). Compared with Ech3937 (phrpN) in MM, a 3- to 3.5-fold higher GFP intensity was observed in the bacterial cells grown in MM supplemented with 5 and 10 μΜ of TCA (Table 2).
Table 3. The expression of hrpN of Dickeya dadantii 3937 (Ech3937) in MM and MM supplemented with different amount of TCA and SA respectively.
GFP Intensity of Ech3937 (phrpN)b
12 h 24 h
M 1 41 .6±3.6 91.3±1 1
TCAa
0.2 μΜ 65.H6.8 163±25
0.5 μΜ 73.4±4.2 158±20
5 μΜ 134±5.6 266114
10 μΜ 147±18 284112
SAa
0.2 μΜ 53.7±4.0 105128
0.5 μΜ 49.5±5.9 99.5118
5 μΜ 49.912.9 97.719.0
10 μΜ 52.0±2.3 10413.1
"Minimal medium (MM) alone and MM supplemented with different concentrations of f-cinnamic acid (TCA) or salicylic acid (SA).
' ηε promoter activities of hrpN were measured at 12 and 24 h of growing in the media. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Three replicates were used in this experiment. The value (Mean Fluorescence Intensity) is present as the average of three replicates with standard deviation.
[00287] Since OCA and TCA induced the expression of hrpN, the effect of these two phenolic compounds on the expression of hrpA, hrpL, and hrpS was investigated further.
Figure 3 shows the promoter activities of hrpA, hrpN, hrpL, and hrpS in Dickeya dadantii 3937 (Ech3937) and hrpL mutant WPP96 grown in MM and MM supplemented with 0.1 mM OCA 12 h post-grown. GFP intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA). The lines labeled "1" stand for the GFP expression control base level of the Ech3937 containing pPROBE-AT vector; lines labeled "2" stand for the promoter activity of hrpS, hrpL, hrpA and hrpN in Ech3937 in MM; lines labeled "3" stand for the promoter activity of Ech3937 in MM supplemented with 0.1 mM OCA; lines labeled "4" stand for the promoter activity of hrpL mutant WPP96 in MM; lines labeled "5" stand for the promoter activity of hrpL mutant WPP96 in MM supplemented with 0.1 mM OCA. Values are representative of at least two experiments. Three biological replicates were used in this experiment, which had similar results, and one replicate was used for the overlay as displayed. Compared with MM alone, the average GFP fluorescence intensity of bacterial cells of Ech3937 {phrpA) was doubled when 0.1 mM of OCA and TCA were added to the medium (Table 4; Figure 3). Compared with MM alone, a slightly higher promoter activity of hrpL was observed in Ech3937 (hrpL) grown in MM supplemented with OCA and TCA, respectively. Compared with MM alone, a slightly lower GFP intensity of Ech3937 (phrpS) was observed when the bacterial cells were grown in MM supplemented with OCA and TCA (Table 4; Figure 3). The mrp, whose protein product has an ATPase conserved domain (2e-06), was used as a reference gene in this study. A slightly higher mrp expression was observed in Ech3937 {pmrp) when the bacterial cells were grown in MM and MM supplemented with 0.1 mM OCA and TCA, respectively (Table 4).
Table 4. The expression of hrpA, hrpN, hrpL, hrpS, and mrp of Dickeya dadantii 3937 (Ech3937) and hrpL mutant WPP96 in MM, MM supplemented with 0.1 mM OCA (MMOCA), and MM supplemented with 0.1 mM TCA (MMTCA).
Gene Promoter3 MM MMOCA MMTCA
Ech3937 {phrpA) b 41 ±3 82±1 78±0
WPP96 (phrpA) 6.0±0 6.5±0.2 6.2±0. 6
Ech3937 (phrpN) 43±4 94±3 103±1
WPP96 (phrpN) 3.1±0.1 3.3±0.1 3.3±0
Ech3937 (phrpL) 14±1 19±0 19±1
WPP96 (phrpL) 103±2 313±29 331 ±27
Ech3937 (phrpS) 63±2 56±1 54±2
WPP96 (phrpS) 320±60 350±17 360±16
Ech3937 (pmrp) 93.5±1.4 97.7±1.6 105±0.3
Ech3937 (pPROBE-AT) 1.9±0 2.0±0 1.9±0 aThe promoter activities were compared at 12 h of growing in the media. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
alues (Mean Fluorescence Intensity) are representative of three experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation.
[00288] To confirm FACS results showing T3SS induction by plant phenolics, the relative mRNA level of hrpY, hrpS, hrpL, dspE, and hrpA of Ech3937 grown in MM and MM supplemented with OCA was examined by qRT-PCR. Compared with MM alone, a significantly higher amount of dspE and hrpA mRNA was observed in Ech3937 supplemented with OCA (Figure 4). Although only a slight increase of hrpL promoter activity was observed in Ech3937 (phrpL) grown in MM supplemented with OCA (Table 4), Ech3937 cultures with the supplementation of 0.1 mM OCA produced about 3-fold more hrpL mRNAs than those grown in MM alone at 12 h of growth (P < 0.01 ) (Figure 4). Three replicates were used in this experiment. The p-value was calculated using Relative Expression Software Tool as described by Pfaffl et al. (2002). No significant difference was found between Ech3937 cells grown in MM and MM supplemented with OCA for gene hrpY, hrpS, and gacA with the p > 0.5, but gene expression of hrpL, dspE, hrpA, and rsmB are significantly different between MM and MM supplemented with 0.1 mM OCA with p < 0.003 (Figure 4).
EXAMPLE 2: Regulators responsible for the OCA and TCA induction
[00289] The expression of T3SS genes dspE, hrpA, and hrpN was reduced in an iaaM mutant Ech138; iaaM encodes an enzyme in the pathway for indole-3-acetic acid (lAA) biosynthesis. To investigate whether lAA biosynthesis is involved in the OCA induction of T3SS, the expression of hrpN in the wild-type Ech3937 and Ech138 was compared with the addition of OCA. As expected, the expression of hrpN was reduced in an iaaM mutant background. However, a similar induction ratio of hrpN by OCA was observed in wild-type Ech3937 and Ech138 at each time point of bacterial growth (Table 5). These results suggest that OCA does not activate T3SS expression through lAA biosynthesis.
Table 5. The expression of hrpN of Dickeya dadantii 3937 (Ech3937) and iaaM mutant Ech138 in MM and MM supplemented with 0.1 mM OCA (MMOCA), and the expression of hrpA of Ech-Rif and gacA mutant Ech137 in MM, MM supplemented with 0.1 mM OCA (MMOCA).
6h 12 h 24 h
Gene Promoter3 MM MMOCA MM MMOCA MM MMOCA
Ech3937 (phrpN) b 19±2 31±3 30±3 91 ±8 33±2 78±8
Ech138 (phrpN) 5.6±0.7 9.1±1.6 11±1 33±5 17±1 39±5
Ech-Rif (phrpA) ' 13±0 18±0 22±0 51 ±2 16±1 49±1
Ech137 (phrpA) 4.7±0 4.9±0.1 5.5±0 5.9±0.1 7.6±0 8.3±0
Ech3937 (pPROBE-AT) 1.9±0 2.0±0 1.9±0 2.0±0 1.8±0 1.9±0
"The promoter activities were compared at 6, 12, and 24 h of bacterial growth. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells.
"Values (Mean Fluorescence Intensity) are a representative of two experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
[00290] Ech3937 gacA plays a role in regulating the expression of T3SS genes by a post- transcriptional regulation of hrpL through the Gac-Rsm regulatory pathway (Yang, S., Q. Peng, Q. Zhang, X. Yi, C. J. Choi, R. M. Reedy, A. O. Charkowski, and C.-H. Yang. 2008. Dynamic regulation of GacA in type III secretion system, pectinase gene expression, pellicle formation, and pathogenicity of Dickeya dadantii. Mol. Plant-Microbe Interact. 21 :133-142.). To investigate whether OCA affects T3SS gene expression through the Gac-Rsm regulatory pathway, the expression of hrpA was compared in wild-type Ech-Rif (phrpA) and gacA mutant Ech137 (phrpA) grown in MM and MM supplemented with OCA, respectively. Compared with Ech-Rif (phrpA) grown in MM alone, a higher GFP intensity was observed in bacterial cells grown in MM supplemented with OCA. However, similar GFP intensity was observed in Ech137 (phrpA) cells grown in MM and MM supplemented with OCA, suggesting that OCA may induce the T3SS gene expression through Gac-Rsm pathway (Table 5). To further confirm that the influence of OCA on T3SS is through the Gac-Rsm system, the expression of gacA and rsmB was examined by qRT-PCR. The results showed that, compared with Ech3937 in MM alone (normalized to 1 ), a significantly higher rsmB mRNA (relative expression ratio 1.4, P = 0.003) was observed in the bacterium grown in MM supplemented with OCA (Figure 4). The effect of TCA on the mRNA level of rsmB of Ech3937 was also examined. Compared with Ech3937 grown in MM alone (normalized to 1 ), a significantly higher amount of rsmB mRNA was observed in Ech3937 grown in TCA (1.58, P = 0.05). However, no significant difference in the level of gacA mRNA was observed in Ech3937 grown in MM and MM supplemented with OCA (Figure 4).
[00291] HrpL appears to be involved in the induction of T3SS gene expression by the phenolic acids OCA and TCA, as the addition of OCA or TCA did not induce the T3SS gene expression (hrpA and hrpN) in the hrpL mutant background (Table 4). Given that T3SS genes are regulated through HrpX/Y-HrpS-HrpL, experiments were performed to investigate whether OCA and TCA were able to induce the expression of T3SS genes in the absence of hrpX, hrpY, and hrpS, respectively. The GFP intensity of the wild-type Ech3937 and hrpX, hrpY, and hrpS mutants carrying phrpN grown in MM and MM supplemented with OCA and TCA, respectively, was measured (Figure 5). Figure 5 shows levels of expression of hrpN of Dickeya dadantii 3937 (Ech3937), hrpS mutant WPP90, hrpX mutant WPP67, hrpY mutant WPP92 in MM, MM supplemented with 0.1 mM OCA (MMOCA), and MM supplemented with 0.1 mM TCA (MMTCA). Ech3937 (pAT) is the wild-type containing the pPROBE-AT vector. The promoter activities were compared at 12 h of growth in the media. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values (Mean Fluorescence Intensity; MFI) are a representative of three experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with
standard deviation (SD). The results showed that OCA and TCA induced the expression of hrpN in Ech3937, but not in hrpX, hrpY, and hrpS mutants (Figure 5).
EXAMPLE 3: Auto-regulation of T3SS regulon
[00292] Compared with Ech3937, a higher GFP intensity was observed in the hrpL mutant WPP96 cells carrying phrpS and phrpL, suggesting that HrpL negatively regulated the expression of hrpL and its upstream hrpS (Table 4; Figure 3). To further confirm the results of GFP-based FACS assays which showed auto-regulation of HrpL, the relative mRNA level of hrpS in Ech3937 and hrpL mutant Ech131 grown in MM was examined by qRT-PCR. Compared with Ech3937, a 4-fold higher level of hrpS mRNA was observed in Ech131 at 6 h of growth in MM (relative expression ratio 5.1 , P= 0.002). These results suggest that feedback inhibition of HrpL on hrpL itself and hrpS takes place in the bacterium. Similar GFP intensity was observed in Ech3937 and the hrpS mutant carrying phrpS, phrpX and phrpY, respectively, suggesting that HrpS did not regulate the expression of hrpS, hrpX and hrpY. Finally, similar GFP intensity was observed in Ech3937 and the hrpY mutant carrying phrpX and phrpY, respectively, suggesting that HrpY was unable to regulate the expression of hrpX and hrpY.
EXAMPLES 4-9
[00293] The following methods apply to Examples 4-9:
Bacterial strains, plasmids. and media
[00294] The bacterial strains and plasmids used in this group of Examiners are listed in Table 6. Wild-type Ech-Rif, and its mutant strains were stored at -80Ό in 15% glycerol and grown in Luria-Bertani (LB) medium (Sambrook, J., and Russell, D.W. 2001. Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, U.S.A.) and MM medium (Yang et al. 2007). Antibiotics were added to the media at the following concentrations: kanamycin, 50 Mg/ml; rifampicin, 100 pg/ml; ampicillin, 100 pg/ml; and spectinomycin, 50 g/ml. The gacA deletion mutant was constructed by a crossover PCR mutagenesis approach as described (Yang, C. H., Gavilanes-Ruiz, M., Okinaka, Y., Vedel, R., Berthuy, I., Boccara, M., Chen, J. W., Perna, N. T., and Keen, N. T. 2002. hrp genes of Erwinia chrysanthemi 3937 are important virulence factors. Mol. Plant-Microbe Interact. 15:472-480); the primers used were gacA_A, 5' GCA CCC GAT TGC CTG TAC TTA3' (SEQ ID NO:19); gacA_B, 5' GCA CCA GTT CAT GGT CAT CAA C3' (SEQ ID NO:20); gacA_C, 5' CGG AGA CAT TGA TTA GTA GTG A3' (SEQ ID NO:21 ); and gacA_D, ATT GGG AAA CGG GCC GAA GT (SEQ ID NO:22).
GFP reporter plasmid construction
[00295] The GFP promoter region of dspE and pelD cloned into the reporter plasmid pPROBE-AT (Leveau, J. H., and Lindow, S. E. 2001. Predictive and interpretive simulation of green fluorescent protein expression in reporter bacteria. J. Bacteriol. 183:6752-6762) was constructed previously (Peng et al. 2006). The DNA fragments of promoter regions of hrpA, hrpN, hrpL, and pelL were PCR amplified from Ech3937 chromosomal DNA and ligated into the pCR2.1-TOPO TA cloning vector system (Invitrogen, Carlsbad, CA, U.S.A.). The primer pair used for pelL promoter in this study is PpelL_F, 5'ATG CGG TAA TGC GGG GAT3' (SEQ ID NO:23) and PpelL_R, 5'GGC CAG AAC TGA TGT ACT GT3' (SEQ ID NO:24), which produces a 609-bp pelL promoter region sequence of Ech-Rif. The inserted DNA was further subcloned into the Xba\ISac\ sites of the promoter-probe vector pPROBE- AT (Table 6). A plasmid pCLgacA containing a full-length gacA in plasmid pCL1920 also was constructed using the primer set gacAco_F, 5'GCC AAT GTT TCG GGT GTA G3' (SEQ ID NO:25) and gacAco_R, 5'CAT CGA TCT GCC GGA TAC TTT3' (SEQ ID NO:26).
[00296] The GFP reporter in combination with the FACS-based approach has been used to evaluate gene activity in several bacteria at the single-cell level. Because the gfp gene in the pPROBE-AT contains its own ribosome binding site, the stability of gfp mRNA should not be interfered by RsmA when a promoter-containing DNA region of Ech3937 is cloned into the reporter vector.
FACS investigation of promoter activity
[00297] The bacterial cells of Ech-Rif and Ech137 carrying GFP reporter plasmid constructs were washed three times with 1 χ phosphate-buffered saline (PBS) buffer (8.0 g of NaCI, 0.2 g of KCI, 1.44 g of Na2HP04, and 0.24 g of KH2P04 per liter, pH 7.2 to 7.4) and diluted to approximately 106 CFU/ml before analysis. Bacterial cells were identified based on forward and side light scatter properties and electronically gated for analysis. The promoter activity was determined by FACS (Becton Dickinson, San Jose, CA, U.S.A.) and the flow cytometry results were analyzed using Cell Quest software (BD Biosciences, San Jose, CA, U.S.A.).
Real-time PCR analysis
[00298] Wild-type Ech-Rif and the gacA mutant Ech137 were grown in MM with glucose as carbon source (Yang et al. 2007). Total RNA from the bacteria was isolated by using TRI reagent method (Sigma-Aldrich, St. Louis, MO) and treated with Turbo DNA-free DNase kits (Ambion, Austin, TX, U.S.A.). An iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, U.S.A.) was used to synthesize cDNA from 0.5 pg of treated total RNA. The Real Master Mix (Eppendorf, Westbury, NY, U.S.A.) was used for real-time PCR reaction to quantify the cDNA level of hrpL, rsmA, rsmB, rsmC, and rplU in different samples. The rplU was used as
the endogenous control for data analysis. The primer pairs used in this study were RplUsF, 5' GCG GCA AAA TCA AGG CTG AAG TCG 3' (SEQ ID NO:27) and RplUsR, 5' CGG TGG CCA GCC TGC TTA CGG TAG 3' (SEQ ID NO:28) for φ/U; HrpLsF, 5' GAT GAT GCT GCT GGA TGC CGA TGT 3' (SEQ ID NO:29) and HrpLsR, 5' TGC ATC AAC AGC CTG GCG GAG ATA 3' (SEQ ID NO:30) for hrpL rsmAf, 5' TTT TGA CTC GTC GAG TTG GCG AAA 3' (SEQ ID NO:31 ) and rsmAr, 5' GCG CGT TAA CAC CGA TAC GAA CCT 3' (SEQ ID NO:32) for rsmA; rsmBf, 5' AGA GGG ATC GCC AGC AAG GAT TGT 3' (SEQ ID NO:33) and rsmBr, 5' CGT TTG CAG CAG TCC CGC TAC C 3' (SEQ ID NO:34) for rsmB; and rsmCf, 5' ACG AAG TGC TCC CGG TTA ATG TCC 3' (SEQ ID NO:35) and rsmCr, 5' ACG AGA GCG TAC TGA GCG GCT TTT 3' (SEQ ID NO:36) for rsmC. Reactions were run and data were collected by the Opticon 2 system (Bio-Rad). Real-time PCR data were analyzed using Relative Expression Software Tool as described (Pfaffl et al., 2002).
Pellicle formation and exoenzyme production
[00299] For pellicle formation assay, bacterial strains were grown in SOBG broth at 28'C as described (Yap et al. 2005). Due to the slow formation of pellicle in Ech137, 10-day-old pellicles from Ech-Rif and Ech137 were used for SEM observation. The samples of pellicle were fixed in 2% glutaraldehyde in PBS buffer (pH 7.0) for 2 h and post-fixed in 1 % osmium tetroxide in the same buffer for 1 h. After dehydration in the graded series of ethanol, specimens were infiltrated with polyethylene glycol (PEG). Cross sections of the pellicles were cut using an ultramicrotome. Then, PEG was extracted from the blocks by soaking in several changes of warm ethanol. After critical-point drying, the specimen was mounted on a stub coated with Duco cement, sputter coated with gold, and examined with a Hitachi S-570 Scanning Electron Microscope.
[00300] Plate assays for activity of Pel, Cel, and Prt and the spectrophotomeric assay of Pel activity for Ech-Rif, Ech137, and the complemented strain Ech137 (pCLgacA) were carried out as described (Matsumoto, H., Muroi, H., Umehara, M., Yoshitake, Y., and Tsuyumu, S. 2003. Peh production, flagellum synthesis, and virulence reduced in Erwinia carotovora subsp. carotovora by mutation in a homologue of cytR. Mol. Plant-Microbe Interact. 16:389-397). Three biological replicates were performed for each treatment.
Virulence assay, growth kinetics, and in planta Pel production
[00301] The local leaf maceration assay was carried out as described (Yang et al. 2004; Yang, C. H., Gavilanes-Ruiz, M., Okinaka, Y., Vedel, R., Berthuy, I., Boccara, M., Chen, J. W., Perna, N. T., and Keen, N. T. 2002. hrp genes of Erwinia chrysanthemi 3937 are important virulence factors. Mol. Plant-Microbe Interact. 15:472-480). Briefly, wild-type bacterial cells and gacA mutant Ech137 cells were syringe-infiltrated in the middle of each symmetric side of the same leaf with approximately 50 μΙ of a bacterial suspension at 106
CFU/ml. Phosphate buffer (50 mM, pH 7.4) was used to suspend the bacterial cells. Three replicate plants with a total of at least 12 leaves were inoculated. In the systemic invasion assay, the pathogenicity of the bacterium was evaluated as described (Franza, T., Sauvage, C, and Expert, D. 1999. Iron regulation and pathogenicity in Erwinia chrysanthemi 3937: Role of the fur repressor protein. Mol. Plant-Microbe Interact. 12:1 19-128), with minor modification. A volume of a 50 μΙ of the bacterial suspension with an optical density at 600 nm of 0.01 was inoculated into the front edge of the African violet leaf. For each bacterial strain, 12 plants were inoculated. Inoculated plants were kept in growth chambers at 28*C, 95% relative humidity, and a photoperiod of 16 h. Development of symptoms induced by bacterial strains in African violet plants was considered as systemic when at least one leaf and its petiole were macerated. Progression of the symptoms was scored daily for 12 days.
[00302] Growth kinetics in planta was carried out in African violet cv. Gauguin as described (Yang et al. 2002). Briefly, leaves were syringe infiltrated with approximately 50 μΙ of bacterial suspension at 106 CFU/ml with a 1-ml syringe. Leaf discs (4 mm in diameter) around the maceration area were harvested at different intervals following infiltration and ground in 50 mM phosphate buffer (pH 7.4). The bacterial concentration, (CFU/cm2) was determined by plating serial dilutions of leaf extracts on LB agar plates. A spectrophotomeric assay was used to monitor the Pel production of Ech-Rif and Ech137 during the in planta growth. A 10-μΙ supernatant of the plant juice from African violet leaves inoculated with the bacteria was added into 990 μΙ of Pel reaction buffer and the Pel production was quantified using the spectrophotomeric assay (Matsumoto et al. 2003). Pel production was the ratio of the optical density at 230 nm unit to the log unit of the bacterial concentration (U/log [CFU/cm2]). Three replicate plants with a total of six leaves per plant were used in each sampling time for the in planta Pel production and bacterial growth kinetics assays.
EXAMPLE 4: GacA affects biofilm-pellicle formation
[00303] Ech3937 is capable of forming a biofilm and pellicle in SOBG broth. A spontaneous rifampicin-resistant derivative of Ech3937, Ech-Rif, was used as a wild-type in this study (Table 6). A gacA deletion mutant Ech137 of Ech-Rif was constructed and confirmed by DNA sequencing analysis. The gacA gene of Ech137 was deleted with only 20 bp of the gacA open reading frame remaining. No significant difference in growth between Ech-Rif and the gacA mutant Ech137 was observed in M9 minimal medium (MM). Ech-Rif formed biofilm-pellicle in SOBG broth grown for 2 days at 28Ό. However, no visible biofilm- pellicle was observed in Ech137 until grown for 3 days in SOBG broth. This delayed biofilm- pellicle formation phenotype of the mutant could be restored nearly to the wild-type level when Ech137 was complemented with a low-copy-number plasmid pCLgacA (Figure 6A). The pellicles of Ech-Rif and Ech137 were sectioned using an ultramicrotome and the interior
textures of the pellicles of the bacteria were compared using a scanning electron microscope. A more compact texture in 10-day-old pellicles was observed in Ech-Rif in comparison with Ech137 (Figure 6B). Pellicles of both Ech-Rif and Ech137 treated with cellulose disintegrated, suggesting that the major component, cellulose, was not altered in Ech137.
[00304] Figure 6A shows biofilm and pellicle formation in SOBG broth (Yap et al. 2005). Figure 6A(a) shows biofilm and pellicle formed in wild-type Ech-Rif in SOBG cultures grown for 3 days at 28Ό. Figure 6A(b) shows delayed biof ilm and pellicle formation in Ech137, the gacA mutant in SOBG cultures grown for 3 days at 28 . F igure 6A(c) shows the gacA gene expressed on plasmid pCLgacA restored biofilm and pellicle formation to the gacA mutant Ech 137 in SOBG cultures grown for 3 days at 28Ό. F igure 6B shows cross sections of the pellicle observed with scanning electron microscopy at different magnifications. Figure 6B(a1 ) shows Ech-Rif; Figure 6B(b1 ) shows Ech137; Figure 6B(a2) shows Ech-Rif; and Figure 6B(b2) shows Ech137. The size bars in the micrographs in Figure 6B(a1) and Figure 6B(b1 ) are 1 mm, while in Figure 6B(a2) and Figure 6B(b2) the size bars are 100 μηη.
Table 6. Bacterial Strains and Plasmids.
Strains, plasmids Characteristics' Reference or source
Strains
Escherichia coli S 17- 1 >.-pir Lysogen of S 17- 1 V. d Lorenzo. Madrid Ech3937 Wild-type strain isolated from Saintpaulia ionanilia D. Expert, Paris Ech-Rif Eeh 937 nfampicin resistant random mutant This work
Echl37 Agii A:: Kan, Km', Ech-Rif derivative This work
Ech-Rif (pDspE) Ech3937-Rif containing plasmid pDspE This work
Echl37fpDspE) Ech 137 containing plasmid pDspE This work
Ech-Rif (pHrpA) Ech3937-Rif containing plasmid pHrpA This work
Echl37ipHrpA> Ech 137 containing plasmid pHrpA This work
Ech-Rif (pHrpN) Ech3937-Rif containing plasmid pHrpN This work
Ech 7(pHrpN) Echl37 containing plasmid pHrpN This work
Ech-Rif (pHrpL) Ech3937-Rif containing plasmid pHrpL This work
Echl 7(pHrpL) Ech 137 containing plasniid pHrpL This work
Ech-Rif (pPelD) Ech3937-Rif containing plasmid pPelD This work
Echl 7ipPelD) Eenl37 containing plasmid pPelD This work
Ech-Rif (pPelL) Ech3937-Rif containing plasmid pPelL This work
Ee l 7ipPelL) Echl37 containing plasmid pPelL This work
Ech 137 (pCLgacA) Echl 7 containing pCLgacA This work
Plasmids
pWM91 Sucrose-based counter-selectable plasmid. Ap* Metcalf el al. 1995 pCR2J-TOPO PCR cloning vector. Ap*, Km* Invitrogen. Carlsbad, CA.
U.S.A.
pPROBE-AT GFP promoter-probe vector. Ap' Miller et ah 2000 pCLI 20 Low copy number plasmid Lemer and Inouye 1 90 pDspE pProbe-AT derivative with PCR fragment containing dspE promoter region. Apr Yang et al. 2004 pHrpA pProbe-AT derivative with PCR fragment containing 412-bp ft/pA promoter region. Ap' Unpublished data pHrpN pProbe-AT derivative with PCR fragment containing 3 6-bp lirpS promoter region. Ap* Unpublished data pHrpL pProbe-AT derivative with PCR fragment containing hrpL promoter region. Ap* Unpublished data pPelD pProbe-AT derivative with PCR fragment containing pelD promoler region, Ap' Pen et al. 2006 pPelL pProbe-AT derivative with PCR fragment containing 609-bp pclL promoter region, Ap* This work pCLgacA pCLI920 with a 1.54S-bp PCR product containing full length of gacA. Stf This work
' Ap\ Km', Rif. and S 1. ampicillin. k an am vein, rifampicin, and spectinomydn resistance, respectively: PCR, polymerase chain reaction; and GFP. green fluorescent protein.
Metcalf, W. W., Jiang, W., Daniels, L L, Kim, S. K., Haldimann, A., and Wanner, B. L. 1996. Conditionally replicative and conjugative plasmids carrying lacZ alpha for cloning, mutagenesis, and allele replacement in bacteria. Plasmid 35:1-13.
Lerner C. G., and Inouye M. 1990. Low copy number plasmids for regulated low-level expression of cloned genes in Escherichia coli with blue/white insert screening capability. Nucleic Acids Res. 18:4631.
EXAMPLE 5: GacA regulates exoenzyme production
[00305] Production of exoenzymes, including pectate lyase (Pel), protease (Prt), and cellulase (Cel) in wild-type Ech-Rif, gacA mutant Ech137, and gacA mutant complemented strain Ech137 (pCLgacA) grown in minimal medium (MM) and MM supplemented with 1 % polygalacturonate (MMP) at 36 h, was examined with semi-quantitative plate assays. Values are a representative of two experiments. Three replicates were used in this experiment. Compared with Ech-Rif, reduced Pel, Cel, and Prt production was observed in Ech137 grown in MM and MM supplemented with 1 % polygalacturonate (PGA) (MMP) at 36 h (Figure 7).
[00306] A spectrophotomeric assay was used to quantify Pel activity in the bacterial strains. Figure 8 shows spectrophotometric quantification of pectate lyase (Pel) activity (U/optical density at 600 nm [OD600]) in Ech-Rif, gacA mutant Ech137, and the complementary strain Ech137 (pCLgacA) grown in minimal medium supplemented with 1 % polygalacturonate at 36 h. Values are a representative of two experiments. Three replicates were used in this experiment; the value is present as average of three replicates and the standard deviation. Consistent with the results from the plate assay, lower Pel production by Ech137 was observed by the spectrophotomeric assay when the bacterial cells were grown at 36 h (late stationary phase) (Figure 8). Compared with the Ech-Rif, a lower Pel production of Ech137 also was observed by the spectrophotomeric assay when the bacterial cells were grown at exponential phase (12 h) and beginning of stationary phase (24 h). The Pel, Cel, and Prt production of Ech137 was restored nearly to the wild-type bacterium level by introducing the plasmid pCLgacA containing wild-type gacA gene into the mutant (Figs. 7 and 8).
EXAMPLE 6: GacA regulates the expression of pe/ and T3SS genes
[00307] PelD and PelL of D. dadantii encode endo-Pels. PelD has higher activity on nonmethylated pectins and PelL prefers partially methylated pectins. The promoter regions of pelD and pe/L, respectively, were cloned into pPROBE-AT to produce pPelD and pPelL (Table 6). The Ech-Rif and Ech137 cells carrying these GFP promoter plasmids were grown in MM-supplemented 1 % PGA and the fluorescence intensity of the bacterial cells was measured with an FACS. The fluorescence intensity collected by FACS was analyzed in a four-decade log scale using CellQuest Pro software from Becton Dickinson, and the gene expression profiles were analyzed as i) total, the average GFP fluorescence intensity of total bacterial cells; ii) GFP+ mean, average GFP fluorescence intensity of GFP expressing bacterial cells; and iii) GFP+%, the percentage of GFP-expressing bacterial cells of the total bacterial cells.
[00308] To study the influence of GacA on the transcription of pel genes in Ech3937, the promoter activities of pe/D and pelL of Ech-Rif and Ech137 were examined. Figure 9 shows expression of pe/D and pelL in Ech-Rif (black line with black filling) and gacA mutant Ech137 (gray line) grown in minimal medium supplemented with 1% polygalacturonate (MMP). The promoter activities were compared after 12 and 24 h of culture in the medium MMP. Green fluorescent protein (GFP) intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA, U.S.A.). The gray line with gray filling stands for the GFP expression control base level of the Ech-Rif containing pPROBE-AT vector without insert. Values are a representative of two experiments. Three replicates were used in this experiment and one replicate was used for the overlay as displayed. Compared with Ech-Rif, a considerably lower expression of pe/D and pelL was observed in gacA mutant Ech137 at 12 and 24 h of growth in the medium, indicating that GacA upregulated the expression of pe/D and pelL (Figure 9). The pe/D expression in wild-type Ech-Rif is more than twofold higher than that of the gacA mutant Ech137 at 12 h postgrown (Figure 9). The Ech-Rif cells carrying pPelD at 12 and 24 h were expressed at a mean fluorescence intensity (MFI) of 190 ± 17 and 459 ± 73, while the Ech137 cells carrying pPelD at 12 and 24 h were expressed with an MFI of 52 ± 3 and 324 ± 11. Similarly, the pelL promoter activity in the Ech-Rif cells was approximately 50% greater than that in the gacA mutant Ech137 cells. The MFI values of Ech-Rif (pPelL) were 31 ± 0.1 and 28 ± 0 at 12 and 24 h postgrown, respectively (Figure 9). The MFI values of Ech137 (pPelL) were 19 ± 1 and 22 ± 1 at 12 and 24 h (Figure 9).
[00309] Regulation of the T3SS genes by GacA has been reported in E. carotovora subsp. carotovora. To study the influence of GacA on the transcription of T3SS genes in Ech3937, the promoter regions of dspE, hrpA, and hrpN of the bacterium were cloned into the pPROBE-AT to produce plasmids pDspE, pHrpA, and pHrpN (Table 6). The total GFP intensity of Ech-Rif (pDspE) was 15 ± 0.8 at 8 h and 17 ± 1.2 at 12 h grown in rtrp-inducing MM (Table 7). A lower total GFP intensity of Ech137 (pDspE) of 3.4 ± 0.01 and 3.4 ± 0.05 was observed at the same period of time. Similarly, compared with Ech-Rif, a lower GFP intensity was observed in the Ech137 cells carrying pHrpA and pHrpN grown in the MM at 8 and 12 h (Table 7). The above data provide evidence that GacA upregulated dspE, hrpA, and hrpN.
Table 7. Expression of dspE, hrpA, and hrpN of Ech-Rif and Ech137 grown in minimal medium.
Mean fluorescence intensity0
Gene promoter 8 h 12 h
Ech-Rif (pDspE) 15.3 ± 0.8 17.0 ± 1.2
Echl 37 (pDspE) 3.4 + 0.01 3.4 ± 0.05
Ech-Rif (pHrpAl 25.9 ± 1.6 39.0 ± 5.0
Echi37 (pHrpA) 5.4 ± 0.2 6.6 ± 0.1
Ech-Rif (pHrpN) 2 I .3 ± 1.S 38.9 ± 2.4
Echl 37 (pHrpN) 2.6 ± 0.05 2.7 ± 0.04
0 Promoter activities were compared after 8 and 12 h of culture in the minimal medium. Values represent total green fluorescent protein intensity and are a representative of two experiments. Three replicates were used in this experiment The value is present as average of three replicates and the. standard deviation.
EXAMPLE 7: The Gac-Rsm regulatory network controls Pel and T3SS gene expression
[00310] Rsm is a novel type of post-transcriptional regulatory system that plays a critical role in gene expression. To investigate whether the influence of GacA on pectinase gene expression is through the Rsm regulatory pathway, the relative mRNA level of rsmC, rsmB, and rsmA was examined by qRT-PCR. The qRT-PCR data were analyzed using the Relative Expression Software Tool as described by Pfaffl and associates (Pfaffl et al. 2002). Figure 10A shows relative levels of rsmA, rsmB, rsmC, and hrpL mRNA in gacA mutant Ech137 compared with wild-type Ech-Rif grown for 6 or 12 h in a minimal medium. Three replicates were used in each experiment and the values are presented as the average of the three replicates and the standard deviation. Compared with wild-type, a lower amount of rsmB mRNA was observed in Ech137. Wild-type Ech-Rif produced approximately 10-fold more rsmB mRNA than gacA mutant Ech137 at 6 h and 24-fold more at 12 h, with a P value less than 0.05. No significant differences in amount of rsmC and rsmA mRNA were observed between Ech-Rif and Ech137 (with a P value range from 0.74 to 1 ) (Figure 10A).
[00311] Figure 10B shows relative levels of gacA and rsmB mRNA in gacA mutant Ech137 and gacA mutant complemented strain Ech137 (pCLgacA) compared with wild-type Ech-Rif grown for 12 h in a minimal medium. The amount of mRNA was examined by realtime polymerase chain reaction assay and analyzed by Relative Expression Software Tool. The normalized value of mRNA for wild-type was 1.0. Three replicates were used in each experiment and the values are presented as the average of the three replicates and the standard deviation. No detectable mRNA of gacA was observed in Ech137 by qRT-PCR (Figure 10B). The gacA and rsmB expression of Ech137 was restored by introducing the plasmid pCLgacA into the mutant. The relative mRNA amounts of gacA and rsmB of Ech137 (pCLgacA) are approximately 180 and 150% of the Ech-Rif (Figure 10B). The higher
amounts of gacA and rsmB mRNAs in Ech137 (pCLgacA) compared with Ech-Rif may be due to the copy number effect of the plasmid.
[00312] To further investigate whether the influence of GacA on T3SS gene expression is through the GacA-RsmA-rsmS-ftrpL regulatory pathway, the amount of hrpL mRNA of the bacteria was examined by qRT-PCR. Compared with Ech-Rif (normalized to 1 ), a significantly lower hrpL mRNA was observed in gacA mutant Ech137 (0.362 ± 0.065) with a P value of 0.001 at 12 h grown in MM (Figure 10A). A similar amount of hrpL mRNA was observed between Ech-Rif and Ech137at 6 h (P = 1 ) grown in the medium. Similar promoter activity of hrpL was observed between Ech-Rif and Ech137, suggesting that hrpL was regulated at a post-transcriptional level.
EXAMPLE 8: GacA influences the expression of Pel and T3SS genes in planta
[00313] To connect the in vitro result with the in vivo condition, the expression of pelL and dspE between Ech-Rif and Ech137 in host plant African violet (Saintpaulia ionantha) leaves was examined further. Compared with Ech137, a higher transcription of pelL and dspE in Ech-Rif in S. ionantha was observed at 24 h postinoculation, which is approximately threefold more for pelL and fourfold more for dspE (Table 8).
Table 8. Expression of pelL and dspE of Ech-Rif and gacA mutant Ech137 in African violet3.
Ceoe Ech-Rif Eehl37 Ech-Rif EchlJ7
promoter (pPdL) (pPdL (pDspE) (pDspE)
Total 51.4 + 20.91 1 1.8 + 7.4 6.0 + 0.8 1.2 ± 0.1
GFP* mean 78.2 + 17.0 40.1 + 0.7 54.4 + 12.2 15.8 + 15.2
GFP*¾ 57.1 + 14.9 1 1.6 + 1 1.3 8.0+ 0.5 Cl ± 0
■ Promoter activities were compared after 24 h of inoculation. Greco fluorescent protein (GFP) intensity was determined on gated populations of bacteria) cells by flow cytometry. Values arc a representative of two experiments. Three replicates were used in this experiment. The value is present as average of thre leplicaics and the standard deviation.
EXAMPLE 9: The gacA mutant reduced maceration and systemic invasion ability
[00314] Because GacA affects multiple phenotypes contributing to pathogenesis, a local maceration assay was carried out with Ech-Rif, Ech137, and the complemented strain Ech137 (pCLgacA) in the African violet cv. Gauguin as previously described (Yang et al. 2002). Figure 11 shows local maceration lesions caused by a, Ech-Rif; b, gacA mutant Ech137; and c, complemented strain Ech137 (pCLgacA). Bacterial cells were inoculated in the middle of each half side of the same leaf. Phosphate buffer (pH 7.4, 50 mM) was used to suspend the bacterial cells and a volume of a 50 μΙ of bacterial suspension with a bacterial concentration of 106 CFU/ml was used. The maceration symptom was examined 2 days postinoculation. The experiment has been repeated twice. Compared with Ech-Rif, Ech137 was dramatically reduced in maceration ability in planta 2 days postinoculation (Figure 11 ). The maceration ability of Ech137 was restored to near the wild-type Ech-Rif level by pCLgacA (Figure 11 ).
[00315] Figure 12 shows the concentration of Ech-Rif and gacA mutant Ech137 in African violet cv. Gauguin (Saintpaulia ionantha). Leaves of African violet were inoculated with a 50- μΙ bacterial suspension at a concentration of 106 CFU/ml. Six leaves from six replicate plants were used at each sampling time for each bacterial strain, the value is present as average of three replicates and the standard deviation; concentration of Ech-Rif (solid diamonds) and Ech137 (solid triangles). The spectrophotometric quantification was carried out as described to measure the pectinase (Pel) activity in the inoculaled leaves from the same sample for population kinetics; Pel production of Ech-Rif (open diamonds) and Ech137 (open triangles). Interestingly, although a lower Pel activity also was observed in plant leaves inoculated with Ech137, in comparison with the leaves inoculated with wild-type Ech-Rif (Figure 12), there was no difference in bacterial concentration between the wild-type Ech-Rif and Ech137 in African violet leaves at day 2 postinoculation analyzed by a paired sample f test (P = 0.23) (Figure 12). Compared with Ech-Rif, a lower bacterial concentration of Ech137 in plants was observed at day 3 (P = 5.9 χ 10_11 ) and day 4 (P = 1.7 χ 10- ).
[00316] A systemic invasion assay (Franza et al. 1999) was further applied to investigate the role of GacA of the bacterium in S. ionantha. For each bacterial strain (Ech-Rif and Ech137), 12 plants (one leaf per plant) were inoculated. Response was considered as systemic when at least one leaf and its petiole were macerated. Values are a representative of two experiments. Eight days after inoculation, 11 of the 12 plants inoculated with Ech-Rif developed systemic invasion symptoms (Figure 13). In contrast, the Ech137 showed a reduced ability to develop a systemic invasion in the plant host; only one plant developed a systemic invasion with the gacA mutant 16 days postinoculation.
EXAMPLE 10: Identification of T3SS Inhibitors
[00317] To identify potential compounds that repress activation of T3SS, analogs and isomers of TCA and intermediates of salicylic acid and phenypropanoid biosynthesis pathways in plants were further screened for their effect on Ech3937 hrpA expression by flow cytometry (Table 9). A green fluorescent protein (GFP) reporter plasmid phrpA (pProbe- AT derivative with PCR fragment containing hrpA promoter region) was constructed, resulting in a transcriptional fusion of hrpA promoter with GFP gene. Bacterial cells containing phrpA plasmid were grown in MM supplemented with 0.1 mM of each compound. GFP intensity, which is a measurement of hrpA promoter activity, was measured by flow cytometry. The TCA analogs p-coumaric acid (PCA) and cinnamyl alcohol were discovered to be inhibitors of the expression of hrpA (Table 9).
Table 9. The expression of hrpA of Dickeya dadantii 3937 (Ech3937) in MM and MM supplemented with different isomers and analogs of f-cinnamic acid.
Phenolic compound3 6hb 12 h 24 h
MM 8.3±0J 78.7±6.3 92.1117.1
f-Cinnamic acid 22.3±2.1 133.9±12.9 203.7116.1 o-Coumaric acid 15.5±1.1 115.5±7.9 225.8115.6 m-Coumaric acid 12.1 ±0.0 133.0±38.2 203.319.6
p-Coumaric acid 6.9±0.1 10.2±0.4 11.411.0
Hydrocinnamic acid 13.7±1.0 200.3±35.8 213.5118.9
Phenoxyacetic acid 18.0±3.1 222.7±64.3 205.711 1 .8 frans-2-Phenylcyclopropane-
7.2±0.1 67.0±18.4 . 84.0114.3
1 -carboxylic acid
frans-3-(3-Pyridyl)acrylic acid 13.1 ±0.4 184.9±35.6 204.0116.8 frans-3-indoleacrylic acid 7.9±0.2 23.9±1.3 121.016.2
2-Methylcinnamic acid 22.8±0.6 157.2111.7 342.5116.6
2-Chlorocinnamic acid 25.7±0.2 166.2±17.8 319.8148.3
Methyl frans-cinnamate 9.7±0.1 135.8±8.1 219.2114.5
Cinnamyl alcohol 6.3±0.1 27.8±5.0 53.812.9
aMinimum medium (MM) and MM supplemented with 0.1 mM of different compounds.
bEch3937 cells carrying GFP reporter phrpA was used in this study. The promoter activities were compared at 6, 12, and 24 h of bacterial growth. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values (Mean Fluorescence Intensity) of GFP are a representative of three experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
[00318] The expression of the T3SS gene hrpA was further examined in MM and MM supplemented with PCA at concentrations of 0.001 , 0.005, 0.01 , 0.05 and 0.1 mM respectively. Figures 16A and 16B show the promoter activities of hrpA in Dickeya dadantii 3937 (Ech3937) grown in minimum medium (MM) and MM supplemented with different amount of p-coumaric acid (PCA) at 12 h (Figure 16A) and 24 h (Figure 16B) post- inoculation. GFP intensity was determined on gated populations of bacterial cells by flow cytometry and analyzed with the Cell Quest software (BD Biosciences, San Jose, CA). The growth of Ech3937 in MM supplemented with different concentrations of PCA was recorded. Compared with MM alone, the average GFP fluorescence intensity of bacterial cells of Ech3937 (phrpA) was reduced more than 4-fold when 0.05 and 0.1 mM of PCA were added to the medium (Figs. 16A, 16B). The addition of PCA at concentrations at 0.001 , 0.005 and 0.01 did not result in substantial reduction of GFP fluorescence intensity of Ech3937. Inhibition of bacterial growth was not observed when PCA was added into the MM (Figs. 16A, 16B).
[00319] To confirm the inhibitory effect of PCA on T3SS of Ech3937, the promoter activity of hrpN of Ech3937 was also examined. A reduced expression of hrpN was observed in MM supplemented with 0.1 mM PCA in comparison with the bacterial cells grown in MM alone (Table 10). The mrp, whose protein product has an ATPase conserved domain (2e-06), was used as a reference gene. Similar mrp expression was observed in Ech3937 {pmrp) when
the bacterial cells were grown in MM and MM supplemented with 0.1 mM PCA respectively (Table 10). The repression effect of PCA on T3SS gene expression was further demonstrated by a q T-PCR assay. Figure 14 shows the relative mRNA level of hrpS, hrpL, dspE, hrpA, hrpN, and rsmB of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) supplemented with 0.1 mM p-coumaric acid (PCA) compared to those in MM without PCA. The amount of mRNA was determined by qRT-PCR. Three replicates were used in this experiment. The p-value was calculated using Relative Expression Software Tool as described by Pfaffl et al. (2002). Levels of gene expression of hrpS, hrpL, dspE, hrpA, and hrpN are significantly different between MM and MM supplemented with 0.1 mM PCA with p < 0.001. Compared with Ech3937 in MM alone (normalized to 1 ), a significantly lower amount of mRNA of dspE (P =0.001 ), hrpA (P =0.001 ), and hrpN (P =0.001 ) was observed in the bacterium grown in MM supplemented with PCA (Figure 14).
Table 10. The expression of type III secretion genes hrpA and hrpN of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) and MM supplemented with 0.1 mM PCA (MMPCA).
12 h 24 h
Gene Promoter3 MM MMPCA MM MMPCA
Ech3937 (phrpA) 64.3±0.9b 10.3±1.3 150.8±4.4 18.5±3.5
Ech3937 (phrpN) 39.8±5.8 6.8±0.8 133.3±3.2 11.3±3.4
Ech3937 (phrpS) 72.7±11.3 37.9±1.3 95.0±17.7 43.6±2.6
Ech3937 (phrpL) 12.8±0.1 7.8±0.1 27.2±1.0 11. 3.3
Ech3937 (pmrp) 113.0±7.7 124.1 ±2.7 93.4±2.6 98.9±1.0
Ech3937 (pPROBE-AT) 2.1±0.1 2.2±0.2 13.4±8.4 14.0±10.1
"The promoter activities were compared at 12 and 24 h of bacterial growth in p-coumaric acid (PCA). bGFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values (Mean Fluorescence Intensity) are a representative of two experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
[00320] GacS/GacA also induced the production of pectate lyase of Ech3937. To investigate whether PCA affects the T3SS gene expression through the Gac-Rsm regulatory pathway, the expression of rsmB was further examined by qRT-PCR. Figure 17 shows pectate lyase (Pel) production of Dickeya dadantii 3937 (Ech3937) grown in minimal medium (MM) and MM supplemented with 0.1 mM of p-coumaric acid (PCA) at 12 h examined by plate assays as described (Mats.umoto et al. 2003). Values are a representative of two experiments. Three replicates were used in this experiment. No significant difference was observed between Ech3937 grown in MM and MM supplemented with PCA for gene rsmB with the p = 0.928 (Figure 14). This result shows that the repression T3SS expression by PCA is not through the Gac-Rsm pathway. That the Gac-Rsm pathway is not interfered by PCA is further suggested by a pectinase assay. Similar pectate lyase production was
observed between Ech3937 grown in MM and MM supplemented with 0.1 mM PCA, demonstrating that GacS/GacA is not influenced by PCA (Figure 17).
[00321] Along with GacS/GacA-RsmA-rsmS-/7rpL regulatory pathway, the T3SS of Ech3937, which belongs to Group I T3SS of phytobacteria, is primarily regulated by a HrpX/Y-HrpS-HrpL pathway. The two-component system HrpX/HrpY activates the gene encoding HrpS, which is required for expression of hrpL. HrpL, an alternative sigma factor, further activates expression of genes encoding the T3SS apparatus and its secreted substrates. To investigate whether PCA represses T3SS gene expression through HrpX/Y- HrpS-HrpL pathway, the promoter activity of hrpS and hrpL was further examined. Compared with Ech3937(phrpS) and Ech3937(phrpL) in MM, a lower GFP intensity was observed in the bacterial cells carrying phrpS and phrpL grown in MM supplemented with 0.1 mM PCA (Table 10). The expression of hrpS and hrpL was also confirmed by qRT-PCR. The result showed that, compared with Ech3937 in MM alone (normalized to 1 ), a significantly lower amount of mRNA of hrpS (relative expression ratio 0.223, P = 0.001 ) and hrpL (relative expression ratio 0.039, P = 0.001 ) was observed in bacteria grown in MM supplemented with PCA (Figure 14).
[00322] To further elucidate whether T3SS gene expression is mainly regulated through the HrpX/Y-HrpS-HrpL regulatory pathway, the expression of hrpA and hrpN in wild-type Ech3937 and hrpX (WPP67), hrpY (WPP92), hrpS (WPP90), and hrpL (WPP96) mutants in MM were examined. The result showed that compared with Ech3937 carrying phrpA and phrpN, very low expression of hrpA and hrpN was observed in WPP67, WPP92, WPP90, and WPP96 grown in MM. Similar expression of hrpA and hrpN was observed among WPP67, WPP92, WPP90 and WPP96 carrying phrpA and phrpN grown in MM and MM supplemented with PCA. These results demonstrate that hrpX, hrpY, hrpS and hrpL are crucial for the T3SS gene expression and PCA inhibits expression of T3SS genes through HrpX/Y-HrpS-HrpL regulatory pathway (Table 11 ). Since PCA represses the expression of several T3SS genes such as hrpN, the effect of PCA on protein production of HrpN was further examined. Figure 15 shows HrpN protein expression of Dickeya dadantii 3937 (Ech3937) in minimum medium (MM) and MM supplemented with 0.1 mM of p-Coumaric acid (PCA). Lane 1 of Figure 15 shows a HrpN overexpression strain. Lane 2 shows Ech3937 grown in MM supplemented with 0.1 mM PCA. Lane 3 shows Ech3937 grown in MM. Lane 4 shows Ech3937 grown in MM supplemented with 0.01 mM PCA. Compared with MM alone, a lower amount of HrpN was observed in Ech3937 grown in MM supplemented with 0.1 mM of PCA (Figure 15).
Table 11. The expression of hrpA and hrpN of wild-type Dickeya dadantii 3937 (Ech3937) and hrpX (WPP67), hrpY (WPP92), hrpS (WPP90) and hrpL (WPP96) mutants in minimum medium (MM) and MM supplemented with 0.1 mM PCA (MMPCA).
12 h 24 h
Gene Promoter3 MM MMPCA MM MMPCA
Ech3937 (phrpA) 53.0±5.8 b 9.2±0.4 139.3±22.2 12J±0.3
WPP67 (phrpA) 8.3±0.1 7.9±0.2 10.3±1.1 9.0±1.3
WPP92 (phrpA) 9.3±0.2 6.9±0.1 9.1±0.2 9.4±0.7
WPP90 (p ?/pA) 7.7±0.4 7.9±0.2 8.1±0.0 9.3±0.2
WPP96 (phrpA) 7.6±0.3 7.3±0.1 7.6±0.1 9.0±1.6
Ech3937 (phrpN) 49.0±3.3 4.3±0.1 112.2±6.7 8.8±2.1
WPP67 {phrpN) 4.4±0.4 3.5±0.2 9.4±1.4 6.3±0.7
WPP92 (phrpN) 3.8±0.1 3.6±0.1 5.7±0.4 5.510.3
WPP90 (phrpN) 3.6±0.2 3.5±0.1 5.0±0.3 5.1±0.1
WPP96 (ρΛφΛ 3.0±0.0 3.0±0.0 3.9±0.1 4.3±0.1
Ech3937 (Pprobe-AT) 2.2±0.1 2.3±0.1 4.3±0.2 4.9±0.1
"The promoter activities were compared at 12 and 24 h of bacterial growth in p-Coumaric acid (PCA). bGFP intensity was determined on gated populations of bacterial cells by flow cytometry. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values (Mean Fluorescence Intensity) are a representative of two experiments. Three replicates were used in this experiment. The value is present as the average of three replicates with standard deviation (SD).
EXAMPLE 11 : Synthesis of Compounds
[00323] The compounds in Table 12 were synthesized or purchased commercially.
Table 12.
Synthesis of hvdroxamates (103. 125. 127. 128. 129. 130. 131. 132)
[00324] Method A: A mixture of cinnamic acid (25 mmol) and concentrated H2S04 (0.1 ml_) in anhydrous MeOH (25 mL) was refluxed at 80¾ (bath temperature) for 16 h. After the excess MeOH was removed by a rotary evaporator, the residue was treated with H20 (50 mL), and the resulting mixture was extracted with EtOAc (3^50 mL). The combined extracts were washed with H20 (50 mL) and brine (50 mL), and dried (anhydrous Na2S04). The solvent was evaporated to dryness, and the crude products were purified by flash silica gel chromatography (eluting with 10-60% hexane in EtOAc) to afford methyl cinnamate. To an ice-cold solution of methyl cinnamate described above (8 mmol) dissolved in anhydrous MeOH (10 mL) and THF (10 mL) was added hydroxylamine hydrochloride (1.67g, 24 mmol, 3 equiv) followed by 25% sodium methoxide in methanol solution (8.4 mL, 36 mmol, 4.5 equiv). The reaction mixture was stirred under argon and at 0Ό for 2 h, then allowed to warm to ambient temperature with the stirring was continued overnight (16 h). The resulting yellow suspension was condensed to dryness with a rotary evaporator, and the residue was treated with 1 N HCI aqueous solution (30 mL). The mixture was extracted with EtOAc (3 <50 mL), and dried (anhydrous Na2S04). Evaporation of the solvent afforded the crude products (480 mg), which was purified by flash silica gel chromatography (eluting with 5-15% MeOH in DCM) to afford the hydroxamate.
[00325] Using Method A, Compounds 103, 125, 129, 130, and 131 were synthesized. The carboxyl acid of PCA was converted to hydroxamite to synthesize compound 103 by reacting methyl ester 101 with hydroxylamine under basic conditions. Compound 103 was a light-brown solid, obtained at 25% yield (based on the methyl ester). The hydroxyl group of 103 was replaced by methoxy group, resulting in the hydroxamate 125. Compound 125 was
light-brown solid, obtained at 67% yield. Compound 129 was light-brown solid, obtained at 21 % yield. Compound 130 was an off-white solid, obtained at 63% yield. Compound 131 was a grey solid, obtained at 25% yield. Identity of compounds was verified by H NMR (75 MHz, CD3OD).
[00326] Method B: To a stirred mixture of cinnamic acid (7 mmol) and diisopropylethylamine (DIEA) (2.45 mL, 17 mmol) in anhydrous DMF (20 ml_) was added HBTU (2.92g, 7.7 mmol) at room temperature, followed by adding a solution of hydroxylamine hydrochloride (0.98g, 14 mmol) and DBU (2.13g, 14 mmol) in anhydrous DMF (8 mL), and then the whole reaction mixture was stirred at room temperature for 1 h. After most of the DMF was removed with a rotary evaporator, the residue was dissolved in EtOAc (150 mL), then washed with H20 (50 mL) and brine (50 mL), and dried (anhydrous Na2S0 ). Evaporation of the solvent afforded the crude products, which was purified by flash silica gel chromatography (eluting with 5-15% MeOH in DCM) to afford the hydroxamate.
[00327] Using Method B, compounds 127, 128, and 132 were synthesized. The indole hydroxamate 127 was synthesized by reacting the corresponding methyl esters with hydroxylamine under basic conditions. Compound 127 was a yellow solid, obtained at 35% yield. Compound 128 was a white solid, obtained at 50% yield. Compound 132 was a white solid, obtained at 60% yield. Identity of compounds was verified by 1H NMR (400 MHz, CD3OD for 127; 300 MHz, DMSO-d6 for 128 and 132).
Synthesis of cinnamyl alcohols (104, 126)
[00328] Compound 101 was reduced with aluminium hydride to generate the 4- hydroxycinnamyl alcohol 104. A cold solution of Aici3 (1 -33 g, 10 mmol) in anhydrous diethyl ether (25 mL) was added dropwise to an ice-cold stirred suspension of LiAIH4 (1.33 g, 35 mmol) in anhydrous diethyl ether (25 mL). After completion of the addition, the mixture was allowed to warm to ambient temperature, with stirring for 30 min, resulting in a grey suspension. To this grey suspension was added dropwise a solution of methyl cinnamate (10 mmol) dissolved in anhydrous diethyl ether (25 mL) within 10 min, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was cooled with an ice bath, and carefully treated with EtOAc (50 mL) and 1 N HCI solution (100 mL). The resulting mixture was extracted with EtOAc (3x50 mL). The combined extracts were washed with H20 (50 mL) and brine (50 mL), and dried (anhydrous Na2S04). The solvent was evaporated to dryness, and the crude products were purified by flash silica gel chromatography (eluting with 20-50% hexane in EtOAc) to afford the cinnamyl alcohol. Compound 104 was a yellow solid, obtained at: 43% yield. Compound 126 was a white solid, obtained at 79% yield. Identity of compounds was verified by 1H NMR (75 MHz, CD3OD for 104; 400 MHz, CDCI3 for 126).
Synthesis of preparing cinnamamide (102)
[00329] PCA was converted into its methyl ester 101 by refluxing in methanol in the presence of sulfonic acid. Compound 101 was transformed to amide 102 by reacting with ammonia. A solution of methyl cinnamate (28 mmol) and 7 M ammonia in MeOH (30 mL) was sealed in a 100 mL thick-wall round bottom flashed, and heated at 90 with stirring for 72 h, resulting in a brown solution. After the solvent was removed by a rotary evaporator, the crude products were purified by flash silica gel chromatography (eluting with 2-10% MeOH in DCM) to afford cinnamamide. Compound 102 was a yellow solid, obtained at 30% yield. Identity was confirmed by 1H NMR (300 MHz, CD3OD).
Synthesis of 2-arylcvclopropane-1 -carboxylic acids (100. 105. 106. 107)
[00330] Compounds 100, 105, 107, and 106 were synthesized under the Corey- Chaykovsky cyclopropanation reaction conditions (TMSOI, NaH, DMSO). A mixture of frans-4-methoxycinnamic acid (18 g, 101 mmol) and concentrated H2S04 (0.5 mL) in absolute EtOH (100 mL) was refluxed at 90 (bath t emperature) for 16 h. After the excess EtOH was removed by a rotary evaporator, the residue was treated with H20 (100 mL), and the resulting mixture was extracted with ether (3x 120 mL). The combined extracts were washed with 1 N aq. NaOH (2x50 mL), H20 (80 mL) and brine (80 mL), and dried (anhydrous Na2S0 ). The solvent was evaporated to dryness to give ethyl frans-4-methoxycinnamate (20g, 96% yield) as light yellow oil.
[00331] To a mixture of trimethylsulfoxonium iodide (TMSOI) (22 g, 100 mmol, 2.6 eq) and 60% NaH (4 g, 100 mmol, 2.6 eq) was added anhydrous DMSO (120 mL) in one portion at room temperature, and the mixture was stirred at room temperature under nitrogen for 1.5 h. A solution of irans-4-methoxycinnamate (7.91 g, 38.4 mmol) in anhydrous DMSO (50 mL) was added dropwise within 10 min to the resulting suspension at room temperature, and the whole mixture was stirred at room temperature for 18h. The reaction mixture was cooled with an ice bath, and quenched with brine (250 mL). The resulting mixture was extracted with ether (5x 100 mL), washed with brine (2x60 mL), and dried. The solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 2-10% EtOAc in hexane) to afford 100 (1 .6 g, 19% yield) as white solid. Identity was verified by 1H NMR (300 MHz, CDCI3).
[00332] Lithium hydroxide monohydrate (252 mg, 6 mmol) was added to a solution of 100 (440 mg, 2 mmol) dissolved in THF/H20 (1 :1 , 20 mL), and the mixture was stirred at room temperature for 16 h. After most of the THF was removed by a rotary evaporator, the aqueous residue was acidified to pH=1 -2 with 1 N HCI (20 mL). The resulting white suspension was extracted with EtOAc (2x50 mL). The combined organic layers were washed with H20 (30 mL) and brine (40 mL), and dried (anhydrous Na2S04). The solvents
were evaporated with rotary evaporator to dryness, and the crude product (400 mg) was recrystallized from hexane/EtOAc in a -20Ό freezer to afford 105 (320 mg, 83% yield) as white solid. Identity was confirmed by 1H NMR (300 MHz, CD3OD).
[00333] A solution of 100 (880 mg, 4 mmol) dissolved in anhydrous DCM (20 mL) was chilled to -78 with a dry ice/acetone bath, and 1 M BBr3 DCM (6 mL, 6 mmol) was added dropwise within 6 min. The reaction mixture was stirred at -78ΧΪ for 3CC, at 0*C for additional 1 h, then allowed to warm to ambient temperature, and with stirring for additional 30 min. The reaction mixture was rechilled to 0 w ith an ice bath, and treated with saturated NaHC03 (40 mL). The resulting mixture was extracted with DCM (3 <50 mL), washed with H20 (40 mL) and brine (40 mL), and dried. The solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 10-20% EtOAc in hexane) to afford 106 (480 mg, 58% yield) as white solid.
[00334] The double bond of PCA was replaced with a cyclopropanyl group, resulting in the cyclopropanic acid 107. Lithium hydroxide monohydrate (326 mg, 7.8 mmol) was added to a solution of 106 (320 mg, 1.5 mmol) dissolved in THF/H20 (1 :1 , 16 mL), and the mixture was stirred at room temperature for 20 h. After most of the THF was removed by a rotary evaporator, the aqueous residue was acidified to pH=1-2 with 1 N HCI (20 mL). The resulting white suspension was extracted with EtOAc (2x50 mL). The combined organic layers were washed with brine (40 mL), and dried (anhydrous Na2S04). The solvents were evaporated with rotary evaporator to dryness, and the crude product (320 mg) was recrystallized from hexane/EtOAc in a -20 freezer to afford 107 (150 mg, 56% yield) as white solid. Identity was confirmed by 1H NMR (300 MHz, CD3OD).
Synthesis of vinyl phosphoric acid (114. 115)
[00335] A mixture of diethylphosphonoacetic acid (1.96 g, 10 mmol), 4- hydroxybenzaldehyde (1.46 g, 12 mmol, 1.2 equiv), piperidine (0.23 g, 2.7 mmol, 0.27 equiv) and AcOH (0.12 g, 2 mmol, 0.2 equiv) in toluene (60 mL) was heated at reflux for 19 h. After the solvent was removed by a rotary evaporator, the residue was taken up in DCM (200 mL), washed with saturated NaHC03 solution (2x50 mL), H20 (50 mL) and brine (50 mL), and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 2-8% MeOH in DCM) to give pure vinylphosphonate 114 (2 g, 78% yield) as yellow oil.
[00336] The carboxyl group of PCA was replaced with phosphoric group, resulting in 2-(4- hydroxyphenyl) vinylphosphoric acid 115. Compound 115 was prepared by Knoevenagel reaction of 4-hydroxybenzaldehyde with diethylphosphonoacetic acid and followed by treating with trimethylsilyl bromide. Bromotrimethylsilane (2 mL) was added to a solution of
114 (760 mg, 3 mmol) in anhydrous DCM (12 mL), and the mixture was refluxed at 45 for 16 h, resulting in a brown solution. After the excess bromotrimethylsilane were evaporated to dryness under the reduced pressure, the oily residue was dissolved in DCM (5 mL) and H20 (5 mL), and stirred at room temperature for 2 h. The resulting white suspension was filtered off, and the solid was washed with DCM (2x10 mL), and air-dried. 115 (370 mg, 61 % yield) was collected as off-white solid. Identity was confirmed by 1H NMR (400 MHz, CD3OD).
Synthesis of cinnamyl amines (117, 119)
[00337] To a stirred mixture of phthalimide potassium salt (20 g, 108 mmol) and tetrabutylammonium bromide (1.04 g, 3.24 mmol, 0.03 equiv) in anhydrous DMF (75 mL) was added allyl chloride (8.84 mL, 108 mmol) at room temperature, and the mixture was stirred at room temperature for 22 h, resulting in a light-yellow suspension. The reaction was quenched by adding cold H20 (150 mL), and the mixture was stirred for 10 min (an ice bath was applied during this time to aid the precipitation). The resulting white suspension was filtered off, washed with H20 (3x50 mL), and air-dried to give N-allylphthalimide (8.5 g, 42% yield) as white solid.
[00338] Aryl bromide (10 mmol), N-allylphthalimide (1.93 g, 10.3 mol, 1.03 equiv) and triethylamine (2.78 mL, 20 mmol, 2 equiv) were placed in a 50 mL three-necked round bottom flask, palladium acetate (23 mg, 0.1 mmol, 0.01 equiv) and tri-O-tolylphosphine (61 mg, 0.2 mmol, 0.02 equiv) were added to the flask under the flash of argon, and the whole mixture was heated at 100Ό (bath temperature) unde r argon and with stirring for 16 h. After the reaction mixture was cooled to ambient temperature, DCM (50 mL) and H20 (50 mL) were added, and stirred at room temperature for 10 min. The DCM layer was separated, and the aqueous layer was extracted with DCM (2x50 mL). The combined DCM layers were washed with H20 (50 mL) and brine (50 mL), and dried. The solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 30-80% EtOAc in hexane) to afford N-cinnamyl phthalimide (116 or 118).
[00339] N-cinnamyl phthalimide (3 mmol) was mixed with 65% hydrazine hydrate (6 mmol, 2 equiv) and MeOH (10 mL), and the mixture was heated at 70 for 2 h. After the solvent was removed by a rotary evaporator, the solid residue was treated with 1 N NaOH (30 mL), and the resulting mixture was extracted with EtOAc (4x50 mL) and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 5-20% MeOH in DCM) to give cinnamyl amine. Compound 117 (white solid) was obtained at 30% yield, and compound 119 (off-white solid) was obtained at 80% yield. Identity was confirmed by 1 H NMR (400 MHz, CD3OD).
Synthesis of ethyl vinylsulphonates and tetrabutylammonium vinylsulphonates (120. 121. 122. 123)
[00340] The carboxyl group of PCA was replaced with sulfonic group, resulting in 2-(4- hydroxyphenyl)ethenylsulfonic acid 123. Compound 123 and its derivatives 114, 120, 121 , and 122 were synthesized by four-step from the corresponding benzaldehydes. To a stirred solution of ethyl methanesulphonate (4.11 mL, 40 mmol) in dry THF (100 mL) was added dropwise at -78'C 2.5 M n-BuLi in hexane (17.8 mL, 44.4 mmol) within 10 min. After the mixture was stirred for 15 min, ethyl chlorophosphate (3.2 mL, 22.2 mmol) was added slowly at the same temperature. The solution was stirred at -78'C for 30 min, then allowed to warm to -45Ό and with stirring for additional 1 h. The reaction was quenched by adding 4.4 M NH4CI solution (1 1 mL), and the mixture was warmed to ambient temperature. After the organic solvents were removed by a rotary evaporator, the residue was treated with H20 (50 mL), and extracted with DCM (3x70 mL), washed with brine (40 mL) and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 30-100% EtOAc in hexane) to give ethyl diethylphosphorylmethanesulphonate (4.6g, 80% yield) as light-yellow oil.
[00341] 2.5 M n-BuLi hexane solution (3.36 mL, 8.4 mmol) was added dropwise to a stirred solution of ethyl diethylphosphorylmethanesulphonate (2.19 g, 8.4 mmol) in anhydrous THF (20 mL) at -78'C, and stirred at the same temperature for 30 min. A solution of aryl aldehyde (7 mmol) dissolved in anhydrous THF (15 mL) was added dropwise, and the mixture was stirred at -78'C for 30 min, then allow ed to warm to ambient temperature within 30 min, and the stirring was continued at rt for additional 1 h (18 h for 122). After the reaction was quenched by adding AcOH (0.53 mL, 9.2 mmol, 1.1 equiv to n-BuLi), the solvents were removed by a rotary evaporator. The oily residue was treated with H20 (50 mL), extracted with EtOAc (3x50 mL), washed with H20 (50 mL) and brine (50 mL), and dried. The crude product was purified by flash silica gel column chromatography (eluting with 10-50% EtOAc in hexane) to give ethyl vinylsulphonates. Compound 120 (light-yellow oil) was obtained at 100% yield and its identity verified by 1H NMR (300 MHz, CD3OD). Compound 122 (white solid) was obtained at 71 % yield and its identity verified by 1H NMR (300 MHz, CD3OD).
[00342] ^ mixture of ethyl vinylsulphonates (2 mmol) and tetrabutylammonium bromide (2.2 mmol, 1.2 equiv) in acetone (12 mL) was refluxed for 21 h. After acetone was removed by a rotary evaporator, the residue was dissolved in DCM (100 mL), washed with H20 (30 mL) and brine (30 mL), and dried. The crude product was purified by flash silica gel column chromatography (eluting with 5-10% MeOH in DCM) to give tetrabutylammonium vinylsulphonates. Compound 121 (white solid) was obtained at 85% yield and its identity
verified by 1H NMR (300 MHz, CD3OD). Compound 123 (white solid) was obtained at 40% yield and its identity verified by 1 H NMR (300 MHz, CD3OD).
Synthesis of 4-hvdroxymethylcinnamic acid (124)
[00343] The hydroxyl group of PCA was replaced by hydroxymethyl group, resulting in compound 4-hydroxymethylcinnamic acid 124. Compound 124 was obtained by reducing 4- formylcinnamic acid with sodium borohydride in aqueous tetrahedron.
[00344] A solution of NaBH4 (0.53 g, 14 mmol) in THF/H20 (4:1 ) (12 mL) was added dropwise to an ice-cold stirred solution of 4-formylcinnamic acid (2.47 g, 14 mmol) in THF (25 mL), and the mixture was stirred at room temperature for 3 h. The reaction was quenched by adding 4 N HCI (20 mL), and the THF was removed by a rotary evaporator. The solid residue was treated with H20 (20 mL), and extracted with EtOAc (4x50 mL). The EtOAc extracts were washed with H20 (50 mL) and brine (50 mL), and dried. The crude product was recrystallized from EtOAc to afford pure 4-hydroxymethylcinnamic acid 124 (1 .3 g, 52% yield) as yellow solid, with its identity verified by 1 H NMR (300 MHz, CD3OD).
Synthesis of trans-3-(4-hvdroxyphenyl)-2-propenohvdrazide (133)
[00345] To a stirred solution of p-coumaric acid (3.28 g, 20 mmol) in anhydrous acetonitrile (40 mL) was added HOBt (3.24 g, 24 mmol) and EDC.HCI (4.6 g, 24 mmol) at room temperature, and the mixture was stirred at room temperature for 2 h. The resulting yellow suspension was cooled with an ice-bath, and an ice-cold solution of hydrazine (1.25 mL, 40 mmol) and cyclohexene (0.61 mL, 6 mmol) in acetonitrile (30 mL) was added in one portion. The mixture was stirred at 0°C for 20 min and followed by an additional 1 h at room temperature. The resulting yellow suspension was filtered off, and the solid was washed with MeOH (3x30 mL), H20 (2x30 mL), saturated NaHC03 (2x30 mL), H20 (2x20 mL) and EtOAc (2x20 mL) successively, and finally air-dried, obtaining 133 (1.3 g, 36% yield), with its identity verified by 1 H NMR (300 MHz, DMSO-d6).
Commercially available compounds
[00346] Compound 111 , with the hydroxyl group of PCA replaced by bromo in the phenyl ring, was commercially available (Sigma-Aldrich, St. Louis, MO). Compounds 108, 110, 112 and 113, had the hydroxyl group substituted by phenyl, fluoro, dimethylamino, and trifluoromethyl groups respectively, and were commercially available (Sigma-Aldrich, St. Louis, MO; Alfa Aesar, Ward Hill, MA). Compound 109 was also commercially available (Alfa Aesar, Ward Hill, MA).
EXAMPLE 12: Activity of Compounds
phrpA Reporter Plasmid
[00347] The minimal inhibitory concentration of the compounds on hrpA was measured by supplement compounds at various concentrations, and the reporter plasmid phrpA was used to measure the effects of these compounds on hrpA expression. Compounds 101 , 102, 104, 105, 106, 113, 116, 125, 126, and 127 showed inhibitory effect on hrpA expression at a concentration of 100 μΜ. Compound 103 showed inhibitory effect on hrpA expression at a concentration of 10 μΜ.
[00348] To test for an inhibitory effect on T3SS hrpS expression, the reporter plasmid phrpS was used to measure the effects of these compounds on hrpA expression. Compounds 103, 104, 106, 111 , 125, 126, and 127 inhibited hrpS, suggesting that these compounds also inhibit T3SS through HrpX/Y-HrpS-HrpL pathway.
[00349] hrpA encodes the T3SS pilus required for protein translocation into plant cells. To test for an inhibitory effect on T3SS hrpA expression, the reporter plasmid phrpA was used to measure the effects of these compounds on hrpA expression. The reporter plasmid phrpA encodes a transcriptional fusion of the hrpA promoter controlling expression of green fluorescent protein (gfp). 50 pL of bacterial suspension of D. dadantii 3937 carrying the hrpA reporter (optical density at 600 nm OD6oo = 0) was used as the initial inoculum and added to 5 mL of MM or MM supplemented with 100 μΜ of one of the compounds. The expression level of hrpA of these bacterial cells was measured by measuring GFP intensity of gated populations of the bacterial cells by flow cytometry and analyzed with Cell Quest software (BD Biosciences, San Jose, CA). The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Compounds were assayed two different times (12 and 24 h of bacterial growth) with T3SS minimal media (MM) as the control treatment for each set of experiment. Results are shown in Table 13 and Table 14. Values presented in Table 14 are mean fluorescence intensity of GFP, representative of two experiments, presented as the average of three replicates with standard deviation (SD). Briefly, 101 , 103, 104, 106, 111 , 112, 116, 125, 126, and 127 showed inhibitory effect on the expression of hrpA. Compound 103 was examined further at various concentrations, with results presented in Figure 22.
[00350] Compound 124 did not show any inhibitory activity (data not shown).
[00351] Compound 111 exhibited moderate potency (Table 13).
[00352] Compounds 108, 110, 112 and 113 were all inactive for inhibition of T3SS gene expression.
[00353] Compound 107 demonstrated no inhibitory activity against T3SS gene expression (data not shown). However, its ethyl ester 106 showed strong inhibitory potency (Table 13).
[00354] Compounds 115 and 123, as well as their derivatives 114, 120, 121 , and 122, did not exhibit any activity against T3SS gene expression (data not shown).
[00355] Compound 101 showed weak inhibitory activity comparing to PCA (data not shown). However, 102 did not show any inhibitory activity against T3SS gene expression (data not shown).
[00356] No inhibitory effect on hrpA was observed when 10 μΜ of PCA was added to a T3SS-inducing minimal medium (MM). However, the expression of hrpA was reduced approximately 4-fold when 10 μΜ of 103 was added to the medium, suggesting that 103 is a more potent inhibitor than PCA. Compared with PCA, a higher potent inhibitory activity was observed with 103 against T3SS gene (data not shown).
[00357] Compound 125 still showed potent inhibitory activity against T3SS gene (Table 13).
[00358] Compound 127 showed moderate potency.
[00359] Compound 104 showed potent inhibitory activity. Similarly, allylic alcohol 126 was also a potent inhibitor of T3SS gene expression.
[00360] Allylic amines 117 and 119 did not show any inhibitory activity.
[00361] Compound 116 exhibited moderated inhibitory activity.
[00362] The results demonstrated the potential of PCA hydroxamates and allylic alcohols as potent inhibitors of T3SS gene expression.
Table 13. The eight compounds listed below showed inhibitory effect on T3SS hrpA expression, using the reporter plasmid, phrpA.
Phenolic compound (Trial 1) Mean Fluorescence Intensity of GFP
MMa 30.5±0.7
p-coumaric acid 9.4±0.1
103 9.3±0.3
104 6.0±1.4
106 9.4±0.1
111 16.5±0.8
Phenolic compound (Trail 2) Mean Fluorescence Intensity of GFP
MMa 68.3±5.2
p-coumaric acid 9.3±0.2
116 27.0±2.1
125 25.9±1.0
126 9.5±0.7
127 26.2±2.6
aT3SS-inducing minimal medium (MM) and MM supplemented with different compounds at 100 pM repectively.
Table 14. The hrpA expression of D. dadantii 3937 in MM and MM supplemented with different isomers and analogs of PCA, TCA, and OCA.
Phenolic Phenolic
compound3 12 h 24 h compound3 12 h 24 h
MM 35.4±0.8 90.6111.7 MM 51.416.7 77.119.1
100 45.3±3.4* 1 19.1122.1 114 55.411.0 76.515.6
101 17.510.7* 19.910.5' 115 57.911.6 79.613.3
102 21.111.2* 60.8110.6 116 24.311.5' 39.313.5*
103 8.7±0.3" 1 1.910.8' 117 49.811.6 73.112.0
104 3.0±0.1 " 12.911.8* 118 59.010.4 83.811.7
105 22.912.6* 82.415.8 119 47.813.2 68.2110.4
106 10.5±0.8* 49.414.1' 120 49.912.6 68.616.0
107 45.912.7* 122.1117.9 121 57.1110.0 72.2110.6
108 31.6±2.5 109.0119.8 122 38.611.8 60.910.8
109 35.7±6.3 81.513.8 123 52.312.0 77.716.8
110 63.4±8.0* 183.8119.2' 124 44.913.5 78.113.4
111 23.9±5.2 54.717.2 125 17.410.9' 25.612.0'
112 23.8±4.3 60.716.4 126 7.810.2' 13.410.3'
113 24.410.9* 68.515.7 127 21.013.0' 35.113.0'
MM-pAT 2.010.0' 3.410.3'
*Means statistically significant different in GFP intensity between bacterial cells grown in MM and MM supplemented with different compounds (P < 0.01 , Student's t-test)
Northern Blot Analysis
[00363] Northern blot analysis was used to quantify rsmB RNA of D. dadanti 3937. As shown in Figure 23, T3SS inhibitors 103 and 125 reduced rsmB mRNA and inhibited regulatory RNA rsmB expression in the bacterial cells. These results suggested 103 and 125 inhibited T3SS through HrpX/Y-HrpS-HrpL and GacS/A-rsmS-HrpL pathways as well.
Expression of other genes in the presence of compound 103
[00364] The effect of compound 103 on the expression of other T3SS genes hrpA, hrpN, hrpS and hrpL of Dickeya dadantii 3937, shown in Table 15, was examined. The GFP reporter plasmids phrpA, phrpN, phrpS, and phrpL were used to measure the effects of these compounds on the expression of hrpA, hrpN, hrpS, and hrpL. The promoter activities were compared at 12 and 24 h of bacterial growth in the presence of compound 103. GFP intensity was determined on gated populations of bacterial cells by flow cytometry. Results are shown in Table 16. The fluorescence intensities were an average GFP fluorescence intensity of total bacterial cells. Values presented in Table 16 are mean fluorescence intensity values, representative of two experiments, and presented as the average of three replicates with standard deviation (SD).
Table 15. Strains and plasmids used
Strains, plasmids
Characters8 Reference or source and primers
Strains
D. dadantii
3937 Wild type, Saintpaulia (African violet) isolate Hugouvieux-Cotte-Pattat, N.
3937 (pAT) 3937 containing pPROBE-AT Peng et al., , 2006(14) 3937 (phrpA) 3937 containing phrpA; Ap Yang et al., , 2008(22) 3937 (phrpN) 3937 containing phrpN; ApR Yang et al., , 2007(23) 3937 (phrpL) 3937 containing phrpL; ApR Yang et al., , 2007(23) 3937 (phrpS) 3937 containing phrpS; ApR
3937 (pmrp) 3937 containing pmrp; ApR Peng et al., , 2006(14) Plasmid
pPROBE-AT Promoter-probe vector, ApR Miller et al. , 2000(11 ) phrpA pProbe-AT derivative with PCR fragment Yang et al., , 2008(22)
containing hrpA promoter region, ApR
phrpN pProbe-AT derivative with PCR fragment Yang et al., , 2007(23)
containing hrpN promoter region, ApR
phrpL pProbe-AT derivative with PCR fragment Yang et al., , 2007(23)
containing hrpL promoter region, ApR
phrpS pProbe-AT derivative with PCR fragment This work
containing 709-bp hrpS promoter region,
ApR
pmrp pProbe-AT derivative with PCR fragment Peng et al., , 2006(14)
containing mrp promoter region, ApR
Table 16. The expression of T3SS genes hrpA, hrpN, hrpS and hrpL of Dickeya dadantii 3937 in MM and MM supplemented with 100 μΜ 103 (MM103).
12 h 24 h
Gene Promoter3 MM MM103 MM MM103
3937 (phrpA) 58.7±6.1b 8.910J' 66.515.4 8.910.2'
3937 (phrpN) 46.8±2.9 5.810.7* 49.912.1 5.410.3'
3937 (phrpS) 73.2±0.6 27.711.5* 90.911.2 26.410.6'
3937 (phrpL) 20.2±1.8 7.610.2' 21.510.5 7.710.2*
3937 (pmrp) 70.6±0.2 81.210/7' 80.910.9 67.712.5"
3937 (pPROBE-AT) 4.210.5 3.010.6 5.711.8 4.310.6
Means statistically significant different in GFP intensity between bacterial cells grown in MM and MM103 (P < 0.01 , Student's f-test).
EXAMPLE 13. Synthesis of compounds.
[00365] Compounds were synthesized at Duke University Small Molecule Synthesis Facility (Durham, NC). The synthetic routes for the compounds are described below and in Figures 24-30.
[00366] NMR (1H, 13C and 32P) spectra were measured on either a Varian Mercury 300 or Inova 400 spectrometer using TMS as the internal standard. Electrospray ionization mass spectrometry (ESI-MS) was performed on an Agilent 1100 Series LC/MSD Trap Spectrometer with a Daly conversion dynode detector. Ionization was achieved in the positive or negative ion mode by application of +5 or -5 kV at the entrance to the capillary. Thin-layer chromatography (TLC) was performed on precoated silica gel 60 F25 plates (Merck, 0.25 mm, purchased from Sigma-Aldrich Company).
[00367] All chemical reagents were purchased from commercial sources and used as received. All dry solvents (diethyl ether, DMF, DMSO, DCM, THF, MeOH, EtOH) were of anhydrous quality purchased from Sigma-Aldrich Company. Commercial grade solvents were used for routine purposes without further purification. All moisture-sensitive reactions were carried out using dry solvents and under a slight pressure of ultra-pure quality argon. Glassware was dried in an oven at 140"C for at leas t 12 h prior to use, and then assembled quickly while hot, sealed with rubber septa, and allowed to cool under a stream of argon. Reactions were stirred magnetically using Teflon-coated magnetic stirring bars. Commercially available disposable syringes were used for transferring reagents and solvents.
[00368] In Figure 24, cinnamic acids were converted into the corresponding methyl ester. The latter were further transformed into hydroxamic acids by treating with hydroxylamine under basic condition. When the substituent in the phenyl group is halo, methyl, methoxy, or other groups which will not form amide/ester, the hydroxamic acids could be obtained directly from the corresponding carboxylic acids. By refluxing with ammonia in methanol, the corresponding amides were obtained from the methyl esters. The esters were readily reduced by LiAIH4/AICI3 system, resulting in cinnamyl alcohols. By employing the reported procedure (Zhang et al. 2002), hydrazides were obtained from cinnamic acids by treating with HOBt and EDC followed by hydrazine.
[00369] Under the Corey-Chaykovsky cyclopropanation reaction conditions (Corey and Chaykovsky, 1965), ethyl 4-methoxycinnamate was transformed into cyclopropanyl ester (100). Upon hydrolysis, acid 105 was obtained. Demethylation of 100 with borane tribromide gave 106. The latter was further hydrolyzed with lithium hydroxide to afford the corresponding carboxylic acid 107 (Figure 25).
[00370] Knoevenagel reaction (Krawczyk and Albrecht 2005) of 4-hydroxybenzaldehydes with diethylphosphonoacetic acid lead to the formation of diethyl trans-2- arylvinylphosphonates 114. Upon treatment with trimethylsilyl bromide (TMSBr), the phosphonate was converted into vinylphosphoric acid 115 (Figure 26). In the similar way, other frans-2-arylvinylphosphoric acids can be obtained from the corresponding arylaldehydes.
[00371] In the presence of n-butyllithium, benzaldehyde was reacted with ethyl diethylphosphoryl-methanesulfonate to generate ethyl frans-2-arylethenylsulfonates (Niimi et al. 2001 ) (Figure 27). The resulting ethyl sulfonates was cleaved with tetra-n- butylammonium iodide (n-Bu4NI), affording the frans-2-arylethenylsulfonic acids.
[00372] Phthalimide potassium salt was alkylated with allyl chloride in DMF to produce N- allylphthalimide. Under the Heck reaction conditions (Patel et al. 1977), N-allylphthalimide
reacted with aryl bromide to give N-cinnamyl phthalimide. Upon treatment with hydrazine, cinnamyl amine was obtained from N-cinnamyl phthalimide (Figure 28).
General procedure for preparing cinnamyl hydroxamates
[00373] Method A: A mixture of cinnamic acid (25 mmol) and concentrated H2S04 (0.1 ml) in anhydrous MeOH (25 ml) was refluxed at 80Ό (bath temperature) for 16 h. After the excess MeOH was removed by a rotary evaporator, the residue was treated with H20 (50 ml), and the resulting mixture was extracted with EtOAc (3x50 ml). The combined extracts were washed with H20 (50 ml) and brine (50 ml), and dried (anhydrous Na2S04). The solvent was evaporated to dryness, and the crude products were purified by flash silica gel chromatography (eluting with 10-60% hexane in EtOAc) to afford methyl cinnamate.
[00374] To an ice-cold solution of methyl cinnamate (8 mmol) dissolved in anhydrous MeOH (10 ml) and THF (10 ml) was added hydroxylamine hydrochloride (1.67 g, 24 mmol, 3 equiv) followed by 25% sodium methoxide in methanol solution (8.4 ml, 36 mmol, 4.5 equiv). The reaction mixture was stirred under argon and at 0Ό for 2 h, then allowed to warm to ambient temperature with continuous stirring overnight (16 h). The resulting yellow suspension was condensed to dryness with a rotary evaporator, and the residue was treated with 1 N HCI aqueous solution (30 ml). The mixture was extracted with EtOAc (3*50 ml), and dried (anhydrous Na2S04). Evaporation of the solvent afforded the crude products (480 mg), which was purified by flash silica gel chromatography (eluting with 5-15% MeOH in DCM) to afford the hydroxamic acid.
103 (R1=4-OH):
[00375] 25% yield (based on the methyl ester); light-brown solid; 1H NMR (300 MHz, CD3OD): δ6.28 (d, J=15.6 Hz, 1 H), 6.75 (d, J=8.1 Hz, 2H), 7.38 (d, J=8A Hz, 2H), 7.49 (d, J=15.6 Hz, 1 H); 3C NMR (75 MHz, CD3OD): δ113.61 , 115.58, 126.46, 129.38, 140.71 , 159.40, 166.00; MS (ESI): m/z 178 (M-1).
125 (R,=4-OMe):
[00376] 67% yield; light-brown solid; 1H NMR (300 MHz, CD3OD): δ3.78 (s, 3H), 6.32 (d, .7=15.6 Hz, 1 H), 6.89 (d, J=8A Hz, 2H), 7.46 (d, J=8.4 Hz, 2H), 7.50 (d, J=15.6 Hz, 1 H); 3C NMR (75 MHz, CD3OD): 654.66, 114.16, 1 14.53, 127.57, 129.23, 140.32, 161.44, 165.75; MS (ESI): m/z 192 (M-1 ).
129 (Rn=2-OH):
[00377] 21 % yield; light-brown solid; H NMR (300 MHz, CD3OD): δ6.64 (d, J=15.9 Hz, 1 H), 6.77 (d, J=7.5 Hz, 1 H), 6.81 (m, 1 H), 7.13 (m, 1 H), 7.40 (d, J=7.5 Hz, 1 H), 7.86 (d, J=15.9 Hz, 1 H); 13C NMR (75 MHz, CD3OD): 6115.85, 116.84, 119.60, 121.86, 128.87, 130.81 , 136.88, 156.81 , 166.34; MS (ESI): m/z 178 (M-1 ).
130 (R^-OH):
[00378] 63% yield; off-white solid; 1H NMR (300 MHz, CD3OD): δ6.42 (d, J=15.9 Hz, 1 H), 6.81 (d, J=8.1 Hz, 1 H), 6.96 (brs, 1 H), 6.98 (d, J=8.1 Hz, 1 H), 7.17 (m, 1 H), 7.48 (d, J=15.9 Hz, 1 H); 13C NMR (75 MHz, CD3OD): 6113.95, 1 16.91 , 117.00, 119.23, 129.82, 136.27, 140.80, 157.77, 165.34; MS (ESI): m/z 178 (M-1 ).
131(R,=3,4-diOH):
[00379] 25% yield; grey solid; 1H NMR (300 MHz, CD3OD): δ6.22 (d, J=15.6 Hz, 1H), 6.75 (d, J=8.1 Hz, 1 H), 6.89 (d, J=8.1 Hz, 1 H), 6.99 (brs, 1 H), 7.42 (d, J=15.6 Hz, 1 H); 13C NMR (75 MHz, CD3OD): δ1 13.56, 1 13.80, 115.28, 120.92, 127.03, 141.06, 145.54, 147.65, 166.00; MS (ESI): m/z 194 (M-1 ).
132(R1=H):
[00380] 71 % yield; white solid; 1H NMR (300 MHz, DMSO-d6): 66.47 (d, J=15.6 Hz, 1 H), 7.30-7.55 (m, 5H), 7.46 (d, J=15.6 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6): δ119.74, 128.16, 129.60, 130.14, 135.49, 139.10, 163.49; MS (ESI): m/z 162 (M-1 ).
[00381] Method B: To a stirred mixture of cinnamic acid (7 mmol) and diisopropylethylamine (DIEA) (2.45 ml, 17 mmol) in anhydrous DMF (20 ml) was added HBTU (2.92 g, 7.7 mmol) at room temperature, followed by adding a solution of hydroxylamine hydrochloride (0.98 g, 14 mmol) and DBU (2.13 g, 14 mmol) in anhydrous DMF (8 ml), and then the whole reaction mixture was stirred at room temperature for 1 h. After most of the DMF was removed with a rotary evaporator, the residue was dissolved in EtOAc (150 ml), then washed with H20 (50 ml) and brine (50 ml), and dried (anhydrous Na2S04). Evaporation of the solvent afforded the crude products, which was purified by flash silica gel chromatography (eluting with 5-15% MeOH in DCM) to afford the hydroxamic acid.
127 (R,-Ar= 3-indole)
[00382] 35% yield; yellow solid; 1H NMR (400 MHz, CD3OD): 56.46 (d, J=15.6 Hz, 1 H), 7.16-7.23 (m, 3H), 7.44 (d, J=7.5 Hz, 1 H), 7.59 (s, 1 H), 7.82 (d, J=15.6 Hz, 1 H), 7.87 (d, J=8 Hz, 1 H); MS (ESI): m/z 201 (M-1 ).
128 (R!=4-Br):
[00383] 50% yield; white solid; 1H NMR (300 MHz, DMSO-d6): 66.46 (d, J=15.9 Hz, 1 H), 7.40 (d, 7=15.9 Hz, 2H), 7.48 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6): 6120.63, 123.28, 130.12, 132.54, 134.77, 137.80, 163.18; MS (ESI): m/z 241 (M- 1 ).
General procedure for cinnamyl alcohols
[00384] Cold solution of AICI3 (1.33 g, 10 mmol) in anhydrous diethyl ether (25 ml) was added dropwise to an ice-cold stirred suspension of LiAIH4 (1.33 g, 35 mmol) in anhydrous
diethyl ether (25 ml). After completion of the addition, the mixture was allowed to warm to ambient temperature, with stirring for 30 min, resulting in a grey suspension. To this grey suspension was added dropwise a solution of methyl cinnamate (10 mmol) dissolved in anhydrous diethyl ether (25 ml) within 10 min, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was cooled with an ice bath, and carefully treated with EtOAc (50 ml) and 1 N HCI solution (100 ml). The resulting mixture was extracted with EtOAc (3x50 ml). The combined extracts were washed with H20 (50 ml) and brine (50 ml), and dried (anhydrous Na2S04). The solvent was evaporated to dryness, and the crude products were purified by flash silica gel chromatography (eluting with 20-50% hexane in EtOAc) to afford the cinnamyl alcohol.
104 (R^-OH):
[00385] 43% yield; yellow solid; 1H NMR (300 MHz, CD3OD): δ4.17 (dd, J=6.0, 1.5 Hz, 2H), 6.18 (dt, J=15.6, 6.0 Hz, 1 H), 6.48 (d, J=15.6 Hz, 1 H), 6.72 (d, J=8.4 Hz, 2H), 7.23 (d, J=8.4 Hz, 2H); 13C NMR (75 MHz, CD3OD): 562.80, 115.16, 125.49, 127.53, 128.83, 130.73, 157.06; MS (ESI): m/z 149 (M-1 ).
126 (R!=4-OMe):
[00386] 79% yield; white solid; 1H NMR (400 MHz, CDCI3): δ1.78 (brs, 1 H, OH), 3.79 (s, 3H), 4.27 (d, J=7.8 Hz, 2H), 6.22 (dt, J=16, 6 Hz, 1 H), 6.53 (d, J=16 Hz, 1 H), 6.84 (d, J=8A Hz, 2H), 7.30 (d, J=8.4 Hz, 2H); MS (ESI): m/z 165 (M+1 ).
General procedure for preparing cinnamamide 5:
[00387] A solution of methyl cinnamate (28 mmol) and 7M ammonia in MeOH (30 ml) was sealed in a 100 ml thick-wall round bottom flashed, and heated at 90Ό with stirring for 72 h, resulting in a brown solution. After the solvent was removed by a rotary evaporator, the crude products were purified by flash silica gel chromatography (eluting with 2-10% MeOH in DCM) to afford cinnamamide.
102 (R,=4-OH):
[00388] 30% yield; yellow solid; 1H NMR (300 MHz, CD3OD): δ6.43 (d, J=15.6 Hz, 1 H), 6.79 (d, J=8.7 Hz, 2H), 7.40 (d, J=8.7 Hz, 2H), 7.45 (d, J=15.6 Hz, 1 H); 13C NMR (75 MHz, CD3OD): 5115.58, 116.64, 126.37, 129.54, 141.80, 159.51 , 170.49; MS (ESI): m/z 162 (M- 1 ).
Procedure for preparing frans-3-(4-hydroxyphenyl)acrylohydrazide 133
[00389] To a stirred solution of 4-hydroxycinnamic acid (3.28 g, 20 mmol) in acetonitrile (40 ml) was added HOBt (3.24 g, 24 mmol) and EDC.HCI (4.6 g, 24 mmol). The mixture was stirred at room temperature for 2 h, and the resulting yellow suspension was cooled to 0Ό by an ice bath. A ice-cold solution of hydrazi ne (1.25 ml, 40 mmol) and cyclohexene (0.61 ml, 6 mmol) in acetonitrile (30 ml) was added into the suspension in one portion, and
the mixture was stirred at OX for 20 min, then all owed to warm to ambient temperature, with the stirring continued for additional 1 h. The yellow suspension was filtered off via suction, washed the solid successively with MeOH (3> 30 ml), H20 (2x30 ml), saturated NaHC03 (2x30 ml), H20 (2x20 ml) and EtOAc (2x20 ml), and air-dried to afford 133 (1.3 g, 36% yield) as yellow solid. 1H NMR (300 MHz, DMSO-d6): δ4.40 (brs, 3H), 6.32 (d, J=15.9 Hz, 1 H), 6.76 (d, J=8A Hz, 2H), 7.33 (d, J=16.2Hz, 1 H), 7.36 (d, J=8.1 Hz, 2H), 9.21 (br s, 1 H); 13C NMR (75 MHz, DMSO-d6): 61 16.49, 1 17.21 , 126.44, 129.83, 139.08, 159.72, 165.86; MS (ESI): m/z 179 (M+1 ).
General procedure for preparing 2-arylcyclopropane-1 -carboxylic acids
[00390] A mixture of frans-4-methoxycinnamic acid (18 g, 101 mmol) and concentrated H2S04 (0.5 ml) in absolute EtOH (100 ml) was refluxed at 90Ό (bath temperature) for 16 h. After the excess EtOH was removed by a rotary evaporator, the residue was treated with H20 (100 ml), and the resulting mixture was extracted with ether (3 120 ml). The combined extracts were washed with 1 N aq. NaOH (2x50 ml), H20 (80 ml) and brine (80 ml), and dried (anhydrous Na2S04). The solvent was evaporated to dryness to give ethyl trans-4- methoxycinnamate (20 g, 96% yield) as light yellow oil, which was pure enough for the next step.
[00391] To a mixture of trimethylsulfoxonium iodide (TMSOI) (22 g, 100 mmol, 2.6 eq) and 60% NaH (4 g, 100 mmol, 2.6 eq) was added anhydrous DMSO (120 ml) in one portion at room temperature, and the mixture was stirred at room temperature under nitrogen for 1.5 h. A solution of frans-4-methoxycinnamate (7.91 g, 38.4 mmol) in anhydrous DMSO (50 ml) was added dropwise within 10 min to the resulting suspension at room temperature, and the entire mixture was stirred at room temperature for 18 h. The reaction mixture was cooled with an ice bath, and quenched with brine (250 ml). The resulting mixture was extracted with ether (5 100 ml), washed with brine (2x60 ml), and dried. The solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 2-10% EtOAc in hexane) to afford 100 (1.6 g, 19% yield) as white solid. 1H NMR (300 MHz, CDCI3): δ1.25 (m, 1 H), 1.27 (t, J=7.2 Hz, 3H), 1 .56 (m, 1 H), 1.82 (m, 1 H), 2.48 (m, 1 H), 3.78 (s, 3H), 4.16 (q, J=7.2 Hz, 2H), 6.82 (d, J=8.4 Hz, 2H), 7.03 (d, J=8.7 Hz, 2H); 3C NMR (75 MHz, CD3OD): 614.50, 16.95, 24.09, 25.84, 55.53, 60.85, 1 14.13, 127.58, 132.31 , 158.56, 173.77.
[00392] Lithium hydroxide monohydrate (252 mg, 6 mmol) was added to a solution of 100 (440 mg, 2 mmol) dissolved in THF/H20 (1 :1 , 20 ml), and the mixture was stirred at room temperature for 16 h. After most of the THF was removed by a rotary evaporator, the aqueous residue was acidified to pH=1-2 with 1 N HCI (20 ml). The resulting white suspension was extracted with EtOAc (2x50 ml). The combined organic layers were
washed with H20 (30 ml) and brine (40 ml), and dried (anhydrous Na2S04). The solvents were evaporated with rotary evaporator to dryness, and the crude product (400 mg) was recrystallized from hexane/EtOAc in a -20 freezer to afford 105 (320 mg, 83% yield) as white solid. 1H NMR (300 MHz, CD3OD): δ1.28 (m, 1H), 1.47 (m, 1 H), 1.73 (m, 1H), 2.40 (m, 1H), 3.74 (s, 3H), 6.81 (d, J=8.7 Hz, 2H), 7.03 (d, J=8.7 Hz, 2H); 13C NMR (75 MHz, CD3OD): 515.91 , 23.55, 25.51 , 54.48, 113.76, 127.11, 132.12, 158.71, 176.07; MS (ESI): m/z 191 (M-1).
[00393] A solution of 100 (880 mg, 4 mmol) dissolved in anhydrous DCM (20 ml) was chilled to -78 with a dry ice/acetone bath, and B Br3 (1 M DCM solution, 6 ml, 6 mmol) was added dropwise within 6 min. The reaction mixture was stirred at -78 for SO'C, at 0*C for additional 1 h, then allowed to warm to ambient temperature, and with stirring for additional 30 min. The reaction mixture was rechilled to 0"C with an ice bath, and treated with saturated NaHC03 (40 ml). The resulting mixture was extracted with DCM (3x50 ml), washed with H20 (40 ml) and brine (40 ml), and dried. The solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 10-20% EtOAc in hexane) to afford 106 (480 mg, 58% yield) as white solid.
[00394] Lithium hydroxide monohydrate (326 mg, 7.8 mmol) was added to a solution of 106 (320 mg, 1.5 mmol) dissolved in THF/H20 (1:1, 16 ml), and the mixture was stirred at room temperature for 20 h. After most of the THF was removed by a rotary evaporator, the aqueous residue was acidified to pH=1-2 with 1N HCI (20 ml). The resulting white suspension was extracted with EtOAc (2x50 ml). The combined organic layers were washed with brine (40 ml), and dried (anhydrous Na2S04). The solvents were evaporated with rotary evaporator to dryness, and the crude product (320 mg) was recrystallized from hexane/EtOAc in a -20 freezer to afford 107 (150 mg, 56% yield) as white solid. 1H NMR (300 MHz, CD3OD): 51.27 (m, 1 H), 1.45 (m, 1H), 1.70 (m, 1H), 2.38 (m, 1 H), 6.69 (d, J=8A Hz, 2H), 6.94 (d, J=8.4 Hz, 2H); 13C NMR (75 MHz, CD3OD): 515.82, 23.47, 25.65, 115.09, 127.15, 130.88, 158.00, 176.21 ; MS (ESI): m/z 177 (M-1).
Procedure for preparing vinyl phosphoric acid 115
[00395] A mixture of diethylphosphonoacetic acid (1.96 g, 10 mmol), 4- hydroxybenzaldehyde (1.46 g, 12 mmol, 1.2 equiv), piperidine (0.23 g, 2.7 mmol, 0.27 equiv) and AcOH (0.12 g, 2 mmol, 0.2 equiv) in toluene (60 ml) was heated at reflux for 19 h. After the solvent was removed by a rotary evaporator, the residue was taken up in DCM (200 ml), washed with saturated NaHC03 solution (2x50 ml), H20 (50 ml) and brine (50 ml), and dried. Evaporation of the solvent under reduced pressure afforded the crude product,
which was purified by flash silica gel column chromatography (eluting with 2-8% MeOH in DCM) to give pure vinylphosphonate 114 (2 g, 78% yield) as yellow oil.
[00396] Bromotrimethylsilane (2 ml) was added to a solution of 114 (760 mg, 3 mmol) in anhydrous DCM (12 ml), and the mixture was refluxed at 45Ό for 16 h, resulting in a brown solution. After the excess bromotrimethylsilane were evaporated to dryness under the reduced pressure, the oily residue was dissolved in DCM (5 ml) and H20 (5 ml), and stirred at room temperature for 2 h. The resulting white suspension was filtered off, and the solid was washed with DCM (2x10 ml), and air-dried. 115 (370 mg, 61% yield) was collected as off-white solid. 1H NMR (400 MHz, CD3OD): δ6.20 (t, J=17.6 Hz, 1H), 6.77 (d, J=8A Hz, 1 H), 7.27 (dd, J=22.8, 17.6 Hz, 1 H), 7.36 (d, J=8.4 Hz, 2H); 13C NMR (100 MHz, CD3OD): 6112.7 (d, J=188.9 Hz), 115.26, 126.75 (d, J=22.7 Hz), 128.88, 145.46 (d, J=5.9 Hz), 159.17; 32P NMR (CD3OD): 518.07; MS (ESI): m/z 399 (2M-1).
General procedure for preparing ethyl vinylsulphonates and tetrabutylammonium vinylsulphonates
[00397] To a stirred solution of ethyl methanesulphonate (4.11 ml, 40 mmol) in dry THF (100 ml) was added dropwise at 2.5 M π-BuLi in hexane (17.8 ml. 44.4 mmol) within 10 min. After the mixture was stirred for 15 min, ethyl chlorophosphate (3.2 ml, 22.2 mmol) was added slowly at the same temperature. The solution was stirred at -78Ό for 30 min, then allowed to warm to -45Ό and with stirring for additional 1 h. The reaction was quenched by adding 4.4 M NH4CI solution (11 ml), and the mixture was warmed to ambient temperature. After the organic solvents were removed by a rotary evaporator, the residue was treated with H20 (50 ml), and extracted with DCM (3x70 ml), washed with brine (40 ml) and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 30-100% EtOAc in hexane) to give ethyl diethylphosphorylmethanesulphonate (4.6 g, 80% yield) as light- yellow oil.
[00398] 2.5 M n-BuLi hexane solution (3.36 ml, 8.4 mmol) was added dropwise to a stirred solution of ethyl diethylphosphorylmethanesulphonate (2.19 g, 8.4 mmol) in anhydrous THF (20 ml) at -78Ό, and stirred at the same temperature for 30 min. A solution of aryl aldehyde (7 mmol) dissolved in anhydrous THF (15 ml) was added dropwise, and the mixture was stirred at -78Ό for 30 min, then allow ed to warm to ambient temperature within 30 min, and the stirring was continued at room temperature for additional 1 h (18 h for 122). After the reaction was quenched by adding AcOH (0.53 ml, 9.2 mmol, 1.1 equiv to n-BuLi), the solvents were removed by a rotary evaporator. The oily residue was treated with H20 (50 ml), extracted with EtOAc (3x50 ml), washed with H20 (50 ml) and brine (50 ml), and
dried. The crude product was purified by flash silica gel column chromatography (eluting with 10-50% EtOAc in hexane) to give ethyl vinylsulphonates.
120 (R=4-OMe):
[00399] 100% yield; light-yellow oil; 1H NMR (300 MHz, CD3OD): δ1.34 (t, J=7.2 Hz, 3H), 3.82 (s, 3H), 4.17 (q, J=7.2 Hz, 2H), 6.88 (d, J=15.3 Hz, 1 H), 6.96 (d, J=8.7 Hz, 2H), 7.52 (d, J=15.3 Hz, 1H), 7.58 (d, J=8.7 Hz, 2H); 13C NMR (75 MHz, CD3OD): δ14.05, 54.78, 66.79, 114.42, 118.60, 125.02, 130.48, 144.54, 162.63; MS (ESI): m/z 243 (M+1).
122 (R=4-OH):
[00400] 71% yield; white solid; 1H NMR (300 MHz, CD3OD): δ1.33 (t, J=7.2 Hz, 3H), 4.16 (q, J=7.2 Hz, 2H), 6.81 (d, J=8.7 Hz, 2H), 6.82 (d, J=15.6 Hz, 1H), 7.48 (d, J=15.6 Hz, 1 H), 7.49 (d, J=8.7 Hz, 2H); MS (ESI): m/z 227 (M-1).
[00401] A mixture of ethyl vinylsulphonates (2 mmol) and tetrabutylammonium bromide (2.2 mmol, 1.2 equiv) in acetone (12 ml) was refluxed for 21 h. After acetone was removed by a rotary evaporator, the residue was dissolved in DCM (100 ml), washed with H20 (30 ml) and brine (30 ml), and dried. The crude product was purified by flash silica gel column chromatography (eluting with 5-10% MeOH in DCM) to give tetrabutylammonium vinylsulphonates.
121 (R=4-OMe):
[00402] 85o/o yie|d ; white S0|id ; i H N M R (300 MHZI CQ3OD): δ1.01 (t, J=7.2 Hz, 12H), 1.39-1.72 (m, 16H), 3.25 (m, 8H), 3.80 (s, 3H), 6.80 (d, J=15.6 Hz, 1H), 6.92 (d, J=8.7 Hz, 2H), 7.20 (d, J=15.6 Hz, 1H), 7.43 (d, J=8.7 Hz, 2H); MS (ESI): m/z 213 (M-1).
123 (R=4-OH):
[00403] 40% yie|d. wh ite S0|id. i H NMR (300 MHz CD3OD): 61.00 (t, J=7.2 Hz, 12H), 1.38-1.68 (m, 16H), 3.25 (m, 8H), 6.74 (d, J=15.6 Hz, 1 H), 6.77 (d, J=8.7 Hz, 2H), 7.16 (d, J=15.6 Hz, 1 H), 7.33 (d, J=8.7 Hz, 2H); MS (ESI): m/z 199 (M-1).
General procedure for preparing cinnamyl amines
[00404] To a stirred mixture of phthalimide potassium salt (20 g, 108 mmol) and tetrabutylammonium bromide (1.04 g, 3.24 mmol, 0.03 equiv) in anhydrous DMF (75 ml) was added allyl chloride (8.84 ml, 108 mmol) at room temperature, and the mixture was stirred at room temperature for 22 h, resulting in a light-yellow suspension. The reaction was quenched by adding cold H20 (150 ml), and the mixture was stirred for 10 min (an ice bath was applied during this time to aid the precipitation). The resulting white suspension was filtered off, washed with H20 (3x50 ml), and air-dried to give N-allylphthalimide (8.5 g, 42% yield) as white solid.
[00405] Aryl bromide (10 mmol), N-allylphthalimide (1.93 g, 10.3 mol, 1.03 equiv) and triethylamine (2.78 ml, 20 mmol, 2 equiv) were placed in a 50 ml three-necked round bottom
flask, palladium acetate (23 mg, 0.1 mmol, 0.01 equiv) and tri-O-tolylphosphine (61 mg, 0.2 mmol, 0.02 equiv) were added to the flask under the flash of argon, and the whole mixture was heated at 100 (bath temperature) under argon and with stirring for 16 h. After the reaction mixture was cooled to ambient temperature, DCM (50 ml) and H20 (50 ml) were added, and stirred at room temperature for 10 min. The DCM layer was separated, and the aqueous layer was extracted with DCM (2x50 ml). The combined DCM layers were washed with H20 (50 ml) and brine (50 ml), and dried. The solvent was evaporated by a rotary evaporator to dryness, and the crude product was purified by flash column chromatography (eluting with 30-80% EtOAc in hexane) to afford N-cinnamyl phthalimide.
[00406] N-cinnamyl phthalimide (3 mmol) was mixed with 65% hydrazine hydrate (6 mmol, 2 equiv) and MeOH (10 ml), and the mixture was heated at 70*C for 2 h. After the solvent was removed by a rotary evaporator, the solid residue was treated with 1 N NaOH (30 ml), and the resulting mixture was extracted with EtOAc (4x50 ml) and dried. Evaporation of the solvent under reduced pressure afforded the crude product, which was purified by flash silica gel column chromatography (eluting with 5-20% MeOH in DCM) to give cinnamyl amine.
117 (R=4-OH):
[00407] 30% yield; white solid; 1H NMR (400 MHz, CD3OD): 53.34 (d, J=6.0 Hz, 2H), 6.20 (dt, J=15.6, 6.0 Hz, 1 H), 6.43 (d, J=15.6 Hz, 1 H), 6.69 (d, J=8.8 Hz, 2H), 7.19 (d, J=8.4 Hz, 1 H); 13C NMR (100 MHz, CD3OD): δ43.12, 115.10, 125.43, 127.17, 129.74, 130.45, 157.29; MS (ESI): m/z 133 (M-NH3).
119 (R=4-OMe):
[00408] 80% yield; off-white solid; 1H NMR (400 MHz, CD3OD): δ3.32 (d, .7=6.0 Hz, 2H), 3.74 (s, 3H), 6.15 (dt, J=15.6, 6.0 Hz, 1 H), 6.42 (d, J=15.6 Hz, 1 H), 6.82 (d, J=8.8 Hz, 2H), 7.28 (d, J=9.2 Hz, 1 H); 13C NMR (100 MHz, CD3OD): 643.23, 54.25, 113.52, 127.04, 127.28, 129.52, 129.87, 159.18; MS (ESI): m/z 147 (M-NH3).
Procedure for preparing 4-hydroxymethylcinnamic acid 124:
[00409] A solution of NaBH4 (0.53 g, 14 mmol) in THF/H20 (4:1 ) (12 ml) was added dropwise to an ice-cold stirred solution of 4-formylcinnamic acid (2.47 g, 14 mmol) in THF (25 ml), and the mixture was stirred at room temperature for 3 h. The reaction was quenched by adding 4N HCI (20 ml), and the THF was removed by a rotary evaporator. The solid residue was treated with H20 (20 ml), and extracted with EtOAc (4x50 ml). The EtOAc extracts were washed with H20 (50 ml) and brine (50 ml), and dried. The crude product was recrystallized from EtOAc to afford pure 4-hydroxymethylcinnamic acid 124 (1.3g, 52% yield) as yellow solid. 1H NMR (300 MHz, CD3OD): δ4.62 (s, 2H), 6.45 (d, J=16.2 Hz, 1 H), 7.38 (d, 8.1 Hz, 2H), 7.56 (d, J=8.1 Hz, 2H), 7.65 (d, J=16.2 Hz, 1 H); 13C NMR (75 MHz,
CD3OD): 563.53, 1 17.81 , 127.17, 128.08, 133.58, 144.25, 144.92, 169.22; MS (ESI): m/z 177 (M-1 ).
[00410] The remaining compounds were synthesized and characterized analogously, or were purchased if commercially available.
EXAMPLES 14-17. Studies in Pseudomonas syringae pv. tomato DC3000
[00411] The following methods apply to Examples 14-17:
Bacterial strains, plasmids, and growth conditions.
[00412] Bacterial strains and plasmids used in this study are listed in the table in Fig. 31. Wild-type Pseudomonas strains were routinely grown in King's B (KB) medium at 28^ (King 1954), and E. coli strains were routinely grown in Luria-Bertani (LB) broth at 37"C. For induction of T3SS genes, DC3000 was grown in HIM supplemented with 10 mM fructose as previously described (Huynh et al. 1989). When necessary, antibiotics were added to growth medium at the following concentrations: kanamycin, 50 pg/ml; rifampin, 34 pg/ml (for sterility of the Pseudomonas cells lines). Primers used for PCR in this report are listed in the table in Fig. 31. The promoter-probe plasmid was constructed as follows. The hrpA promoter region was amplified by PCR using phrpAF and phrpAR primers incorporating SamHI and EcoRI restriction sites, respectively. A 496-bp DNA fragment encoding the hrpA promoter was digested with SamHI and EcoRI and cloned into pPROBE-NT digested with the same enzymes. This construct was mobilized into DC3000 by conjugation using E. coli S17-1 K-pir as the donor strain.
Promoter activity assay.
[00413] Expression of hrpA was analyzed using a FACS Calibur flow cytometer as previously described (BD Biosciences, CA) (Peng et al. 2006). Wild-type DC3000 carrying the promoter-probe phrpA or pPROBE-NT (vector control) was grown in KB broth overnight and transferred to HIM or HIM supplemented with different compounds as described (Li et al. 2009). The promoter activity of hrpA in DC3000 was monitored by measuring GFP intensity using flow cytometry.
Hypersensitive response and virulence assays
[00414] Bacterial cells from overnight cultures grown in KB broth were resuspended in sterile dH20. Cell suspensions were mixed with chemicals and allowed to sit for 30 minutes before plant inoculation. Nicotiana tabacum cv. Xanthi plants were used for HR assays. Tobacco leaves were pressure infiltrated by use of a needless syringe (Fu et al. 2006) with 1 * 108 cells/ml and 25 μΜ, 50 μΜ, 100 μΜ, 250 μΜ, or 500 μΜ TCA. Plants were photographed and assessed for macroscopic tissue collapse indicative of HR 18 h post- inoculation.
[00415] Virulence assays were performed in 4-5 week old tomato plants. Bacterial cell suspensions were adjusted to 6><105 cells/ml in dH20 with 0.02% Silwet L-77 (Lehle Seeds, Round Rock, TX). Lycopersicon esculentum cv. Moneymaker plants were dip-inoculated into negative control solution (dH20 with 0.02% Silwet L-77 and DMSO), positive control solution (DC3000 in dH20 with 0.02% Silwet L-77 and DMSO), or with a chemical treatment solution (DC3000 in dH20 with 0.02% Silwet L-77 and 250 μΜ TCA). Leaves were air-dried and plants were covered with a plastic dome and returned to the growth chamber. Plants were scored for disease symptoms using a modified scoring system (Kozik and Nowakowska 2010) five days post-inoculation. Lesions of bacterial speck on tomato were counted and the plants were scored using the following DSI scale: 0 = no lesions per plant, 1 = 1-10 lesions, 2 = 11-20 lesions, 3 = 21-40 lesions, 4 = >40 lesions.
RNA extraction and real-time PCR analysis.
[00416] DC3000 was cultured in KB medium overnight at 28Ό and subcultured in HIM medium supplemented with DMSO or with 250 μΜ TCA for 9 h. Total bacterial RNA was isolated using RNeasy Mini Kit (QIAGEN, Valencia, CA) and treated with Turbo DNA-free DNase kit (Ambion, Austin, TX). cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) from 0.8 g of total RNA. The Real Master Mix SYBR ROX (5 PRIME, Gaithersburg, MD) was used for real-time PCR reactions to quantify the cDNA level of target genes in different samples. Data were collected by the Opticon 2 system (Bio-Rad) and analyzed using Relative Expression Software Tool as described by Pfaffl and associates (Pfaffl et al. 2002). Two housekeeping genes, gyrA (PSPT01745) and gapl (PSPT01287) were used as endogenous controls for data analysis. The primer pairs used in this study are listed in Table 1. The PCR efficiencies of the primers are: gyrA, 1.93; gapl, 2.08; and hrpW, 1.93.
Immunoblot analysis
[00417] The HrpW protein level was determined by immunoblot using anti-HrpW antibody provided by Dr. Alan Collmer (Cornell University, Ithaca, NY). Sample preparation was performed as previously described with modifications (Yuan and He 1996). Wild-type DC3000 was grown overnight in King's B medium at 28"C. The culture was washed with Λ -inducing medium (HIM) and resuspended in 40 ml of the same medium to an optical density (OD) at 600 nm of 0.1. To determine the effect of TCA on the HrpW protein level, TCA dissolved in DMSO was added to the culture at the final concentration of 250 μΜ and the culture was grown with moderate shaking at 28*C . DMSO was added to a separate culture as a negative control. After 9 h, the cells were collected by centrifugation at 4,000 * g for 10 min and resuspended in 1 ml of phosphate buffered saline (PBS; 137 mM NaCI, 2.7 mM KCI, 4.3 mM Na2HPO„, and 1.47 mM KH2P04 [pH 7.4]). Pelleted cells were
resuspended in 1 χ sample buffer (2% w/v sodium dodecyl sulfate, 2% v/v glycerol, 2 mM β- mercaptoethanol, 50 mM Tris-HCI [pH6.8], and 0.01 % w/v bromophenol blue) and heat- treated at 98 for 10 min using Dry Bath Incubator (Fisher Scientific, Pittsburgh, PA). The supernatant proteins were concentrated 100-fold with Amicon Ultra-4 Centrifugal Filter Unit (30 kDa cut-off) (Millipore, Billerica, MA) and mixed with the same volume of 2 * sample buffer and heat-treated. Cell pellets were similarly heat-treated. Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis were performed as previously described (Li et al. 2009). The chemiluminescent detection using BrightStar BioDetect Kit (Ambion, Austin, TX) was performed following the manufacturer's instructions.
EXAMPLE 14. TCA inhibits gene expression of T3SS hrpA but not bacterial growth
[00418] To determine the maximum concentration of TCA that will inhibit hrpA promoter activity without affecting bacterial growth, DC3000 carrying phrpA was cultured in HIM and HIM supplemented with 25 μΜ, 50 μΜ, 100 μΜ, 250 μΜ, or 500 μΜ of TCA. Promoter activity was measured at 6 h and 9 h as mentioned above using flow cytometry. Bacterial growth was determined by withdrawing samples of each culture and spot-plating serial dilutions onto King's B agar (King et al. 1954) in tandem with promoter activity assays. Colonies were counted after 48 h of incubation at 28'C. Addition of 100 μΜ of TCA to the growth medium (concentration used to screen chemical library) resulted in a 3-fold reduction in hrpA promoter activity, whereas lower concentrations of TCA (25 μΜ or 50 μΜ) had a less substantial effect (Fig. 32). HIM supplemented with TCA concentrations of 250 μΜ and 500 μΜ caused almost complete repression of hrpA promoter activity which was similar to expression levels measured in the empty vector control (DC3000 containing pPROBE-NT; Fig. 32 and Fig. 33). Colony counts of DC3000 at 6 h and 9 h were similar among the control culture (0 μΜ TCA) and the cultures to which TCA was added at concentrations of 250 μΜ or less, whereas colony counts were slightly lower in cultures containing 500 μΜ TCA (Fig. 33). These results suggest that the degree of inhibition on DC3000 hrpA is proportional to the concentration of TCA added to the growth medium. In addition, TCA does not significantly inhibit nor enhance growth of DC3000 when TCA was added to HIM at or below concentrations of 250 μΜ.
EXAMPLE 15. TCA suppresses ability of DC3000 to elicit HR in tobacco
[00419] In DC3000, mutations in genes which encode components of the T3SS result in the inability to elicit HR in non-hosts (Collmer et al. 2000). Since TCA represses expression of hrpA (a major component of the T3SS) in vitro, the ability of TCA to suppress HR in planta was examined. DC3000 (OD600 = 0.1 ) with 25 μΜ, 50 μΜ, 100 μΜ, 250 μΜ, or 500 μΜ of TCA in DMSO was injected into leaves of tobacco (Nicotiana tabacum cv. Xanthi). Concentrations of DMSO which correspond to similar amounts of TCA were also injected
into the tobacco plants as negative controls. Tobacco leaves were assessed for HR symptoms 18 hours post-infiltration. No visible signs of tissue damage or HR were observed when DMSO or TCA was separately infiltrated into the tobacco leaves (data not shown). When bacterial cells were infiltrated into plants in combination with 250 μΜ of TCA, elicitation of HR by DC3000 was completely suppressed (Fig. 34A). 100 μΜ of TCA was unable to completely block HR, but the symptoms were slightly less severe than those seen when either 50 μΜ or 25 μΜ was infiltrated with bacterial cells into tobacco leaves. These results revealed that TCA not only inhibits expression of the hrpA gene encoding the major structural component of the T3SS pilus, but also functions in planta to suppress the ability of DC3000 to elicit HR on a non-host. This effect is most likely due to lack of a functional T3SS.
[00420] Following the initial screen of the chemical library, several compounds were found to have little or no affect on hrpA promoter activity. One of these TCA analogs (104), was chosen as a negative control to evaluate the specificity of TCA to inhibit T3SS in planta. DC3000 (ODeoo = 0.1 ) with DMSO or with 25 μΜ, 50 μΜ, 100 μΜ, 250 μΜ, or 500 μΜ of Υ104 (same concentrations as those used to evaluate TCA) was infiltrated into tobacco leaves and scored for HR symptoms after 18 h. 104 was ineffective at suppressing HR at all concentrations tested (Fig. 34B). These results indicate that the inhibitory activity of TCA on the ability of DC3000 to cause HR is specific. In addition, the structure of TCA is important for its repressive effect on HR.
EXAMPLE 16. Effect of TCA on HrpW of DC3000.
[00421] The T3SS is responsible for the translocation of virulence and accessory proteins which contribute to disease in plants (Lindeberg et al. 2006). HrpW is a T3SS-secreted harpin capable of eliciting HR on tobacco (Charkowski et al. 1998). The amount of hrpW mRNA and HrpW protein levels in the DC3000 cells grown in TCA can serve as an indicator of the HR response in tobacco plants by the bacterium (Wei et al. 2000). Real-time PCR was performed to examine the effect of TCA on hrpW expression. Compared to induction of T3SS in HIM alone, a significantly lower amount of hrpW mRNA (relative expression ratio 0.07, P = 0.04) was observed in HIM supplemented with 250 μΜ TCA. Immunoblot analysis was performed on DC3000 cultured in HIM or in HIM supplemented with 250 μ·Μ TCA. When DC3000 cells were grown in HIM supplemented with 250 μΜ of TCA, HrpW was absent from the culture supernatants and was also undetectable in the whole cell lysates (Fig. 35). These results indicate that TCA inhibited the production and secretion of HrpW protein from the cells. Our results showed that the HrpW protein was detected at similar levels of intensity when DC3000 was grown in HIM or in HIM with DMSO (TCA solvent),
which suggests that the concentrations of DMSO used in this study did not cause alteration of HrpW production in the bacterium.
EXAMPLE 17. TCA prevents DC3000 from causing disease in tomato.
[00422] Taken together, the above results indicate that TCA specifically blocks the action of T3SS by inhibiting its expression. The effects of TCA on virulence in tomato plants were examined. Lycopersicon esculentum cv. Moneymaker plants were dip-inoculated with a negative control treatment (dH20 with 0.02% Silwet L-77 and DMSO), a positive control treatment (DC3000 in dH20 with 0.02% Silwet L-77 and DMSO), or with a chemical treatment (DC3000 in dH20 with 0.02% Silwet L-77 and 250 μΜ TCA) as described in the methods. The lesions of bacterial speck on leaves per plant were counted and plants were classified with a disease severity index (DSI) as described in the methods. At five days post- inoculation, no bacterial speck lesions were observed in tomato plants treated with DC3000 and 250 μΜ TCA or with the negative control treatment (Fig 36A), which were all scored with a DSI of zero. Plants treated with DC3000 were all scored with a DSI of four (Fig. 36B).
EXAMPLE 18. Screening for Inhibitors/lnducers of the T3SS of P. aeruginosa
[00423] To identify T3SS inhibitors of PA01 , a promoter-probe vector pPROBE-AT containing the promoterless green fluorescent protein (gfp) gene was used to construct an exoS promoter-g/ plasmid reporter, pATexoS. PA01 containing pATexoS was cultured in T3SS-inducing medium containing dimethyl sulfoxide (DMSO; solvent of chemical compounds), or supplemented with 250 μΜ of each compound, and promoter activity was assessed at 6 h by measuring GFP intensity using flow cytometry. 101 compounds (58 synthesized and 43 commercially available) were screened. Compounds 027, 032, 101 , and 149 repressed exoS expression at the final concentration of 250 μΜ by at least one standard deviation below the sample average (Z score≤— 1) (Fig. 37 A-E). Z score (or standard score) indicates how many standard deviations an observation or datum is above or below the mean [z = (χ-μ)/σ, where x is a raw score to be standardized, μ is the mean of the population, and σ is the standard deviation of the population]. 027, 032, 101 , and 149 were found to function as T3 inhibitors of P. aeruginosa with minor alterations in bacterial growth at 250 μΜ (Fig. 37 A, C, and D). Additionally, two compounds 103 and 134 were found to induce exoS expression at the same concentration by at least 4 standard deviations above the sample average (Z score≥ 4) (Fig. 37A and B). However, 103 and 134 showed some inhibition on bacterial growth.
EXAMPLE 19. Evaluation of the dose-dependent effects of compounds on exoS expression and bacterial growth.
[00424] To determine the effective concentration of compounds, the dose-dependent effect of potential inhibitors on exoS expression and bacterial growth were tested. P.
aeruginosa cells carrying pATexoS were pre-cultured in LB supplemented with 200 mM NaCI and transferred to fresh LB with 200 mM NaCI, 10 mM NTA, and various concentrations of compounds (20, 50, 100, and 250 μΜ) or DMSO for 6 h. As shown in Fig. 37A and Table 17, 027 inhibited exoS expression at 20 μΜ but 101 did not. At 50 μΜ dosage, both 027 and 101 inhibited exoS expression at similar levels, and this inhibitory effect increased as compound concentration increased (Fig. 38A and Table 17). These two compounds had only minor effects on bacterial growth at different compound concentrations (up to 250 μΜ for 101 and up to 500 μΜ for 027) (Fig. 39A). On the other hand, two T3 inducers 103 and 134 showed significant induction of exoS expression at 20 μΜ (Fig. 38B and Table 17). This induction effect increased as compound concentration increased (Fig. 38B and Table 17), and inverse relationship was observed between the compound concentration and bacterial growth (Fig. 39B). These inhibitions/inductions of exoS expression are caused by the shifting bacterial population between low-state expression cells and high-state expression cells (Fig. 40).
Table 17. Actual readings of flow cytometry (exoS expression) at various concentrations of compounds.
NC 50.42 ± 0.51
NC-NTA 125.11 ± 1.98
EXAMPLE 20. Structure-activity relationships (SARs).
[00425] While screening for T3SS inhibitors, several compounds were found to have little or no effect on exoS promoter activity, such as 004, 132, and 137. Comparison of the effective T3SS inhibitors vs. non-effective chemicals reveals that the structure of 027 is identical to that of 004 except the hydroxyl group of the phenol ring has been replaced with an amide group (Table 18). Also, 101 is similar to 004 (carboxyl group was replaced with a carboxymethyl group) (Table 8). Given that 004 has almost no effect on exoS expression (Fig. 38A and Table 17) signifies that these two functional groups may be important for their exoS-inhibitory effect. Meanwhile, the P. aeruginosa T3 inducer 103 shares its structure with less-functional 132 (no hydroxyl group on the phenol ring) and nonfunctional 137 (the hydroxyl group on the carbonyl-nitrogen group was replaced with a methyl group), indicating
that of these two functional groups, one enhances the effect of the compound and the other is crucial for its induction activity, respectively (Table 18).
Table 18. Structure-activity relationships.
Fraction of
Compound
Stracture untreated
O
Yang-103 2.04 ± 0.13
EXAMPLE 21. Studies in Erwinia amylovora 273
[00426] Wild-type Erwinia amylovora 273 was used in this study. The promoter-probe plasmid phrpA was constructed as follows. The hrpA promoter region of Erwinia amylovora 273 was amplified and cloned into pPROBE-NT to produce PhrpA. Plasmid PhrpA was electroporated into Erwinia amylovora 273. Expression of hrpA was analyzed using a FACS Calibur flow cytometer (BD Biosciences, CA). Wild-type Erwinia amylovora 273 containing phrpA was cultured in a rtrp-inducing medium (HIM) containing dimethyl sulfoxide (DMSO; solvent of chemical compounds), or HIM supplemented with 100 μΜ of each compound, and promoter activity was assessed at 6 h and 9 h by measuring GFP intensity using flow cytometry (Table 19). Treatment:
Ea273 (pPROBE-NT): Erwinia amylovora 273 carrying pPROBE-NT (vector control)
Ea273 (phrpA): Erwinia amylovora 273 carrying phrpA
HIM: hrp inducing medium
###: HIM supplemented with the indicated compound
Table 19. Expression of Erwinia amylovora273 hrpA in HIM or HIM supplemented with the indicated compound.
010, trans-2-Phenylcyclopropane-l-carboxylic acid 336.7±28.1 293.0±4.7
013, trans-3-(3-Pyridyl)acrylic acid 468.3±7.7 245.7±3.1
035, 3-(2-naphthyl) acrylic acid 178.9±9.7 89.0±6.2
012, trans-3-Indoleacrylic acid 33.7±8.9 47.9±6.9
Oi l, trans-3-(2-Thienyl)acrylic acid 230.1±5.8. 167.3±8.2
015, trans-2-Methoxycinnamic acid 342.6±7.0 255.1±1.7
018, trans-2-Methylcinnamic acid 303.8±8.7 262.5±9.3
021, trans-2-Chlorocinnamic acid 225.7±35.8 192.7±8.6
014, trans-3-(4-Imidazolyl)acrylic acid 874.6±23.1 839.2±17.6
002, 2,4-Dihydroxycinnamic acid 1365.3±104.9 1479.8±72.9
007, 3-(4-Hydroxyphenyl)propionic acid 1093.1 ±62.8 121 1.0±58.7
023, trans-4-Chlorocinnamic acid 171.8±7.7 125.8±3.9
017, trans-4- ethoxycinnamic acid 132.5±5.5 76.4±2.7
020, trans-4-Methylcinnamic acid 208.5±2.7 145.4±3.7
003, 3,4-Dihydroxycinnamic acid 783.4±80.2 787.3±25.2
108, trans-4-Phenylcinnamic acid 197.7±5.5 99.3±3.3
022, trans-3-Chlorocinnamic acid 332.9±16.9 238.3±8.7
016, trans-3-Methoxycinnamic acid 265.3±24.4 198.5±20.0
019, trans-3-Methylcinnamic acid 31 1.5±18.6 251.6±13.3
Compound No. Avg MFI ±SDb at:
6 h 9 h
HIM 458.1±10.2 587.4±36.0
025, trans-4-Carboxycinnamic acid 421.0±10.6 496.7±98.9
031, trans-Cinnamamide 98.0±18.4 88.1±4.6
100, Ethyl trans-2-(4-methoxyphenyl)-l-cyclopropanecarboxylate 447.8±20.2 594.6±3.5
1 13, trans-4-Trifluoromethylcinriamic acid 84.2±7.5 97.4±23.6
1 14, Diethyl trans-2-(4-hydroxyphenyl)-vinylphosphonate 495.8±14.2 661.2±134.3
1 15, trans-2-(4-Hydroxyphenyl)-vinylphosphonic acid 442.4±2.3 553.3±32.7
1 16, N-(para-Coumaryl)phthalimide 889.1±61.8 1466.4±17.8
1 17, para-Coumarylamine 452.6±9.5 547.9±1 12.4
1 18, N-(4-Methoxycinnamyl)phthalimide 361.3±28.6 520.4±16.2
1 19, trans-4-Methoxycinnamylamine 208.6±18.6 232.9±44.4
120, Ethyl trans-2-(4-methoxyphenyl)-ethenylsulfonate 371.5±29.7 492.0±37.6
121, trans-2-(4-Methoxyphenyl)ethenylsulfonic acid tetra(n- 358.3±24.0 477.4±40.0 butyl)ammonium salt
Compound No. Avg MFI ±SDb at:
6 h 9 h
HIM 1100.1±30.8 1351.9±62.4
153 , /rans-3-Fluorocinnamohydrc>xamic acid 177. 1 1.9 1 10.6±3.2
154, /r< s-2-Fluorocinnarnohydroxarnic acid 11 1.4±15.1 77.8±1.3
155, /ra/7i-4-Nitrocinnamohydroxamic acid 108.4±8.5 132.5±2.6
156, /ro/?i-3-Nitrocinnamohydroxamic acid 67.8±17.9 99.5±4.9
157, /rara-2-Nitrocinnarnohydroxarnic acid 104.6±7.3 96.2±3.3
158, /ro«i-3-Methoxycinnamohydroxamic acid 216.2±12.5 250.6±13.9
159 , /ran5-2-Methoxycinnamohydroxamic acid 256.3±10.8 337.3±15.2
160, ira/w-2-Methylcinnamohydroxamic acid 122.7±1.9 95.7±3.7
161, /rowj-3-(2-Thienyl)acrylhydroxamic acid 132.4±13.2 145.0±1 1.7
162, /ra«5-2-PhenylcycIopropane-l-carbohydroxamic acid 71 1.1±2.8 701.9±2.8
163, /rani-3-(2-Furyl)acrylhydroxamic acid 231.5±7.0 196.5±14.9
164, /rans-4-(Benzylcarbonyl)cinnamic acid 155.7±22.2 1 16.4±6.7
165, rra/w-2-[(4'-Benzylcarbonyl]phenylcyclopropane-l-carboxylic acid 292.8±17.1 229.4±15.0
166, /rawj-4-(Carbc-phenylarnide)cinnamic acid 105.0±53.0 221.2±22.2
167, /ra/75-4-(Carbo-N-methyl-phenylamide)cinnamic acid 729.7±67.5 707.3±55.9
Compound No. Avg MFI ±SDB at:
6 h 9 h
HIM 1 132.3±93.6 1295.0±86.5
137, N-Methyl-4-hydroxycinnamamide I064.1±99.3 1 I21.1±52.1
138, N-(2-Hydroxyethyl)-4-hydroxycinnamamide 1474.5±30.4 1907.0±39.8
139, 3-Phenylpropionohydroxamic acid 306.3±1 1.9 286.3±10.0
140, /ranj-4-Phenylcinnamohydroxamic acid 101.7±17.1 82.8±4.3
141, /ranj-4-Fluorocinnamohydroxamic acid 167.6±4.7 119.0±7.1
142, /ra/w-4-Methylcinnamohydroxamic acid 126.2±5.6 106.0±13.6
143, 2-Phenoxyacetohydroxamic acid 228.7±4.6 178.5±27.1
144, 4-Hydroxybenzoic acid 434.4±22.1 424.7±24.8
145, 3-Hydroxybenzoic acid 559.4±23.6 529.9±32.0
146, /rani-4-Formylcinnamohydroxamic acid 414.3±31.6 435.2±36.2
147, /rans-4-Hydroxymethylcinnamohydroxamic acid 688.6±39.2 746.8±96.3
148, /ra«i-4-Chlorocinnatnohydroxamic acid 22.5±3.7 21.8±25.2
149, /ranj-3-Chlorocinnamohydroxamic acid 31.2±34.1 21.7±28.5
150, ira -2-Chlorocinnamohydroxamic acid 25.9±3.2 30.5±3.3
151, /ra i5-3-Bromocinnamohydroxamic acid 6.3±1.2 3.9±1.2
152, /r<3/is-2-Bromocinnamohydroxamic acid ~ - 15.7±2.3 11.1±1.2
[00427] Throughout this disclosure, various aspects of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity, and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, as will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof, as well as integral and fractional numerical values within that range. The above detailed description of the invention is illustrative of certain embodiments of the invention and is not intended to limit the scope of the invention.
[00428] All patents, publications and references cited herein are hereby fully incorporated by reference. In case of conflict between the present disclosure and incorporated patents, publications and references, the present disclosure should control.
Claims
1 . A method of reducing virulence in a bacterium comprising at least one of a
GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound of formula (III):
wherein:
A is aryl or heteroaryl;
is selected from oxygen, sulfur and a bond;
n is O, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
2. The method of claim 1 , wherein A is aryl.
3. The method of claim 1 , wherein A is heteroaryl.
4. The method of any of claims 1 -3, wherein n is 0.
5. The method of any of claims 1 -3, wherein n is 1 or 2.
6. The method of any of claims 1 -3 or 5, wherein each R2 is independently selected from alkyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester and amido groups.
7. The method of any of claims 1 -6, wherein R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester, amino, amido, sulfonic acid, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups.
8. A method of reducing virulence in a bacterium comprising at least one of a
GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound of formula (IV):
wherein:
A is aryl or heteroaryl;
is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is O, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
9. The method of claim 8, wherein A is aryl.
10. The method of claim 8, wherein A is heteroaryl.
1 1 . The method of any of claims 8-10, wherein is alkylene, heteroalkylene or a bond.
12. The method of any of claims 8-1 1 , wherein n is 0.
13. The method of any of claims 8-1 1 , wherein n is 1 or 2.
14. The method of any of claims 8-1 1 or 13, wherein each R2 is independently selected from alkyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester and amido groups.
15. The method of any of claims 8-14, wherein R7 is selected from hydroxamic acid, hydrazinocarbonyl, amino, amido, sulfonic acid, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups.
16. A method of reducing virulence in a bacterium comprising at least one of a
GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound of formula (V):
wherein:
A is aryl or heteroaryl;
is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, fluoro, bromo, iodo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
17. The method of claim 16, wherein A is aryl.
18. The method of claim 16, wherein A is heteroaryl.
19. The method of any of claims 16-18, wherein is alkylene, heteroalkylene or a bond.
20. The method of claim any of claims 16-19, wherein each R2 is independently selected from alkyl, hydroxyalkyl, alkoxy, sulfhydryl, fluoro, bromo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester and amido groups.
21 . The method of any of claims 16-20, wherein R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester, amino, amido, sulfonic acid, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups.
22. A method of reducing virulence in a bacterium comprising at least one of a
GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound of formula (VI):
wherein:
A is selected from imidazole, thiophene, furan, oxazole, thiazole, quinoline, benzofuran, benzothiofuran and carbazole;
is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is O, 1 , 2, 3, 4 or 5;
each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
23. The method of claim 22, wherein is alkylene, heteroalkylene or a bond.
24. The method of any of claims 22-23, wherein n is 0.
25. The method of any of claims 22-24, wherein R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester, amino, amido, sulfonic acid, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups.
26. A method of reducing virulence in a bacterium comprising at least one of a
GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound of formula (VII) :
wherein:
A is aryl or heteroaryl;
RT is selected from alkylene, heteroalkylene, oxygen, sulfur and a bond;
n is 2, 3, 4 or 5; each R2 is independently selected from alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, thioether, sulfo, silyl, phosphono, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester, amido and heterocyclyl groups; and
R7 is selected from hydroxy, hydroxyalkyl, alkoxy, carboxy, hydroxamic acid, hydrazide, hydrazinocarbonyl, aryl, ester, amino, amido, thioamido, sulfonyl, sulfinic acid, sulfonic acid, sulfinate, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups;
or a salt thereof.
27. The method of claim 26, wherein A is aryl.
28. The method of claim 26, wherein A is heteroaryl.
29. The method of any of claims 26-28, wherein is alkylene, heteroalkylene or a bond.
30. The method of any of claims 26-29, wherein each R2 is independently selected from alkyl, hydroxy, hydroxyalkyl, alkoxy, sulfhydryl, halo, carboxy, nitro, amino, formyl, aryl, haloalkyl, ester and amido groups.
31 . The method of any of claims 26-30, wherein R7 is selected from hydroxy, carboxy, hydroxamic acid, hydrazinocarbonyl, ester, amino, amido, sulfonic acid, sulfonate, phosphonic acid, phosphonate, and substituted or unsubstituted bicyclic heteroaromatic groups.
32. A method of reducing virulence in a bacterium comprising at least one of a
GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound selected from the group consisting of:
109
110 WO 2011/103189
or a salt thereof.
33. The method of any of claims 1 -32, wherein the bacterium is Gram negative.
34. The method of any of claims 1 -33, wherein the bacterium is a member of the Enterobacteriaceae family.
35. The method of any of claims 1 -33, wherein the bacterium is of a bacterial genus selected from the group consisting of Pseudomonas, Dickeya, Erwinia, Azotobacter, Vibrio, Yersinia, Pectobacterium, Salmonella, Chlamydia, Xanthomonas, Ralstonia, Shewanella, Shigella and Escherichia.
36. The method of any of claims 1 -33, wherein the bacterium is a Pseudomonas spp. selected from the group consisting of P. aureofaciens, P. chlororaphis, P. fluorescens, P. marginalis, P. syringae, P. tolaasii, P. viridiflava, and P. aeruginosa.
37. The method of claim 36, wherein the bacterium is P. aeruginosa.
38. The method of any of claims 1 -33, wherein the bacterium is an Env/n/a-related strain selected from the group consisting of Dickeya dadantii, Pectobacterium carotovora, Pectobacterium atroseptica, and Erwinia amylovora.
39. The method of any of claims 1 -33, wherein the bacterium is a Salmonella spp.
selected from the group consisting of S. typhimurium and S. enterica.
40. The method of any of claims 1 -33, wherein the bacterium is Ralstonia solanacearum.
41 . The method of any of claims 1 -33, wherein the bacterium is a Xanthomonas spp. selected from the group consisting of X. campestris, X. axonopodis and X. oryzae.
42. The method of any of claims 1 -41 , wherein the bacterium is associated with a subject, and wherein the bacterium is contacted with the compound by administering the compound to the subject.
43. The method of claim 42, wherein the subject is a plant.
44. The method of claim 43, wherein the composition is formulated as a wettable powder, a water-soluble powder, an emulsifiable concentrate, an aqueous solution or concentrate, an emulsion, a sprayable solution, a capsule suspension, a dispersion on an oil or water base, a suspoemulsion, a suspension concentrate, a dusting powder, a solution which can be mixed with oils, a seed-dressing agent, a granule, an ultra-low volume formulation, a microcapsule or a wax.
45. The method of any of claims 43-44, wherein the composition is administered via at least one of water or solvent.
46. The method of any of claims 43-45, wherein the composition is administered topically.
47. The method of any of claims 43-46, wherein the composition is administered to at least one of leaves, stems, roots, buds, fruits, frill, stump, bark, roots, soil or rhisozphere.
48. The method of any of claims 43-47, wherein the composition is administered daily, weekly, monthly, or annually.
49. The method of any of claims 43-48, wherein the composition is sprayed on the plant.
50. The method of claim 42, wherein the subject is an animal.
51 . The method of claim 50, wherein the animal is a human.
52. The method of any of claims 50-51 , wherein the composition further comprises a pharmaceutically-acceptable carrier or diluent.
53. The method of any of claims 50-52, wherein the composition is administered topically, orally, or parenterally.
54. The method of any of claims 50-53, wherein the composition is administered intravenously, subcutaneously, intramuscularly or intraperitoneally.
55. The method of any of claims 1 -41 , wherein the bacterium is on a surface, and wherein the bacterium is contacted with the compound by contacting the surface with the compound.
56. The method of claim 55, wherein the surface is in a medical, industrial, commercial, or residential setting.
57. A compound selected from the group consisting of:
or a salt thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11745175A EP2536275A1 (en) | 2010-02-16 | 2011-02-16 | Methods of reducing virulence in bacteria |
CN201180019127.2A CN102883602B (en) | 2010-02-16 | 2011-02-16 | The method for reducing the virulence of bacterium |
US13/579,373 US9260382B2 (en) | 2010-02-16 | 2011-02-16 | Methods of reducing virulence in bacteria |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30502710P | 2010-02-16 | 2010-02-16 | |
US61/305,027 | 2010-02-16 | ||
US33238510P | 2010-05-07 | 2010-05-07 | |
US61/332,385 | 2010-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011103189A1 true WO2011103189A1 (en) | 2011-08-25 |
Family
ID=44483288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/025082 WO2011103189A1 (en) | 2010-02-16 | 2011-02-16 | Methods of reducing virulence in bacteria |
Country Status (4)
Country | Link |
---|---|
US (1) | US9260382B2 (en) |
EP (1) | EP2536275A1 (en) |
CN (1) | CN102883602B (en) |
WO (1) | WO2011103189A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059582A2 (en) * | 2011-10-20 | 2013-04-25 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
WO2013101600A1 (en) * | 2011-12-29 | 2013-07-04 | Pharmacyclics, Inc. | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8 |
WO2013178575A1 (en) | 2012-05-30 | 2013-12-05 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarb oxylic acids |
CN103553968A (en) * | 2012-06-29 | 2014-02-05 | 常州大学 | Cinnamic hydroxamic acid compounds and preparation method thereof |
WO2014028600A3 (en) * | 2012-08-15 | 2014-04-24 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
CN104365598A (en) * | 2014-10-30 | 2015-02-25 | 江苏科技大学 | Caffeic acid and application of alkyl ester of caffeic acid in control of bacterial wilt |
US20150218087A1 (en) * | 2012-08-10 | 2015-08-06 | Toray Industries, Inc. | Method of manufacturing coumaramide |
CN104823974A (en) * | 2015-04-13 | 2015-08-12 | 江苏科技大学 | Applications of caffeic acid alkyl ester |
WO2016149099A1 (en) * | 2015-03-13 | 2016-09-22 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
US9556168B2 (en) | 2012-08-15 | 2017-01-31 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof |
US9603838B2 (en) | 2011-02-11 | 2017-03-28 | Merck Sharp & Dohme Corp. | RORgammaT inhibitors |
US9745265B2 (en) | 2012-08-15 | 2017-08-29 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof |
CN109251090A (en) * | 2018-10-22 | 2019-01-22 | 河南工业大学 | A kind of microorganism seed dressing agent for promoting wheat germination and improving disease-resistant wheat |
US10221142B2 (en) | 2015-02-11 | 2019-03-05 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
WO2019151664A1 (en) * | 2018-01-31 | 2019-08-08 | 서울대학교산학협력단 | Rtx toxin production inhibitor and composition for treating symptom of vibrio infection by using same |
KR20190093111A (en) * | 2018-01-31 | 2019-08-08 | 서울대학교산학협력단 | Inhibitor to RTX toxin synthesis and composition for treatment to Vibrio infection disease |
EP3455203A4 (en) * | 2016-05-12 | 2019-11-13 | Research Triangle Institute | Vinylogous phenethylamines as neurotransmitter releasers |
US10584121B2 (en) | 2015-10-27 | 2020-03-10 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101897881B1 (en) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2015026796A1 (en) | 2013-08-20 | 2015-02-26 | The Trustees Of Princeton University | Heterocycle analogs of cai-1 as agonists of quorum sensing in vibrio |
JP2016530273A (en) | 2013-08-20 | 2016-09-29 | シティ・オブ・ホープCity of Hope | HDAC8 inhibitor for treating cancer |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN105669519B (en) * | 2016-01-04 | 2018-01-05 | 北方民族大学 | Benzazole compounds, preparation method and its application as drug-resistance bacteria medicine |
CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2020092802A1 (en) * | 2018-11-01 | 2020-05-07 | The University Of Memphis Research Foundation | Controlling biofilms with cyclopropanated fatty acids |
CN113233993B (en) * | 2021-05-18 | 2022-07-01 | 贵州大学 | Ferulic acid amide derivative and synthetic method thereof |
CN113318000A (en) * | 2021-05-28 | 2021-08-31 | 福建莲珂科技有限公司 | Cosmetic preservatives and their use as ingredients in cosmetic formulations |
CN114145300B (en) * | 2021-12-17 | 2022-09-23 | 华南农业大学 | Application of salicylic acid and/or p-hydroxybenzoic acid in preparing preparation for preventing and/or treating bacterial soft rot |
CN114480226B (en) * | 2022-04-02 | 2023-06-02 | 华南农业大学 | Enterobacter alboldii and application thereof in preventing and treating bacterial soft rot of plants |
CN114773237B (en) * | 2022-04-24 | 2023-03-24 | 南京大学 | Novel phenyl propenyl hydroximic acid derivatives containing sulfonate structure, and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058714A2 (en) * | 1998-05-13 | 1999-11-18 | Institut Pasteur | Method for screening for inhibitors and activators of type iii secretion machinery in gram-negative bacteria |
US7026155B2 (en) * | 1999-02-02 | 2006-04-11 | Regents Of The University Of California | Method of reducing bacterial proliferation |
US7339043B2 (en) * | 2001-01-12 | 2008-03-04 | Trustees Of Dartmouth College | Compositions and methods for affecting virulence determinants in bacteria |
WO2008115118A1 (en) * | 2007-03-21 | 2008-09-25 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting type iii secretion in infections caused by gram-negative bacteria |
WO2008124836A2 (en) * | 2007-04-10 | 2008-10-16 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0832612B2 (en) | 1989-10-18 | 1996-03-29 | ヘキスト・アクチェンゲゼルシャフト | Herbicidal active substance combination agent |
US5994077A (en) | 1997-01-31 | 1999-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Flourescence-based isolation of differentially induced genes |
US20020102246A1 (en) | 2000-05-08 | 2002-08-01 | Novozymes A/S | Antimicrobial compositions |
ATE478684T1 (en) | 2002-02-20 | 2010-09-15 | Ninkov Dusan Dr | ANTIMICROBIAL THERAPEUTIC COMPOSITIONS AND USE THEREOF |
JP4500161B2 (en) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | Phthalazinone derivatives |
US20070128328A1 (en) | 2004-12-10 | 2007-06-07 | Shozo Tanada | Bacterial growth inhibitor or bacteriostatic agent utilizing substances derived from acerola fruit |
KR20080103090A (en) | 2006-03-10 | 2008-11-26 | 유조 츠치다 | Antimicrobial agent and antimicrobial composition |
WO2008134836A2 (en) * | 2007-05-02 | 2008-11-13 | Ouro Fino Participações E Empreendimentos S.A. | Process to produce biodiesel and/or fuel oil |
-
2011
- 2011-02-16 US US13/579,373 patent/US9260382B2/en active Active
- 2011-02-16 EP EP11745175A patent/EP2536275A1/en not_active Withdrawn
- 2011-02-16 WO PCT/US2011/025082 patent/WO2011103189A1/en active Application Filing
- 2011-02-16 CN CN201180019127.2A patent/CN102883602B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058714A2 (en) * | 1998-05-13 | 1999-11-18 | Institut Pasteur | Method for screening for inhibitors and activators of type iii secretion machinery in gram-negative bacteria |
US7026155B2 (en) * | 1999-02-02 | 2006-04-11 | Regents Of The University Of California | Method of reducing bacterial proliferation |
US7339043B2 (en) * | 2001-01-12 | 2008-03-04 | Trustees Of Dartmouth College | Compositions and methods for affecting virulence determinants in bacteria |
WO2008115118A1 (en) * | 2007-03-21 | 2008-09-25 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting type iii secretion in infections caused by gram-negative bacteria |
WO2008124836A2 (en) * | 2007-04-10 | 2008-10-16 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9603838B2 (en) | 2011-02-11 | 2017-03-28 | Merck Sharp & Dohme Corp. | RORgammaT inhibitors |
US9884043B2 (en) | 2011-02-11 | 2018-02-06 | Merck Sharp & Dohme Corp. | RORgammaT inhibitors |
WO2013059582A2 (en) * | 2011-10-20 | 2013-04-25 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
WO2013059582A3 (en) * | 2011-10-20 | 2013-07-11 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
WO2013101600A1 (en) * | 2011-12-29 | 2013-07-04 | Pharmacyclics, Inc. | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8 |
JP2015504056A (en) * | 2011-12-29 | 2015-02-05 | ファーマサイクリックス,インク. | Cinnamic acid hydroxyamide as an inhibitor of histone deacetylase 8 |
WO2013178575A1 (en) | 2012-05-30 | 2013-12-05 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarb oxylic acids |
CN103553968A (en) * | 2012-06-29 | 2014-02-05 | 常州大学 | Cinnamic hydroxamic acid compounds and preparation method thereof |
US9527802B2 (en) * | 2012-08-10 | 2016-12-27 | Toray Industries, Inc. | Method of manufacturing coumaramide |
US20150218087A1 (en) * | 2012-08-10 | 2015-08-06 | Toray Industries, Inc. | Method of manufacturing coumaramide |
CN104822657A (en) * | 2012-08-15 | 2015-08-05 | 默沙东公司 | 3-aminocycloalkyl compounds as RORgammat inhibitors and uses thereof |
US9556168B2 (en) | 2012-08-15 | 2017-01-31 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof |
WO2014028600A3 (en) * | 2012-08-15 | 2014-04-24 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
US9663522B2 (en) | 2012-08-15 | 2017-05-30 | Merck Sharp & Dohme Corp. | 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof |
US10196354B2 (en) | 2012-08-15 | 2019-02-05 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof |
US9745265B2 (en) | 2012-08-15 | 2017-08-29 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof |
CN104365598B (en) * | 2014-10-30 | 2016-03-30 | 江苏科技大学 | Caffeic acid and the application of Arrcostab in bacterial wilt control thereof |
CN104365598A (en) * | 2014-10-30 | 2015-02-25 | 江苏科技大学 | Caffeic acid and application of alkyl ester of caffeic acid in control of bacterial wilt |
US10221142B2 (en) | 2015-02-11 | 2019-03-05 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
US10508077B2 (en) | 2015-03-13 | 2019-12-17 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
CN107531660A (en) * | 2015-03-13 | 2018-01-02 | 福马治疗股份有限公司 | α cinnamide compounds and composition as HDAC8 inhibitor |
US11919839B2 (en) | 2015-03-13 | 2024-03-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
US9745253B2 (en) | 2015-03-13 | 2017-08-29 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
WO2016149099A1 (en) * | 2015-03-13 | 2016-09-22 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
US10266487B2 (en) | 2015-03-13 | 2019-04-23 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
EP3932914A1 (en) * | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
US10988441B2 (en) | 2015-03-13 | 2021-04-27 | Valo Early Discovery, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
CN104823974A (en) * | 2015-04-13 | 2015-08-12 | 江苏科技大学 | Applications of caffeic acid alkyl ester |
US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
US10584121B2 (en) | 2015-10-27 | 2020-03-10 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof |
US10689369B2 (en) | 2015-10-27 | 2020-06-23 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
EP3455203A4 (en) * | 2016-05-12 | 2019-11-13 | Research Triangle Institute | Vinylogous phenethylamines as neurotransmitter releasers |
US10899699B2 (en) | 2016-05-12 | 2021-01-26 | Research Triangle Institute | Vinylogous phenethylamines as neurotransmitter releasers |
AU2017263457B2 (en) * | 2016-05-12 | 2021-07-08 | Research Triangle Institute | Vinylogous phenethylamines as neurotransmitter releasers |
WO2019151664A1 (en) * | 2018-01-31 | 2019-08-08 | 서울대학교산학협력단 | Rtx toxin production inhibitor and composition for treating symptom of vibrio infection by using same |
KR102171321B1 (en) * | 2018-01-31 | 2020-10-28 | 서울대학교산학협력단 | Inhibitor to RTX toxin synthesis and composition for treatment to Vibrio infection disease |
KR20190093111A (en) * | 2018-01-31 | 2019-08-08 | 서울대학교산학협력단 | Inhibitor to RTX toxin synthesis and composition for treatment to Vibrio infection disease |
US11510899B2 (en) | 2018-01-31 | 2022-11-29 | Seoul National University R&Db Foundation | RTX toxin production inhibitor and composition for treating symptom of vibrio infection by using same |
CN109251090A (en) * | 2018-10-22 | 2019-01-22 | 河南工业大学 | A kind of microorganism seed dressing agent for promoting wheat germination and improving disease-resistant wheat |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
Also Published As
Publication number | Publication date |
---|---|
US9260382B2 (en) | 2016-02-16 |
US20120322769A1 (en) | 2012-12-20 |
EP2536275A1 (en) | 2012-12-26 |
CN102883602A (en) | 2013-01-16 |
CN102883602B (en) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9260382B2 (en) | Methods of reducing virulence in bacteria | |
US20100249234A1 (en) | Methods of reducing virulence in bacteria | |
JP5107579B2 (en) | Zn2 + chelate motif tethered short chain fatty acids as a novel class of histone deacetylase inhibitors | |
US10035819B2 (en) | PPAR agonists and methods of use thereof | |
US9938234B2 (en) | PPAR agonists | |
US8252841B2 (en) | Methods of inhibiting bacterial virulence and compounds relating thereto | |
JP4976354B2 (en) | Hydroxamic acid compounds containing sulfonamide linkages as histone deacetylase (HDAC) inhibitors | |
US9758472B2 (en) | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing | |
US20100016259A1 (en) | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | |
JP5193862B2 (en) | Compounds specific for PPAR and EGF receptors and their salts and their use in the medical field | |
US9751851B2 (en) | Molecules and compositions that inhibit gram negative bacteria and their uses | |
US20190328687A1 (en) | Antibacterial Compounds | |
MX2021014372A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same. | |
US20170231962A1 (en) | Compound Combinations for Attenuation of Bacterial Virulence | |
WO2008068170A1 (en) | Hdac inhibitors | |
Hase et al. | Antimicrobial activity of hydroxamic acids | |
US9604946B2 (en) | Methods for modulating bacterial virulence and related compounds | |
CN107286149B (en) | N- (5-piperonyl thiazole-2-yl) piperidyl amide and application thereof | |
KR20180087157A (en) | Pharmaceutical compositions for preventing or treating chronic obstructive pulmonary disease comprising the compound having BLT-inhibitory activity as an active ingredient | |
JP2003528850A (en) | Inhibition of angiogenesis and tumor growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180019127.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11745175 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13579373 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011745175 Country of ref document: EP |